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Chapter 1 
1.1 BONE MARROW TRANSPLANTATION 
Bone marrow transplantation (BMT) is the intravenous infusion of hemopoietic stern cells 
and progenitor cells with the aim to fe-establish normal marrow function and immunity in a 
recipient with damaged or defective bone marrow (BM). 2 Although some have traced the 
origin of this procedure to the end of the past century, when patients were given bone marrow 
orally as trcatment for hematologic disorders,3 a more realistic starling point is a J939 report 
of a patient who received intravenously 18 ml of marrow from his brother as a treatment for 
aplastic anemia.4 The beginning of modern BMT can be traced to experiments showing that 
rodents could be protected against lethal hemopoietic injury by the intravenous infusion of 
BM. 5 Thc extensive studies on BMT in animal models, the subsequent identification of 
transplantation antigens and the development of techniques for freezing and thawing 
hemopoietic cells laid the groundwork for the difficult and time-consuming clinical trials that 
have brought BMT to its present, albeit imperfect, state. Few areas in medicine illustrate so 
well the development of a new treatment through the close interaction between advances in 
laboratory and in clinical sciencc. 
In the Jate 1960s, the nrst successful allogeneic bone marrow transplantations have been 
performed which led to the gradual acceptance of this therapy. 6.7 Autologous BMT was first 
successfully employed to cure patients with lymphoma in the late 1970s,8 and its lise became 
widespread in the 1980s. 
Table 1.1 Malignant diseases treated with bone marrow transplantation* 
Acute leukemia 
Chronic leukemia 
Myelodyspla'itic syndrome (r\1DS) 
Multiple myeloma 
Lymphomas 
Solid tumors 
* adapted from reference9 
Acute myelocytic leukemia (AML) 
Acute lymphocytic leukemia (ALL) 
Chronic myelocytic leukemia (CML) 
Chronic lymphocytic leukemia (CLL) 
Hodgkin's disease 
Non-Hodgkin's lymphoma 
Neuroblastoma 
Geml cell tumors 
Breast carcinoma 
BMT is now widely accepted as a method of treatment for patients with life~threatening 
diseases such as leukemias, aplastic anemia, severe immunodeficiencies and inborn errors of 
metabolism. to The success of BMT for malignancy (Table 1.1) is dependent 011 the ability of 
the cytotoxic drugs and/or radiation used to eliminate the malignant cells in the patient and on 
the ability of the donor cells to mediate immunologic reactions termed graft-versus-tumor 
effects. 9 The success of BMT to treat immune deficiencies or genetic diseases (Table 1.2) is 
10 
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based on the replacement of defective host hemopoietic cells with normal hemopoietic stem 
cells capable of manufacturing the deficient cellular product or cell lineage. 9 
Table 1.2 Nonmalignant diseases treated with bone marrow transplanlation* 
Aplastic anemia I PNH 
Immunologic disorders 
Metabolic disorders 
Sickle cell :memin 
Thalassemia 
* adapted from reference9 
1.1.1 Allogeneic and Syngeneic BMT 
Severe combined immunodeficiency disease (SCID) 
Wiskotl-Aldrich syndrome 
Chediak-Higashi syndrome 
Gaucher's disease 
Osteopetrosis 
Al10geneic BMT involves the transfer of marrow from one person to another. In the special 
case of a donor and a recipient who are genetically identical, that is identical twins, the 
correct term is syngeneic or isologous transplantation. 
For patients without a twin, a major histocompatibility complex (MHC)-matched sibling 
donor is the best choice for an allogeneic BMT. 
An individual's immunologic identity is expressed in cell-surface proteins encoded by the 
MHC. MHC proteins, termed HLA (human leukocyte antigens) in humans, are critical to the 
proper function of the immune system. Antigen presentation in the (peptide-presenting) 
groove of the MHC-complex enables effector cells to identify and destroy foreign invaders 
while preserving normal, healthy tissues. 1 I MHC antigens and nOll-MHC antigens (also 
termed minor histocompatibility antigens) expressed on transferred cells can lead to graft 
rejection by immunocompetent cells of the recipient. t t,I2 Since the genes for the MHC 
antigens in humans are found on chromosome 6, the MHC type follows the rules of simple 
mendelian genetics. That is, any two siblings have a 25% chance of sharing the same MHC 
type, except for a 1 % chance of crossover (a switch in genetic material between chromosomes 
during meiosis).') These rules form the basis for MHC family typing. Because of the 
relatively small average family size in the Western countries, only 30-40% of the patients 
have an MHC identical sibling. 
For patients who may benefit from an allogeneic BMT but lack an HLA-matched sibling 
donor, there are two possible solutions. One is to identify an unrelated but closely HLA-
matched person willing to donate BM, and the other is to use marrow from a related donor 
who is less than perfectly matched. An early report of the use of an HLA-matched, unrelated 
marrow donor for transplantation in a child with acute leukemia demonstrated that this 
approach call be successful. 14 Subsequent reports have shown that the results improve when 
the degree of MHC-compatibiJity of the unrelated donor increases. 15 Concomitantly it was 
II 
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shown that the removal ofT-celJs, which arc the major mediators of graft-versus-host discnse 
(GVHD), 16 from the graft may ameliorate the severe manifestations of this disease often seen 
in patients receiving transplants from unrelated donors. 17 The extreme large number of 
possible MHC phenotypes makes the search for an unrelated donor difficult. International 
effort has resulted in a worldwide registry of BM donors which have been HLA-typed, 
greatly increasing chances to find a suitable HLA-matched unrelated donor. It has been 
estimated that a registry of 200,000 potential donors of European ancestry would provide a 
40-50% chance of finding an HLA-matched donor. t8-20 
An alternative approach is to identify a related person who shares some but not all of the 
patient's MHC antigens.21 Successful allogeneic transplantation can be performed with 
marrow from such donors, although the risk of graft rejection and GVHD appears to be 
increased compared with MHC-matched BMT. 2t 
Once a donor has been identified, the next step is to use high doses of chemotherapy 
(mostly alkylating agents) and/or total body irradiation to accomplish three goals: provide a 
sufficient degree of immunosuppression to avoid destruction/rejection of the allograft by 
residual, immunologically active cells of the host; destroy malignant cells; and provide space 
for'the new marrow to lodge and to proliferate. The combinations of the high dose chemo-
radiotherapy regimens used are not always fully myeloablative. \Vith T-cell depleted 
allogeneic transplants, some patients are eventually found to have mixed chimerism, 
indicating the survival of host hemopoietic stem cells. 22-24 Although the expected reduction 
in GVHD has been achieved with T-cell depletion, increased rates of graft failure and 
leukemia relapse in these patients led to the recognition that allogeneic T -cells, in addition to 
causing GVHD, also mediate several beneficial effects. 25,26 The increased risk of take failure 
after T-cell depletion of allogeneic marrow grafts was recognized earlier by van Bekkum and 
co_workers. 27,28 Applying BMT in dogs and monkeys, they have shown that an intensified 
pre-BMT conditioning regimen, e.g. an increased (two-fraction) dose of total body 
irradiation, allows reproducible engraftment ofT-cell depleted allogeneic marrow.27,29 At the 
same time it appeared that leukemia relapse rates were lower with this intensified 
conditioning regimen. 30 Thus approaches to control GVHD should be chosen such that 
increased relapse and engraftmentltake failure rates are avoided. 
1.1.2 Autologous BMT 
Autologous BMT involves the use of the patient's own marrow to re-establish hemopoietic 
cell function after the administration of high dose chemo-radiotherapy. Autologous BMT 
differs from allogeneic HMT in various ways (Table 1.3)13. Unlike allogeneic transplantation, 
autologous transplantation can be performed in older patients with relative safety, probably 
because there is no risk of GVHD as a complication. Until it becomes practical for commonly 
occurring genetic diseases to remove hemopoietic stem cells from a patient, to replace a 
12 
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defective gene or to add a missing one, and then transplant the altered cells (gene therapy), 
autologous BMT is not likely to become a common treatment for genetic disorders. It has 
been suggested, however, that autologous transplantation may be an effective therapy for 
certain immune disorders because of an immunomodulating effect.31 
Table 1.3 Comparison of certain features of allogeneic and autologous bone marrow transplantation* 
FEATURE 
Age limit for candidates (yr) 
Primary problem in obtaining 
transplant 
Most serious complication 
Antitumor effect of infused cells 
Use in nonmalignant disorders 
ALLOGENEIC BMT 
50-55 
Finding a closely HLA-matched 
sibling or unrelated donor 
Graft-versus-host disease 
Proven and suspected in a 
number of cases 
Potentially curative in both 
genetic and immunologic dis-
orders 
* adapted from reference. 13 CsA=cyclosporine 
AUTOLOGOUS BMT 
60-70 
Collecting a sufficient number afhe-
mopoietic progenitor cells uncontami-
nated by tumor cells 
Relapse of original disease 
Not proven, but a possible 'syngeneic 
anti~tumor effect' (CsA-induced) 
Not useful until gene therapy becomes 
practical 
A primary concern with autologous BMT in the treatment of malignancies is to make sure 
the graft contains no viable tumor cells. Numerous methods, including ill vitro treatment with 
chemotherapeutic agents or monoclonal antibodies (MeNs) plus complement, have been 
developed to remove contaminating tumor cells from the graft32-36 or to concentrate' the 
hemopoietic stem cells,37,38 referred to as 'marrow purging' and 'positive selection', 
respectively. Retrospective analyses have suggested that purging leads to a reduced rate of 
relapse in patients with certain subtypes of acute myelocytic leukemia.32 However,tumor 
cells can be cultured from histologically negative BM in some patients with lymphoma, 
leukemia or breast cancer,39-42 and such patients have a higher rate of relapse than those with 
negative cultures. 
Experimental and clinical data have indicated that residual tumor cells in the marrow graft 
re-infused after the conditioning regimen do contribute to tumor relapse,43-46 but that the 
majority of relapsing cells seem to originate from the patient, having survived the remission 
induction treatment and the pre-BMT conditioning regimen. Today, purging is not commonly 
used in the majority of patients undergoing autologous transplantation. 13 
1.2 GRAFT-VERSUS-HOST DISEASE 
The post BMT period can be complicated by various life-threatening problems (Table 1.4)9,13 
Today, GVHD remains one of the major causes of morbidity and m.ortality after allogeneic 
13 
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BMT47-49 The first description of GVHD was published in 1954,50 its nature being 
unknown. Initially this syndrome was detected in experimental animals and was called 
secondary disease (opposed to the irradiation induced primary disease aplasia) or runting 
disease. After total body irradiation (TBI) and allogeneic marrow transplantation in contrast 
to syngeneic BMT. animals developed fatal diarrhea and skin lesions. 51 Other symptoms of 
what was latcr referred to as graft-verslIs-host disease, were varying degrees of hypoplasia of 
the lymphatic system, focal necrosis of liver cells and growth retardation. From this 
experience in animals it was stated that the essential requirements for induction of GVHD 
were: a) the marrow graft must contain immunocompetent cells; b) the host must express 
tissue antigens that are lacking in the marrow donor; and c) the host mllst be incapable of 
rejecting the marrow graft. 52 
Table 1.4 Possible complications after BMT* 
Graft-versus-host disease 
Host-versus-graft reaction 
Vena-occlusive disease (VOD) of the liver 
IlIullunological incompetence 
* adapted from reference. 13 
causing both severe morbidity and mortality 
could lead to a take failure or graft rejection 
infections - bacterial 
- fungal 
- viral 
In man, as well as in a variety of animal species, lymphoblasts, small and large granular 
lymphocytes appear in the skin, gut and liver of allogeneic but not syngeneic transplanted 
animalsSt The main effector cells of GVHD are thought to be cytotoxic T-cells and early 
after BMT the invading lymphocytes are mainly CD4-positive (CD4+), although in a later 
stage CDS+ cells predominate. 53 However, acute GVHD may also occur in the absence of 
detectable cytotoxic T -cells in the affected tissues. 53 In experimental animals and in humans 
it is well established that the removal of T -cells from the donor marrow may completely 
prevent acute GVHD. 16,54-57 
GVHD can develop when donor and host are mismatched for MHC antigens, but also 
when they are fully MHC compatible. It has been suggested that disparity of minor 
histocompatibility (mH) antigens elicit the GVH reaction in the latter case, 12,58 In mice, in 
certain donor-recipient combinations mH antigens appeared to be able to induce severe 
GVHD. 59 It is generally accepted that the incidence and severity of GVHD increases as the 
difference between donor and recipient is greater as regards both major and minor 
histocompatibilityantigens,21,60,61 
It has been reported that a GVHD-like syndrome can even occur after syngeneic BMT.62 
In this event, syngeneic GVHD might be the result of inappropriate recognition of self-
antigens 11,51,63,64 Studies in rats suggest that the essential component for the induction of 
syngeneic GVHD is the inhibition of clonal deletion of autoreactive T lymphocytes in the 
14 
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thymus by cyclosporine A (CsA)63 It can be questioned whether the term GVHD is correctly 
used. It has been proposed to lise 'autologous BMT -associated immune disease' rather than 
GVHD. 64 
As regards allogeneic BMT, two distinct syndromes can be distinguished: acute and 
chronic GVHD. In humans, acute GVHD may appear from I week up to 3 months after 
allogeneic BMT, whereas chronic GVHD by definition develops from 3 months after 
transplantation.49 Acute GVHD is graded from I to IV65 When GVHD is absent it is called 
grade O. Mild GVHD (grade I) is a local skin rash (starting in the palms, soles or face), which 
in some cases disappears without therapy; grade II or moderate GVHD can be a skin rash 
affecting most of the body, or a skin rash in association with gut (diarrhea) or liver symptoms; 
grade III is severe GVHD involving skin, gut and liver and grade IV is life-threatening. The 
reason why the skin, liver and the intestinal tract are the principal target organs of acute 
GVHD 66 remains unclear. It has been postulated that primitive cell surface antigens on 
undifferentiated epithelial cells are the targets64 Others hypothesized that these organs are all 
barriers to microorganisms and that these barriers are damaged by the conditioning regimen. 
Endotoxins released by the gram-negative organisms present, may induce local cytokine 
release and subsequently increased expression of MHC antigens and adhesion molecules.47 
The manifestations of chronic GVHD include skin disease, keratoconjunctivitis, generalized 
sicca syndrome, severe oral mucositis, malabsorption, wasting, liver disease and pulmonary 
insufficiency. Severe chronic GVHD often leads to a syndrome which has similarities with 
some autoimmune diseases.66,67 A serious problem with chronic GVHD is decreased immune 
function leading to bacterial and viral infections.68,69 Incidence and severity of acute GVHD 
is closely related to the number of mature T-cells in the graft70 It has been suggestedthat 
chronic GVHD in humans, usually following acute GVHD, may be caused by low numbers 
of long lived lymphocytes of donor origin that have been sensitized to unknown antigens of 
the host7 ! 
It has to be emphasized that the diagnosis of GVHD must be supported by proof of 
engraftment of donor cells as well as by histological confirmation of the presence of 
characteristic lesions. Clinical observations alone are not enough, since they can be easily 
confused with symptoms caused by a variety of infections which occur as a result of the 
severe immunosuppression or by toxicity from the conditioning regimen which complicates 
the post BMT course in many cases.72 
1.2.1 GVHD and lymphocytes essential for allol'eeognition 
The antigen-binding site of most ml\ior histocompatibility complex (MHC) class I and II 
antigens is occupied by peptides that are derived from the proteolysis of endogenous proteins. 
Together with MHC proteins, these 'self-peptides define our immunological self and shape 
the repertoire of both T cells and NK cells that recognize 'nonself. Self-peptide expression 
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allows the recognition mechanism of T and NK cells to check the integrity of the cell 
genome. The distinction between self and nOllself permits the rejection of nonself or 
neoplastic cells. This objective is particularly pertinent to the area ofBMT. 73 
1.2.1.a T-cells 
Before the discrepancy between T and B-cells was established, it was clear that GVHD was 
induced by lymphocytes. 70 Subsequently, it has been clearly shown that, more specifically, 
T-cells playa major role in GVHD 11,55 Initially, T-cells respond to nonself antigens only 
when presented by antigen-presenting cells (APC), such as dendritic cells and macrophages. 
The recognition of antigens presented by APe occurs in the context of class I and/or class II 
MHC antigens, and is referred to as MHC presentation. Foreign antigens arc processed 
intracellularly to small peptides which are bound in the groove of MHC molecules. These 
MHC-peptide complexes can be recognized by non-activated T -cells74 Once evoked, the 
activated T-cells no longer need APC to perceive these peptides. 
Class I and class II molecules have similarities in their structure and function, but differ in 
their fine structure and in their expression on various cell types. Class I molecules are 
cOIistitutively expressed on almost all nucleated cells,75 whereas class II molecules are 
expressed only on specific cell types such as B-cells, macrophages, monocytes, Langerhans 
cells and dendritic cells. They can be induced on T-cells, endothelial cells, renal tubular cells, 
pancreatic and thyroid cells as well as on several other cell types by certain cytokines, 
especially interferon-gamma (IFNy).76,77 
T lymphocytes can be divided into two subclasses, based on their cell surface antigen 
expression: a CD4+ and a CDS+ T-cell subset. CD4+ T-cells are mainly class II restricted, 
whereas CDS+ T-cells are mostly MHC class I restricted. Although previously it was 
accepted that the phenotype of a T-cell correlated with its function, it has now become clear 
that phenotype and function are not strictly related. 78 In general, helper functions are 
performed by CD4+ T-cells and cytotoxic/suppressor functions by CDS+ T-cells. But 
sometimes CD4+ and CDS+ T-cells exert capacities normally ascribed to CDS+ and CD4+ T-
cells, respectively. 
Based on their cytokine profile T-cells can be further subdivided. In this context, two 
CD4 + T helper (Th) cell subsets can be recognized: Th I and Th2. Th I cells produce 
interleukin-2 (IL-2) and IFNy, whereas Th2 cells produce IL-4, IL-S, IL-6 and IL-lO. 
Recently, it has been suggested that these Th subsets have a common precursor (Thp), which 
secretes IL-2 and differentiates into a ThO cell, which secretes IL-2 and IFNy as well as IL-4 
and IL_S79 The cytokine profile of CDS+ T-cells resembles that of the Thl subset, but their 
capacity to produce IL-2 is limited. 80 Although these data are obtained from in vitro studies, 
evidence is increasing that certain strong immune responses in mice and humans are 
preferentially mediated by Thl or Th2 cells8t Preferential upregulation of Thl and 
downregulation of Th2 cells has been reported for cytokines such as IL-I, IL-12 and TNF.82 
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Th I and Th2 cells also crossregulate each other: Th2 cells inhibit the cytokine synthesis of 
Thl cells by IL-lO (originally named cytokine synthesis inhibitory factor). On the other hand, 
Thl cells inhibit the proliferation ofTh2 cells through the production ofIFNy83,84 Improving 
our knowledge of the cytokine network in relation to T-cell activity may reveal new 
therapeutical approaches to minimize the devastating effects of GVHD. 
T lymphocytes use the T-cell receptor (TCR), which consists of two subunits, the a and p 
chain, to recognize antigens. Other cell surface molecules contribute to the interaction 
between T -cells and target/stimulator cells: co-receptors such as CD4 and CD8, accessory 
molecules like CD28, CD44 and CD45, lymphocyte function associated antigens such as 
LFA-I (CDllalCDI8), LFA-2 (CD2), LFA-3 (CD58)76,85-87 and the adhesion molecules 
ICAM-I (CD54), ICAM-2 (CDI02), ICAM-3 (CD50) and ELAM-l. These molecules may 
intensify the binding/contact between T-cells and APC. Some of these molecules may also 
provide co-stimulatory signals for T-cell activation. 
Upon contact of T-cells with multivalent (allo)antigens, TCR signal transduction occurs 
via the CD3 complex, which consists of transmembrane polypeptide chains that are 
associated with the TCR. This leads to intracellular activation and a cascade of events that 
result in the transcription of genes for cytokine production and their receptors. Among the 
first to be activated are the genes for IL-2 and the IL-2 receptor (IL-2R). IL-2 production is 
essential for T-cell proliferation. Slightly later, IFNy, IL-4, IL-5 and IL-6 production starts. 
As a consequence, T lymphocytes differentiate and thereby gain specialized functions and/or 
cytokine production profiles. 76 
Both CD4 + and CD8 + T lymphocytes have been shown to playa role in GVHD in mice. It 
appears that the T-cell subset involved was dependent on the MHC or mH antigen differences 
between donor and recipient. Highly purified CD4 + T-cells were able to cause lethal GVHD 
in a class II incompatible mouse strain combination. whereas purified CDS+ T-cells caused 
GVHD in a class I disparate strain combination. 88 In mH antigen disparate strain 
combinations, either the CD4+ or the CDS+ T-cell subset can playa dominant role. In some 
mH antigen disparate strain combinations both subsets appear to be equally involved. 55 
1.2.1.b NK cells 
Natural killer cells are generally defined as lymphocytes that spontaneously mediate the non 
MHC-restricted or MHC-independent lysis of certain transformed or virally infected 
cells. 89,90 Strictly speaking, NK cells are CD3-negative large granular lymphocytes, which 
express certain surface markers such as CDI6 and CD569t A variable percentage (30-80%) 
of NK cells also express CD5792 NK cells do not express the T-cell receptor or the T-cell 
receptor associated protein complex. CD3.93 However, they do express a signal-transducing 
subunit (CD3!;) of the CD3 complex on their surface which is associated with their Fc 
receptor for immunoglobulins (CDI6)94.95 
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Murine NK cells generally do not have T-cell markers such as CD4 and CDS,96,97 or B-
lymphocyte markers and have therefore also been called 'nulr cel1s.96 When activated 
however, a percentage of murine NK cells express Thy-I, a marker commonly associated 
with T-cells. 98 A sUbpopulation of human NK cells do express CDS.97 
NK cells are also noted for their ability to mediate antibody-dependent cell mediated 
cytotoxicity (ADCC) through their expression of the Fc receptor (CDI6)99 Muriue NK cells 
express the glycolipid asialo GMI (ASGMl), which is also found on some macrophages and 
activated T-cells. Therefore, ASGMI is not considered to be NK-specific96 Unlike resting T-
cells, which require both the antigen-MHC complex and cytokines (IL-IIIL-2) for 
proliferation. NK cells are activated and proliferate directly in response to IL-2. both in vitro 
and in vlvo.100,101 In addition, NK ceUs constitutively express the p75 medium affinity IL-
2R.9297 Moreover, NK cells are activated in response to interferons,I02 When activated, NK 
cells exhibit a broad lytic spectrum and undergo a morphologic change, i.e. an increase in 
intracellular granules (containing perforins, a C9 homologue).93,97 These granules are 
believed to playa role in the cytolytic process; activated NK cells are known as large granular 
lymphocytes (LGL). Recently, a novel cytokine called NK cell stimulatory factor (NKSF) or 
IL-12, produced by peripherul blood mononuclear cells (monocytes and lymphoctes), was 
described and shown to augment human NK activity, and to have a role in immune and 
inflammatOIY cell responses. to3, 104 
NK cells produce numerous cytokines, many of which may be mediators for the ill vivo 
effects of NK cells. Human NK cells produce granulocyte-macrophage colony-stimulatory 
factor (GM-CSF),105 IFNy, 105 and tumor necrosis factor alpha (TNFa). t06 In one of these 
studies,105 IL-2 activated peripheral blood lymphocytes were used, which do not consist 
solely of NK cells. Purified murine NK cells have been demonstrated to produce GM-CSF, 
INFy, G-CSF, IL-l, and transforming growth factor p (fGFP).I07 
NK celJs exert a variety of immunological functions and are considered to be an essential 
component of 'natural immunity', the immediate immune response system which lacks the 
capacity of antigen-specific recognition. Unlike T-cells, NK cells have no 'memory' and act 
spontaneously at first contact to lyse tumor cells both in vitro and in vivo. to8 Furthermore, 
NK depletion promotes metastases in experimental animals. 109 This tumor cell-kHling 
capability led to the hypothesis that NK cells playa critical role in tumor surveillance. t to 
Abundant in vivo data suggest that NK cell do provide significant antitumor effects. 93,97 To 
date, the mechanism by which NK cells recognize target cells is unknown, although in some 
models, an inverse correlation has been found between tumor cell MHC expression and their 
susceptibility to NK lysis. til 
Mouse and human lymphokine-activated killer (LAK) celis, which comprise activated T-
cells and NK cells, have been shown to suppress alloreactivity; 112 this result suggests that 
LAK cells can suppress the generation of GVRD ill vivo .113 Studies on BMT lIsing mice, in 
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which NK cells were transferred with an allogeneic graft, suggested that donor NK cells 
suppressed GVHD,l14 Because activated NK cells produce immunosuppressive factors such 
as TGF~, 107 the mechanism behind the lack of GVHD in the recipients may be the direct 
suppression of alloreactive donor T -cells by donor NK cells. 
Though these studies suggest that activated donor NK cells may prevent GVHD, 
controversially, NK cells may be potential effector cells capable of mediating this disease. I 15-
117 However, many of these studies have used ASGMI as an NK cell marker. This antigen is 
also expressed on some activated T ~cells. 97 Additionally, NK cells do not recognize classic 
MHC differences and therefore are unlikely to be the primalY mediators of GVHD. Yet, the 
presence of NK cells in the tissues affected in GVHD 118-121 indicate that NK cells may play 
a supportive role during the end stage of the disease. While donor T-cells are clearly involved 
in the primary cause of GVHD in allogeneic BMT, it may be that they can recruit donor NK 
cells participating in the damage through the production of inflammatory cytokines such as 
IL-l and TNFa. The role of NK cells in mediating the pathology of GVHD is still to be 
resolved. 
1.2.2 .Acute GVHD as a three step process 
It has been well established in experimental and clinical studies that acute GVHD is caused 
by T-cells in the donor graft. 88.122-126 Efforts to control GVHD have therefore been directed 
against the donor derived T-cell. Still, the precise mechanisms by which host tissues arc 
damaged remain unclear. Recently. several convergent lines of evidence have suggested that 
inflammatory cytokines act as mediators of acute GVHD,127,128 Most of the clinical 
manifestations of GVHD may in fact be due to significantly increased levels of certain 
cytokines produced by T cells and other inflammatory cells. Data are accumulating that 
mechanisms other than direct T-cell mediated cytotoxicity may generate tissue damage 
associated with GVHD. Recently it has been hypothesized and described by Antin and 
Ferrara that the activation of T-cells is just one critical step in a three step process of GVHD 
pathophysiology (Figure 1.1)47.129 Their hypothesis is described below. 
1.2.2.a Step one: The role of host tissue in the development of acute GVHD 
First, the expression of cell-surface histocompatibility proteins and adhesion molecules on 
host target tissues such as skin, intestinal mucosa and liver is increased by inflammatory 
cytokines, 130 released by endothelial and epithelial cells as a result of conditioning regimen 
toxicity, infections and possibly the underlying disease. 131-133 For example, endotoxin from 
the gut may leak through the intestinal wall and stimulate endothelial cells andlor 
macrophages to produce cytokines such as interleukin-l (IL-l), TNFa. IL-6, and NKSF, also 
known as IL_12,134 even in the absence of clinical sepsis. Recent clinical data indicate that 
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the kinetics of increased serum levels of TNFa are predictive for transplant related 
complications and survival,135,136 Experiments in a murine model showed that the single 
Conditioning regimen 
Disease 
Endotoxin 
endothelium 
epHheHum 
macrophages 
3 
TNFa ~L.' 
x:: activation/amplification 
'V-" Inflammalionltlssue Injury 
Donor 
Teall 
~'2 IFNy 2 
Donor 
mononuclear cell 
Figure 1.1 Schematic representation of the role of inflammatory cytokines in acute GVHD. In step It injury to 
host tissues, either directly by the conditioning regimen or indirectly through the production of cytokines, result'> 
in alterations in the host tissues, such as increased expression of MHC antigens, adhesion molecules, 
procoagulants etc. In step 2, mature T-cells infused with the bone marrow respond to these changes in the 
allogeneic host tissues. This response includes the autocrine production of IL-2 and IFNy, which in turn activate 
mononuclear cell effectors from donor marrow. In step 3, additional production of inflammatory cytokines by 
these donor mononuclear cells results in direct tissue injury. Endotoxin released by gram-negative bacteria as 
well as production of other cytokines such as IL-6, IL-8 and NKSF (IL-12) may further amplify the injury and 
recruit additional effectors.47 
injection of an anti-TNFa antibody before recipient irradiation and transplantation, 
significantly reduced subsequent GVHD mortality.t36 
As opposed to allogeneic BMT with 'full marrow'. in syngeneic. autologous, or T-cell 
depleted allogeneic marrow transplants, the production of inflammatory cytokines by the 
endothelial and epithelial cells is self·limiting and resolves within 7 to 10 days47 
1.2.2.b Step two: The role of T ·cells in acute GVHD 
In allogeneic BMT, a second step occurs when mature donor T~cel1s recognize host-MHC 
antigens and become activated. T-cell recognition of histocompatibility antigens and adhesion 
to targets is facilitated by consequences of the first step. i.e .• the cytokine~induced increase in 
host cell surface receptors in these tissues and the activation of T -cells by cytokines. The 
activated donor T-cells then proliferate, express the IL-2R, and secrete ILM2. Nevertheless, 
evidence that acute GVHD is directly mediated by cytotoxic T lymphocytes is meager. 
Typically, pathologic specimens of skin, liver or gut involved with acute GVHD arc striking 
for the disproportion between tissue damage and the intensity of the lymphocytic infiltrate in 
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the organ. In addition, controlled trials of antithymocyte globulin (ATG) and immunotoxins 
have been disappointing in the therapy of acute GVHD. t37,t38 
IL-2 is critical for the activation and proliferation of T-cells. It has been considered, 
therefore, to play an important role in acute GVHD. However, the role of IL-2 as an effector 
molecule of GVHD-induced damage has been difficult to establish. Serum IL-2 levels are not 
increased in acute GVHD, and while increases in IL-2R levels have been observed,139 the 
significance of this observation is uncertain because many cell types express IL-2R. Anti IL-
2R MeA's provide only transient benefit in steroid resistant GVHD and their mechanism of 
action is unclear. 140 Furthermore, IL-2 can be administered safely after T-cell depicted 
allogeneic, or autologous marrow grafting without causing or accelerating GVHD,14J,142 The 
only setting in which IL-2 can be directly implicated in causing a 'GVH like' syndrome is 
when high doses of IL-2 are administered together with LAK cells. t43 Even then, much of the 
IL-2 toxicity is probably mediated through the induction of other inflammatory cytoldnes. t44 
Arguments favoring an indirect mechanism ofIL-2loxicity include: a) the induction ofTNFo: 
and IL-I synthesis by peripheral blood mononuclear cells incubated with IL-2 t45; b) the 
extensive overlap between IL-2 toxicity and IL-l and TNFa induced toxicities in both 
experimental and clinical settings 146,147; and c) the inability of IL-2 to act directly on a 
variety of cell types ill vitro, even when those same cell types afc clearly affected by 
administration of IL-2 ill vivo,148 Corticosteroids, which arc often an effective therapy for 
acute GVHD, are typically thought to reduce T-cell numbers, but they also diminish the 
production of inflammatory cytokines, particularly IL-2 and TNFa., independent of their 
effect on T-cell viability. Thus, while the importance of T-cells in acute GVHD is 
unquestioned, their primary role may reflect cytokine production and recruitment of other 
effectors, rather than direct cell-mediated cytotoxicity. 
1.2.2.c Step three: The role of cytokines as effectors 
IL-2 activates newly engrafted mononuclear cells from the donated marrow to secrete more 
inflammatory cytokines, such as IL-2, TNFa and IFNy. The resulting inflammatory response 
results in additional release of cytokines and amplifies local organ injury. 
Preclinical animal studies have revealed strong evidence of the link between excessive or 
dysregulated cytokine production and clinical GVHD. TNFo: is well established as a cytokine 
that causes organ damage in experimental acute GVHD. Mice receiving transplants of 
allogeneic BM plus additional T-cells develop severe skin, gut, 149 and lung lesions that are 
associated with high levels of TNFo: messenger RNA (mRNA) in these tissues. t50 More 
recent evidence demonstrates TNFa mRNA in the skin of mice developing GVHD after 
transplants across minor histocompatibility barriers. 151 Studies on TNFa in humans confirm 
thal serum TNF a levels are elevated in patients with GVHD 135 and TNF a message is 
expressed in blood mononuclear cells. 152 Recent data further implicated inflammatory 
cytokines in the pathogenesis of GVHD by showing an association between increased TNFa 
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and IFNy synthesis in a skin explant model and the development of acute GVHD,I53 Anti-
TNFa MeArs are capable of temporarily abrogating steroid resistant acute GVHD in human 
GVHD, but the transience of the response suggests that the underlying pathophysiology had 
not been entirely interrupted,154 
Experimental data demonstrated that IL-l, a central mediator of illi1ammation, plays an 
important role in GVHD. IL-I mRNA increases in the skin of mice after transplant only if the 
skin is involved with GVHD,ISJ A similar increase in mononuclear ceU TL-l mRNA has been 
observed during clinical acute GVHD. t52 If IL-I is a central mediator of GVHD, specific 
inhibition of IL-l should result in a reduction or elimination of GVHD. IL-l receptor 
antagonist (IL-Ira) is a specific, competitive inhibitor of both IL-Ia and IL-Ip. When 
administered to mice either for profylaxis t5t or therapy of GVHD, t55 mortality from GVHD 
was strikingly diminished. The role of JL-l may also be indirectly inferred from the high dose 
y-globulin trials of GVHD prophylaxis. High dose y-globulin appears to reduce the incidence 
of acute GVHD. 156 A relevant ill vilro observation is that IgG bound to mononuclear cell Fc 
receptors increases IL-lra production preferentially over IL-Ia or IL-I p, 157 suggesting that a 
similar mechanism might occur il1 vivo. GM-CSF seems to potentiate this preferential 
production of IL_lra. 157 Ongoing studies may determine whether GM-CSF can reduce the 
incidence of clinical GVHD. 
At least two mechanisms by which TNFa can cause cell death are known. The first is by 
activation of phospholipase A2 (PLA2). Arachidonic acid metabolites are observed in 
supernatants of cell cultures exposed to the cytokine before cell death, and quinacrine, a 
PLA2 inhibitor, completely protects against cytokine cytotoxicity. 158 A second mechanism 
by which TNFa can mediate cytotoxicity is the production of intracellular hydroxyl 
radicals. 159 The sensitivity of several cell lines to cytokine toxicity appears to be inversely 
related to the radical scavenge capacity of those cells, and compounds that inhibit the 
production of free radicals can prolong the survival of cells which are exposed to TNFa. 160 It 
is likely that the production of IL-l and TNFa can also stimulate the release of cytokines 
from the IL-8 family, which in turn help to recruit and activate secondary cellular effectors 
(e.g. neutrophils, NK cells and monocytes) as well as contribute directly to capillary fragility, 
edema, and cell death. Other cytokines may also be part of this network; e.g. macrophage-
derived NKSF may stimulate NK cells to produce INFy and to display enhanced cytolytic 
activity against host tisslles. t04,!6! Recent data indicate that the frequency of lymphocytes 
producing lFNy mRNA is dramatically increased in mice with acute GVHD. t62 Such 
observations suggest that the effects of cytokines such as NKSF (IL-12) may be enhanced if 
the frequency of responding cells increases. 
Thus, multiple inflammatory cytokines may play an important role in augmenting the 
reactivity of the allogeneic cytotoxic cells, causing direct damage to target organs. But it is 
conceivable that the role of cytokines as direct mediators of local tissue destruction is very 
important as well,47 though cytokines alone have not been shown to induce GVHD-like 
22 
_________________________ GelJerallntrodliction 
symptoms. Further studies will elucidate the value of this hypothesis in the treatment of 
GVHD. 
1.3 GRAFT-VERSUS-LEUKEMIA 
BMT is an effective treatment for acute and chronic leukemias. In the management of these 
disorders, the procedure was originally proposed to allow escalation of myelotoxic 
chemoradiotherapy to supralethallevels, followed by BMT to rescue hemopoiesis65 
The assumption that the (pretransplantation) conditioning regimen is inadequate to 
completely eradicate leukemia and that the infused cells contribute to a cure was first 
proposed in 1956. t Although studies in rodent models generally confirmed the existence of a 
graft-versus-leukemia (GVL) effect after allogeneic BMT, t63,164 GVL data in humans used 
to be entirely indirect (retrospective). 
1.3.1 GVL effect ill animals 
Considerable data from preclinical studies clearly show that an antileukemic effect exists. 165 
It was shown that mice which died of GVHD showed a marked reduction in leukemic cell 
load. By transferring cells from animals that did Of did not develop GVHD into secondary 
recipients, the antileukemic effect of GVHD could be assessed by monitoring (leukemia free) 
survival. i ,166,167 
In several studies showing antileukemic effects associated with allogeneic BMT, efforts 
were made to reduce GVHD morbidity Hnd mortality e.g. by using germ-free conditions or 
reduction of the number of lymphocytes in the marrow inoculuffi.167-171 It has been shown 
that donor T -cells in allogeneic BMT, which are the major contributors to GVHD. 55 are 
responsible for a reduction in the incidence of leukemia relapse also. I72, 173 With a murine T-
cell leukemia (spontaneously arising in AKR mice), a potent GVL effect without GVHD was 
induced by immunizing the MHC-compatible donors with pooled allogeneic lymphocytes. t74 
The induction of this GVL effect within the donor required CDS+ T -cells and was activated 
by non-MHC determinants on the immunizing cells. 175 
The potential of either depletion or administration of donor lymphocyte subsets to improve 
the outcome of allogeneic BMT has attracted considerable interest. An association between 
increased NK activity with GVHD has been widely observed, 118,119, 121 and donor NK cells 
or LAK cells have been implicated as effectors of GVHD. Studies involving a variety of 
GVHD patterns and several strain combinations indicate that the role ofNK cells in GVHD is 
complex and may vary considerably between host-donor combinations. 176 Johnson and 
Truitt 116 reported a reduction in GVHD, without loss of antileukemic effects or impaired 
engraftment in MHC-matched, minor antigen mismatched allogeneic BMT when donor NK 
cells were selectively depleted. However, the lymphocytic atrophy and immunosuppression 
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resulting from GVHD was not reduced, and this approach was ineffective in a more severe, 
MHC-mismatched GVHD model. 
Studies on the effects of murine T-cell subsets show that CD4+ T-cells contribute to GVL 
effects, t77 and that predominantly CDS+ cells playa role in causing GVHD in most (4/6) 
host-donor combinations ofMHC-matched. mI-l antigen mismatched BMT. 59 However, these 
results can not be extrapolated to the setting of both major and minor histoincompatibilities. 
The majority of studies evaluating T-cell subsets show that CD4+ T-cells playa critical role 
in causing GVHD in fully mismatched strain combinations, and that CD8+ T-cells given 
alone do not cause acute GVHD,l77-179 This observation is surprising, as CD8+ cells can 
cause GVHD directed against isolated mH antigen or MHC class I disparities. 59,88 Another 
approach to separating the beneficial from the harmful effects of allogeneic T-cells involve 
the ill vitro expansion and cloning of donor T -cells that specifically react to host leukemia 
associated antigens, but that do not recognize non-malignant recipient cells. The existence of 
such CTL clones has been reported in mice, 180 but it still needs to be proven that these cells 
do not lose their specificity and do not cause GVHD after prolonged in vltro selection, 
cloning and expansion. 
As described earlier, IL-2 is crucial in T-cell proliferation and has therefore been used in 
many GVLlGVHD studies. Experimental data on the GVL effect of IL-2 therapy post BMT 
are controversial. In syngeneic BMT in mice it has been postulated that the marrow graft 
should be activated with JL-2 (ex vivo) and IL-2 therapy should be initiated immediately after 
BMT to induce a syngeneic GVL effect. 181 The mechanism of this approach is unknown and 
was observed to be transient. 
Following allogeneic BMT of low doses of IL-2 during the first week of GVHD enhanced 
the severity and mortality seen in class I disparate, but not in class II disparate mouse strain 
combinations presumably mediated by CD4+ cellsl82 Aggravation of GVHD induced by 
recombinant IL-2 was observed both in MHC disparate rats 120 and mice mismatched for mH 
antigens. [83 In contrast, Merluzzi et al. reported not to aggravate GVHD with ll.,-2 doses able 
to induce allospecific cytotoxic T lymphocytes (CTLs), using a different murine minor 
histoincompatibility model. 184 It appears that IL-2 plays a critical role in the early 
development of acute GVHD, most likely by facilitating the development of donor-anti-host 
CTLs. 185 Since GVHD and GVL usually coincide, IL-2 may therefore be of importance in 
the induction of GVL as well. 
The effect of IL-2 treatment after allogeneic BMT on GVHD has recently become even 
more controversial. Sykes et al. found (using the EL4 leukemia growing in B 10 recipients and 
AlJ as donor mice) that administration of high doses of IL-2 at the time of infusion of MHC 
mismatched BM and spleen cells together with T-cell depleted syngeneic BM, to delay 
GVHD related mortality, further reduces lethal GVHD, promotes alloengraftment and 
maintains the GVL effect. 171,186 However, initiation of IL-2 administration at later time 
points, e.g. day 7 post BMT, can exacerbate GVHD. 186,187 Further studies using mice (EL4 
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and 2B-4-2Ieukemia in AlJ -> BIO and BIO -> BALB/c BMT, respectively) revealed that in 
fully MHC mismatched transplantation, early IL-2 treatment selectively inhibits the GVHD 
producing CD4 activity, but does not inhibit the antileukemic effects of CD4+ and CD8+ T-
cells. 178,188.189 Using allogeneic BMT in several murine donor~host combinations in which 
both GVL and GVHD were CD4 dependent, IL-2 treatment inhibited GVHD but not the 
antileukemic effects of CD4+ cells. t88 These findings suggest that the inhibitory effect of IL-
2 is directed against a limited subset or function of CD4+ T-cells and that GVL and GVHD 
are mediated through different CD4 mechanisms. t88 Finally, it was shown that the effect of 
CD4+ cells on GVHD is determined by the histoincompatibility between donor and host. 179 
Unfortunately, to date the clinical use of IL-2 for enhancing the antileukemic effect in 
allogeneic BMT has been prevented by the property of IL-2 to aggravate GVHD. Though 
highly interesting, the complicated data of Sykes et aJ. do not describe the 'separable' CD4-
mechanisms of GVL and GVHD, therefore not solving the risk of increased GVHD induced 
by IL-2 treatment, which leaves this treatment clinically inapplicable. 
1.3.2 GVL effect in humans 
First clinical evidence for this phenomenon (Table 1.5) was provided by Weiden et al. t90,t91 
They showed that the likelihood of leukemia relapse was substantially lower in patients with 
either acute or chronic GVHD compared with unaffected patients. Patients experiencing both 
acute and chronic GVHD had an even lower rate of leukemia relapse compared to those with 
either acute or chronic GVHD alone. 192,193 A higher relapse rate after syngeneic 
transplantation compared with allogeneic transplantation without clinical signs of GVHD was 
shown retrospectively 194 and confirmed by a larger retrospective study performed by the 
International Bone Marrow Transplant Registry (IBMTR).I92 These data suggest that the 
GVL effect can be induced without being accompanied by clinically apparent GVHD. Ex vivo 
T-cell depletion (TCD) of allogeneic donor BM decreases the incidence of both acute- and 
chronic GVHD but at the same time significantly increases the rate of leukemia relapse. 195 
Table 1.5 Clinical evidence for the existence of a graft-versus-Ieukemia effect 
Acute and/or chronic GVHD versus no GVHD 
Allogeneic BMT (without GVHD) versus autologous BMT 
GVHD prophylaxis: T-cell depletion 
post-BMT immunosuppression 
INCIDENCE OF LEUKEMIA RELAPSE 
reduced 
reduced 
increased 
increased 
Likewise, leukemia relapse was shown to be increased by post-BMT GVHD prophylactic 
immuno-suppression (cyclosporine, CsA), 196-198 The discontinuation of CsA at first signs of 
leukemia relapse induced complete hematologic and cytogenetic remission and these patients 
remain free of disease with a long follow up. Though few cases have been reported,l96,197 
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they indicate that GYHD is associated with the GYLR which eradicates the residual leukemic 
cells. 
Several investigators have attempted to deplete T-cells to a lesser dergree prior to BMT. 
with the aim to reduce GVHD and preserve GVL Results of these studies suggest that there 
may be an optimal treatment of the marrow by which the T-cell depletion will decrease the 
incidence and severity of GYHD while preserving the GYL effect. t6,t99,200 An other 
approach to prevent GYHD may be depletion of a specific subset of lymphocytes (or 
inhibition of a specific T-cell function), according to the asslImption that there is not only it 
quantitative effect of allogeneic T-cells on GVHD and/or GVL but also a qualitative 
difference between the T-cells. A promising clinical trial of selective donor CDS cell 
depletion (2 log) provided information on T-cell subsets mediating GYHD and GYL in man, 
This study demonstrated a reduction in, but not absence of, GVHD. whereas leukemic relapse 
rates were low (Table 1.6)201,202 
Table 1.6 Allogeneic BMT (HLA-id.sibl.) in CML patients in chronic phase* 
MARROW GYHD (" gmde II) RELAPSERA1E DFS (lyr) 
Unmodified (n=31) 58% 0% 45% 
CDS depleted (n=IS) 22% 0% 66% 
pan T depleted (n=20) 5% 65% 35% 
*, deduced from20I ; Il, the number of patients; DFS, disease free survival; pan T depleted, all T-cells have been 
removed (2 logs). 
It has been demonstrated that leukemia 'specific' CTL lines and clones could be generated 
from the peripheral blood of MHC identical siblings of patients with leukemia20J,204 Both 
MHC class I as well as class II restricted CTL clones could be generated.204 To explore the 
possibility of clinical application of donor-derived CTL lines directed against the leukemic 
cells from patients who relapsed after allogeneic BMT, a pilot study was performed using 
eight donor-recipient combinations. In seven of eight combinations donor-derived CTL lines 
could be generated that showed specific lysis of the leukemic cells from the patient. In five of 
these cases, the CTL lines showed reactivity with the leukemic cells, but not with the IL-2-
stimulated lymphocytes from the same individual. In two cases, the CTL lines were cytotoxic 
for the IL-2-stimulated lymphoblasts as well as the leukemic cells. 205 It is likely that such 
leukemia specific T-cells are quite rare in normal peripheral blood. Separation from T-cells 
that do induce GVHD, prolonged in vitro selection, cloning and expansion, (for ;/1 vivo 
administmtion) may be impractical for use in the setting of BMT, in which leukemia reactive 
cells must eliminate exponentially expanding leukemic cells,48 
LAK cells and NK cells have also been implied to play a role in the GYL 
reaction. 192,206,207Thesc cells are able to lyse, most efficiently in the presence of IL-2, a 
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variety of tumor cells with limited effect on normal cells. Acute lymphocytic leukemia (ALL) 
and acute myelocytic leukemia (AML) blasts arc reported to be susceptible to the lytic 
activity of autologous and allogeneic LAK cells in vitro as weJ1.208-212 Clinical studies 
confirm these preclinical results for acute leukemias. 213,214 Other studies suggest that in 
AML, but not in ALL, the LAK cell compartment plays a role in the clinical course and 
overall outcome of the disease. 215 
Results of pilot studies indicate that treatment of acute leukemia of both myelocytic and 
lymphocytic origin with recombinant IL-2 alone is feasible and may result in the 
disappearance of chemotherapy-resistant blasts in patients with limited but detectable disease. 
The IL-2 treatment was shown capable of inducing profound immunophenotypic and 
functional modifications in PB and in BM lymphocytes, particularly in patients with more 
limited disease. The evidence of the in vivo activation of cytotoxic cells (a.o. LAK cells), 
particularly in the BM, helps to explain the clinical responses observed in individual acute 
leukemia patients216,217 
Concerns have been raised that IL~2 therapy might accelerate the growth of residual 
leukemia cells. Human if! vitro and murine if! vivo data (human leukemia cells growing in 
immunosuppressed nude mice) indicated that IL-2 in generul does not promote the 
proliferation and growth of human acute leukemia cells of myelocytic and lymphocytic 
origin. 2lS However, more recently, relapses were reported after IL-2 treatment of AML 
patients in complete remission, where the IL~2R-a chain was detected on the surface of 
leukemia cells from sllch patients during relapse.219 Similarly, in vitro proliferation of 
leukemic blasts of the monocytic lineage (FAB M4 and M5) from a number of patients, was 
stimulated by IL-2, which was significantly correlated with the expression of the IL-2R-~ 
chain. 220 
Overall findings suggest that measures that simply reduce GVHD may also impair the 
GVL effect of allogeneic BMT andlor that the induction of GVL concomitantly leads to 
GVHD221 As calculated for human allogeneic HLA-matehed BMT with full marrow, the 
GVLR induces a I log leukemic cell kill together with significant (lethal) GVHD. 30 
Therefore in acute leukemia it is strongly advised to apply T-cell depletion which eliminates 
death from GVHD and seek for other means to achieve additional leukemic cell kill, such as 
intensification of the conditioning regimen andlor treatment with low dose chemo- or 
immunotherapy after BMT,222,223 as is currently being applied in many medical centers. 
Nevertheless, the first direct evidence of a GVL effect induced in humans was recently 
provided by Kolb et al,224 They used a combination of IFNu and donor buffy coat cells 
obtained by ieukapheresis to induce cytogenetic remission in three patients whose CML had 
relapsed after allogeneic BMT. Excitement over these observations led to rapid confirmation 
by several other groups. 225-232 Although details of the protocols differed, these investigators 
have shown that allogeneic buffy coat mononuclear cells have a striking capacity to identify 
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and destroy CML ill vivo, resulting in a clinical response rate of 83%, The potency of this 
GVL response is velY impressive (Table 1.7). 
Table 1.7 Summary of reports on donor buffy coal transfusions for relapsed CML after allogeneic BMT* 
reference n lFNa mononuclear clinical bcr/abl- cytopenia acute therapy 
number cell dose response by peR GVHD related 
(~ I08lkg) death 
224 3 3/3 4.4,5.1,7.4 3/3 ND 0/3 2/3 0 
227 2 012 1.8,2.7 212 212 0/2 1/2 0 
229 6 3/6 0.34-5.2 5/6 4/5 2/6 5/6 
226 8 6/8 2.5 - 5.0 7/8 5/6 4/8 7/8 
230 3 3/3 3.8,5.7, 12.3 3/3 212 3/3 3/3 
232 8 8/8 0.9 -7.9 7/8 5/8 7/8 7/8 I 
233 6 6/6 NR 5/6 212 6/6 5/6 3 
234 1O¢ 4n 2-3 infusions NR t\1~ 3/10 7/10 3 
Summary 33/43 0.34-12.3 32136 20/25 25146 37/46 10/46 
(77%) (83%) (80%) (54%) (80%) (22%) 
*, adapted from reference235 ; acute GVHD, grade I-IV GVHDj 11, number of patients; NR, not reported; ND, 
not done;¢, seven of ten were treated for CML. 
A retrospective comparison of the disease free survival reported in these studies with the 
results of a second conditioning regimen and BMT, shows that both the relapse rate and 
therapy-induced morlality are substantially lower with buffy coat infusions, 236,237 
Interestingly, it appears that the GVL reaction is more effective in chronic-phase CML 
than in other hematologic malignancies. Retrospective analyses support the presence of a 
GVL effect in non-Hodgkin's lymphoma238 and the acute leukemias,I92,228 but further 
studies will be needed 10 determine whether it can be induced reliably with buffy coat or T -
cell infusions. The ability to treal relapsed CML with reduced morbidity and withoul 
mortality of a second transplant would unquestionably be a valuable contribution to the care 
of Ihese patients. 
1.4 OUTLINE OF THIS STUDY: ARE GVL AND GVHD SEPARABLE? 
It is not clear whether the processes operating in the GVLR are separable from those 
operative in GVHD. Evidence has been reported about at least two elements of the GVLR; 
one that is dependenl on the presence and the intensity of GVHD239 and the other one 
operating without clinically overt GVHD.240,241 Thus, the latter may allow enhancing the 
GVLR. In this way a more safe and complete eradication of leukemic cells still present after 
the conditioning regimen may be achieved. However, to determine whether this can be 
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accomplished, a better understanding of the mechanisms of the GVLR and its mediators is 
warranted. 
In some animal models, the GVLR can be separated from the GVHD reactivity 170,242 
leading to the speculation that GVL and GVH reactive cells are distinct. These preclinical 
data support the assumption that specific antigens are present on leukemic cells, not shared by 
normal cells of the host. However, no leukemia-associated specific surface markers have been 
identified so far on human leukemia cells. Alternatively, the same cells may mediate both 
GYL and GVH reactions, but quantitative differences in sensitivity of leukemic and normal 
cells could account for apparently distinct GVLlGVH reactions, indncing a 'threshold' effect. 
Several reports mention the in vitro induction of cytotoxic T-Iymphocytes specific for 
MHC-matched allogeneic leukemic cells, nonleukemic cells, or lysing both leukemic and 
non leukemic target cells,203,204,243 and their correlation to the GVLR in vivo in a murine 
model. t80 
The question remains whether it will be possible to optimize the beneficial GVL effects 
without increasing the risk of lethal GVHD? So far, no convincing clinical evidence has been 
reported on a GVLR separable from GVHD. 
To study GVL in animal models relevant to human leukemia, the studies reported here 
were performed applying the acute myelocytic leukemia (AML) growing in the inbred Brown 
Norway rat strain (BNML)222,244,245 and the L44l5 acute lymphocytic leukemia (ALL) 
growing in the inbred W AG/Rij rat strain. 246,247 Both leukemia models show a reproducible 
growth pattern upon intravenous (Lv.) transfer. Survival time following Lv. inoculation is 
inversely related to the logarithm of the number of leukemic cells in the inoculum. This log-
linear relationship between leukemic cell load and survival time allows an accunite estimation 
of the treatment-induced antileukemic effect, expressed in terms of log leukemic cell kill 
(LCK), by recording prolongation of survival. Thus, these rat models offer the opportunity to 
compare the antileukemic effects of syngeneic, semi-allogeneic and (fully mismatched) 
allogeneic BMT and additional treatment regimens in the treatment of minimal residual 
lenkemia, i.e. AML and ALL. 
The first aim was to induce, in a reproducible manner, a GVL effect in these rat models. 
Secondly, when the GVL-inducing treatment of the recipient rats was established, the main 
purpose of this study was to analyze whether the induction of GYL is feasible in the treatment 
of leukemia. The question whether the GVL reaction was separable from GVHD was 
emphasized. If GVL seemed inextricably bonnd up with GVHD, it would be attempted to 
define if there is a therapeutical window and how this could be maximally enlarged without 
evoking irreversible GYHD-induced tissue damage. 
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CHAPTER 2 
ANIMAL MODELS 
CHAPTER 2.1 
THE BROWN NORWAY ACUTE MYELOCYTIC LEUKEMIA (BNML); 
ASUMMARY* 
2.1.1 SUMMARY 
The studies in the BNML model have added considerably to the understanding of various 
processes that occur during the development of leukemia, e.g. the interactions of leukemic 
cells and normal hemopoiesis. The methodology developed in the BNML model allows the 
quantification of the relative effectiveness of any given treatment with regard to the 
antileukemic activity compared with the toxicity for normal host tissues, e.g. the bone 
marrow. Furthermore, the comparison of various treatment modalities, employed for 
remission-induction treatment or the conditioning regimen prior to bone marrow 
transplantation (BMT), made it possible to determine the efficacy of the various approaches. 
Obviously. there are restrictions with regard to the extrapolation of the rat data to the human 
disease. Leukemia growth in inbred rats is highly reproducible, while in humans it presents a 
high degree of individual variation, However, several characteristics are shared and the aim 
should be to identify and study the similarities as well as the dissimilarities between human 
and rat leukemia. In that way progress may be envisaged with respect to optimizing the 
treatment for leukemia and finally reaching the goal of curing human leukemia, 
*Most of the data presented have extensively been reviewed in; Hagenbeek A and Martens 
ACM. 'Minimal residual disease in acute leukaemia: preclinical studies ill a relevant rat 
model (BNML) , Bailliere's Clinical Haemalology 1991,4: 609-635; and Marlells ACM, vall 
Bekklllll DIV and Hagellbeek A. 'The BN oelile myelocytic lellkemia (BNML) -a ral model for 
studying humlln acute myelocytic leukemia (AML)-', Leukemia 1990, 4: 241-257. 
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2.1.2 INTRODUCTION 
'Minimal residual disease' (MRD) in leukemia is defined as the relatively low number of 
leukemic cells which have survived successful remission-induction chemotherapy. out of 
sight below the conventional cytological detection level. Obviously, the presence of MRD 
predicts a leukemia relapse at a later stage and therefore todats leukemia research and 
treatment arc focused on developing methods to decrease the detection level of residual 
leukemic cells to immediately continue treatment and on defining strategies to subsequently 
eradicate MRD. 
As much of the questions to be answered arc difficult to approach in human leukemia, 
there is a great need for realistic animal models to translate clinical problems into laboratory 
experiments and to extrapolate new diagnostic and therapeutic tools from models to man. A 
particular animal model should be chosen based upon the specific question to be answered. In 
bone marrow transplantation research. various animal species are employed, such as rodents, 
dogs and subhuman primates. However, if leukemia is the main subject of investigation only 
rodents remain as there are no reproducibly growing (transplantable) leukemias available in 
the larger mammals. 
Apart from investigations in 'spontaneously' arising rodent leukemias, the majority of 
experimental studies are performed in transplantable leukemias. Two imp0l1ant prerequisites 
for evaluating the efficacy of a given treatment are a) a reproducible growth pattern upon 
injection of leukemic cells; and b) a linear relationship between the number of inoculated 
leukemic cells and the survival time. 
2.1.3 THE BN ACUTE MYELOCYTIC LEUKEMIA (BNML) 
In 1974 an acute myelocytic leukemia (AML) transplantable in the inbred Brown Norway rat 
Table 2.1.1 Major characteristics of the BNML 
induced by 9,10~dimelhyl-l,2-benzanthracene (DMBA) 
analogy with human acute (pro)myelocytic leukemia: 
I. cytology- cytochemistry 
2. slow growth rate (107 cells Lv.: death at day 23) 
3. severe suppression of normal hemopoiesis due to nn absolute numerical decrease in normal 
hemopoietic stem cells 
4. diffuse intravascular coagulation (DIe) 
5. response to chemotherapy as in human AML 
6. leukemic c1onogenic cells present 
7. low antigenicity 
8. no virus 
strain (BNML) was developed. The major characteristics of this model have been described 
in detail 1-4 and are sunmlarized in Table 2.1.1. In particular as regards its biology of growth 
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and its sensitivity to chemotherapy, the BNML has now widely been accepted as a relevant 
model for human AML. 
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Figure 2.1.1 Main characteristics of the BNML model; a, promyelocytic nature; b. linear dose-survival 
relationship; c, increase in Iiver- and splcen weight during leukemia progression; d, discriminative splcen 
colony assays to quantify normal hemopoietic stem cells (CFU-S) and cionogenic leukemic cells (LCFU-S); e, 
normal hemopoietic stem cells (HSC) in bone marrow and spleen during leukemia progression; f, detection of 
leukemic cells with a monoclonal antibody and flow cytomelry (1y, lymphocytes; gr, granUlocytes; I, leukemic 
cells). 
The Brown Norway acute myelocytic leukemia (BNML) was classified as an acute pro-
myelocytic leukemia (Figure 2.1.1.a), with signs of diffuse intravascular coagulation as the 
leukemia progresses. The leukemia can be transferred by intraperitoneal (Lp.), subcutaneous 
(s.c.), inlrathecal (i.t.) or intravenous (i.v.), injection of single cell suspensions. The i.p. 
injection of leukemic cells results in the formation of greenish colored colonies of leukemic 
cells in the mesenterium (chloromas), followed eventually by disseminated leukemia growth. 
No ascites fluid is formed. The s.c. transfer of leukemic cells results in the slow development 
of a subcutaneous tumor, followed by scattered outgrowth of the leukemia. The Lp. and s.c. 
transfer of leukemia cells were not investigated in depth, in contrast to the Lt. transfer of 
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leukemic cells 5 which was studied extensively with the purpose of the development of a 
model for central nervous system (eNS) leukemia. 
Most studies, however, were done after intravenolls transfer of leukemia, The survival 
time after Lv. injection of leukemic cells is linearly correlated with the injected cell number 
(Figure 2.1.1.b). After injection, leukemic cells spread to all organs, but they predominantly 
home to the bone marrow, liver and spleen where they start to proliferate6 The ED50, which 
represents the number of cells that is required to induce leukemia in 50% of the animals, was 
found to be 24.7 cells (as deduced from the sigmoid curve, representing the number leukemic 
cells inoculated versus the percentage of rats killed). The leukemic cells are transferred in a 
syngeneic system, Le. the inbred BN rat strain, and were found not to be immunogenic. The 
growth pattern of the leukemia appeared to be highly reproducible. 
The liver and spleen increase in size and weight during the progression of the disease 
(Figure 2. I. I.c). During the development of leukemia the bone marrow is rapidly replaced by 
leukemic blast cells. At this stage leukemic cells are appearing in the peripheral blood leading 
to increased numbers of peripheral white blood cells, predominantly leukemic cells. 
The fate of the pluripotent hemopoietic stem cells during this process has been studied. 
Hemopoietic stem cells are detected by a spleen-colony-assay (SCA) (Figure 2.l.l.d). 
Normal stem cells form colonies on the surface of the spleen and are therefore named colony 
forming unils~spleen (CFU ~S). Lethally irradiated mice or rats are inoculated with bone 
marrow cells; the number of ceHs is chosen such that 5-30 colonies are expected to appear on 
the surface of the recipient spleen 7-14 days after inoculation. Each colony is derived from 
one clonogenic stem cell. The fraction of inoculated hemopoietic stem cells entering the 
spleen was found to be 0.007 (~f-factor). 7 By counting the number of CFU-S and correcting 
for the f-factor, the number of clonogenic stem cells in a cell suspension can be calculated. 
Concurrently, with the replacement of the normal bone marrow, the number of hemopoietic 
stem cells decreases and reaches very low levels during the terminal stage of the disease. 
Simultaneously, the number of stem cells in the spleen and in the peripheral blood increases 
(Figure 2. I. I.e). 
Another important characteristic of the BNML is the c1onogenic property of the leukemic 
cells. The i. v. injection of low leukemic cell numbers (less than 105) into (unirradiated) 
normal recipient rats results in the development of leukemic colonies in the spleen, defined as 
LCFU-S (Ieukemic-colony-forming-unit-spleen). The colonies are clearly visible on the 
spleen surface 19-20 days after injection (Figure 2. 1. l.d). This indicates that normal 
hemopoietic stem cells proliferate approximately twice as fast as clonogenic leukemic cells. 
In analogy to the spleen colony formation of normal stem cells, it is assumed that each colony 
is derived from one clonogenic leukemic cell. The fraction of inoculated leukemic cells 
entering the spleeu, the f-factor, was found to be 0.0027 By multiplying the number of 
LCFU-S with the reciprocal of the f-factor, the number of clonogenic (leukemic) cells in the 
inoculated cell sllspension is derived. Every viable leukemic cell has clonogenic potential,8 
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however, after the l.v. injection, a certain proportion of the cells home to places which are 
unfavorable for leukemic cell growth. This explains the discrepancy between an ED 50 value 
of 24.7 cells and a clonogenic potential of close to 1. 
Finally, the BNML has the advantage that the leukemic cells can be discriminated from 
normal bone marrow cells by the use of a mouse anti-BNML monoclonal antibody (MeA). 
The MeA reacts with an antigen, present in a low density on normal granulocytes and in a 
high density on leukemic blast cells, but which is absent on normal lymphocytes and normal 
blast cells. Flow cytometry enables the specific detection of leukemic cells (Figure 2.1.1.0. 
2.1.4 DETECTION OF BNML 
2.1.4.a Cylology!cylochemislry 
Simple total nucleated cell counting in combination with May-Griinwald-Giemsa staining for 
differential cell counting is sufficient to determine leukemic cell numbers when they are 
present in frequencies between 5 % and 100 %, Cytochemical characterization revealed that 
the leukemic cells were promyelocytes. 
2.1.4.b Tlte organ weighl parameler 
The growth of leukemic cells in liver and spleen results, during the later stages of leukemia 
development, in an increase in the weight of both organs. It was found that 1 gram increase in 
weight corresponds to an increase of 109 cells (schematically shown in Figure 2.1.2). 
Once the organ weight is significantly increased, the leukemic cell number can be deduced 
from it. The spleen increases in weight from about 350 mg to 3-4 g towards the terminal 
stages of leukemia. The liver increases in weight from 6-8 to 20-25 g. To become 
significantly different from the normal background organ weight, the spleen has to be 
increased more than 200 mg (corresponding to 2xlO8 cells). For the liver the increase has to 
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Figure 2.1.2 Measuring the leukemic cell load by increase in spleen and liver weights (one grJnl equals 109 
cells), 
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be at least 1 gram to become evident, corresponding with lxl09 cells. By weighing the 
spleen and the liver the effectiveness of a treatment can be quantified. The method is valuable 
for studying advanced disease. Changes in the tumor load in the range of 5xl08 to 1-2x10IO 
can be studied corresponding to one and a half decade (expressed as 1.5 log). 
2.1.4.c The survival fillle assay 
A morc sensitive method is based on the relation between the survival time and the number of 
injected cells. This is schematically illustrated in Figure 2.1.3. A single cell suspension can be 
prepared from the total content of a femoral bone by flushing the marrow cavity with a 
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Figure 2.1.3 The dose-survival assay for measuring slllall numbers of leukemic cells. 
physiological fluid (e.g. phosphate buffered saline). The total volume of this suspension is 
measured as well as its cell content. A fraction of the total volume is injected Lv. into 
previously untreated recipient rats. If leukemic cells are present in the cell sllspension, the 
animals will eventually die from leukemia. The survival time is recorded. Based on the 
known relation. between the number of leukemic cells injected and the survival time, the 
originally injected leukemic cell content can be deduced. To determine the leukemic cell 
content of any organ, the survival time assay can be used which implies that the total 
leukemic cell content for each organ of choice can be determined at any time. For very low 
numbers of leukemic cells (Le. below 100 cells) the survival times deviate from the straight 
line: i.e., the survival times increase disproportionally.2 However, by using the results from 
the dose-survival curve, the leukemic cell number can be deduced from the percentage of 
animals that develop leukemia. The limits of detection of this dose-survival bioassay spans 8-
9 logs. 
2.1.4.<1 1111111lmophellotypillg 
A monoclonal antibody (MCA) was developed against BNML cells, i.e. Rml24 (Dr. RJ. 
Johnson, Johns Hopkins University, Baltimore, Md, USA), which detects an antigen that is 
present in a high density on leukemic cells, in a low density on normal granulocytes and 
absent on lymphocytes and normal blast cclls9 • to After labeling of cells with the FITC 
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(fluorescein isothiocyanate) conjugated MeA under standard conditions it is possible to 
discriminate between normal and leukemic cells on the basis of fluorescence intensity using a 
flow cytometer. 
BM peripheral blood spleen 
Monoclonal antibodies used 
Figure 2.1.4 Comparison of antigen expression in BM-, peripheral blood- and spleen cells of healthy and 
terminal BNML leukemic rals. Monoclonal antibodies used were specific for: BN class I, RT_1.An (OX-27), 
WAGlRij class I, RT-I.Au (U9F4), class II [Ia), RT-1.B (ER-13), CD5 (OX-19), erythroid cells and 
granulocytes (HIS 48), and BNML (Rm124). 
When bone marrow (EM), splenocytes and peripheral blood samples were taken from healthy 
and terminal stage leukemic animals for immunophenotypic analysis, significant changes in 
percentages of cells reacting with the various antibodies were found. This is a result of 
changes in the cell population-composition, because of BNML infiltration, rather than 
changes in antigen expression itself (Figure 2.1.4). Taking into account that the BM and the 
spleen are highly infiltrated with leukemic cells, figure 2.1.4 indicates that the BNML not 
only specifically binds the MCA Rml24,9 but also attaches to the MCA's specific for BN 
MHC class I (OX-27; RT_I.An)t t and erythroid cells/granulocytes (HIS 48).t2 
Concomitantly, it shows that BNML is negative for WAG/Rij-specific MHC class I (U9F4; 
RT_I.AU),13 class II (ER_I3)14 and CD5 (OX_19).IS,16 
A number of different techniques to detect MRD have been studied in the BNML model as 
well, such as the leukemic colony forming unit assay (LCFU-S), flow karyotyping and 
genetic marking of leukemic cells. These studies will not be discussed here. 
2.1.5 TREATMENT OF MINIMAL RESIDUAL DISEASE 
One of the major problems in today's leukemia treatment employing either allogeneic or 
autologous bone marrow transplantation (BMT) is leukemia relapse. Apparently, leukemic 
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cells have survived high dose conditioning treatment prior to BMT. In case of autologous 
BMT, leukemic cells reinfused with the graft might in addition contribute to leukemia relapse 
afterBMT. 
Table 2.1.2 Efficacy of ablative conditioning regimens prior to BMT in AML 
Bu +TBI 
TBI + Bu 
Cy +TBI 
TBI +Cy 
Cy+Bu 
HDAC + Cy +TBI 
Bu+Cy 
A 
log leukemia 
cell kill (BNML) 
5' 
6 
8-9 
9 - 10** 
10 
>10*** 
>10 
B 
% relapse after allo-BMT 
in first remission human AML 
25 
10 
5 - 10 
8 
A, rat BNML; n, human AML; Cy, cyclophosphamide; TBl, total hody irradiation; Bu, busulphan; HDAC, 
high-dose cytosine arabinoside. 
*70%; **20%; ***25% treatment-related mortality 
Studies in the BNML have contributed to the development of more effective rcmissioll-
induction and maintenance regimens. including anthracyclines, 17,18 AMSA 19 and high-dose 
cytosine arabinoside timed sequential treatment. 20,21 
In addition, in the BNML a variety of high-dose marrow ablative conditioning regimens 
has been studied prior to BMT.22,23 With methods described before, e.g. the survival time 
assay, their efficacy could be evaluated in terms of 'log leukemic cell kill' (LCK). A 
summary of the data obtained so far is given in Table 2.1.2. It is of interest to see that the 
efficacy of the various regimens in the BNML shows an inverse relationship with relapse 
rates in human acute myelocytic leukemia (AML) treated with similar conditioning regimens. 
Obviously I this points at the relevance of the BNML in predicting the outcome of treatment in 
man. 
Furthermore, the BNML has served as the preclinical model to develop the concept of 
eliminating leukemic cells from autologous marrow grafts with in vitro chemotherapy. 24,25 
A major drawback in allogeneic BMT is graft-versus-host disease (GVHD)26 Clinical and 
preclinical data indicate however, that GVHD is associated with a significant graft-versus-
leukemia (GVL) effect which may eradicate the residual leukemic cells27 The intriguing 
question remains whether it will be possible to optimize the beneficial GVL effects without 
increasing the risk of lethal GVHD. 
What is the optimal treatment after patients enter a phase of complete remission (CR; 
number of leukemic cells below detection limits) induced by the remission-induction 
treatment (Figure 2.1.5)? Though cures are induced by the subsequent conditioning regimen 
find BMT, eradicating the minimal residual disease (MRD), 50-60% of patients with AML 
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Figure 2.1.5 Cure after allogeneic bone marrow transplantation: enema-radiotherapy and/or Graft~versus­
Leukemia? GVL, Graft-versus-Leukcmia; BMT, bone marrow transplantation; CR, complete remission; MRD, 
minimal residual disease. 
receiving nil autologous graft in first CR will relapse.28,29 The probability of leukemia relapse 
after allogeneic, HLA-identical sibling transplants for AML in first remission was reported to 
be 7-27%, depending on the occurrence and severity of GVHD29 Post-BMT chemotherapy 
could lead to a further reduction in leukemia relapse rates but may also jeopardize the marrow 
graft. After allogeneic BMT, the GVL effect can contribute to an increase in cure rates by 
eradication of the residual leukemic cells or may suppress their growth and keep the leukemic 
cells in a so called 'dormant state' (Figure 2.1.5). The BNML offers the opportunity to study 
the GVL effect (and GVHD) after syngeneic, allogeneic and semi-allogeneic BMT in a well 
characterized model relevant for human AML. 
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L441S: FURTHER CHARACTERIZATION OF THE RAT MODEL FOR 
HUMAN ACUTE LYMPHOCYTIC LEUKEMIA * 
Ted C. Kloosterman 1, Margret 1. C, Tielemans 1, Anton C. M, Martens 1, Peter M. 
Hoogcrbrugge l.2• Dirk W. van Bckkum l and Anton Hagenbeek l.3 
1 Institute of Applied Radiobiology and Immunology TNO. Rijswijk. 2Dept. of Pediatrics, 
University Hospital, leMen and 3Dept. of Hemalo-Ollco!ogy, The Dr. Daniel den Hoed 
Cancer Center, Rotterdam, The Netherlands 
2.2.1 SUMMARY 
The biological properties of a transplanlable lymphocytic leukemia, L441S in the WAG/Rij 
rat, are described. The radiation-induced L4415 leukemia is characterized as a relatively 
slowly growing, non-immunogenic, immature T-cell leukemia which shows a reproducible 
growth pattern upon intravenolls (Lv.) transfer. Survival time following Lv. inoculation is 
inversely related to the number of leukemic cells in the inoculum, which allows a quantitative 
estimate in terms of log leukemic cell kill of the effect of treatment. The first signs of 
leukemic growth are found in the bone marrow, the spleen and the liver. Leukemic cells can 
be detected in the peripheral blood 13 days after inoculation. Due to replacement of normal 
hemopoietic tissue by leukemic cells and their number increasing exponentially thereafter, 
normal hemopoiesis is inhibited in the later stages of the disease as indicated by severe 
thrombocytopenia and anemia. Death is caused by a combination of splenic rupture, 
gastrointestinal- and pulmonary hemorrhage and impaired functions of heavily infiltrated 
organs. Hepatosplenomegaly and lymphadenopathy are prominent features at autopsy. 
Cyclophosphamide- and radiosensitivity of the clonogenic leukemic cells have been 
determined, a 2.9 log cell kill could be induced by single dose cyclophosphamide inoculation 
and a dosage giving a surviving fraction of 0.37 (Do) of 0.99 Gy with an extrapolation 
number (N) of 8.S were calculated. Based OIl these data the L441S ral leukemia may be 
regarded as a relevant model for human acute lymphocytic leukemia and may thus serve to 
explore new treatment strategies. 
* Leukemia 1992; 6: 1161-1166. 
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2.2.2 INTRODUCTION 
The understanding of normal and pathological processes in the biology of man has benefited 
a great deal from studies of animal models, with the common goal of exploiting the results 
obtained in solving clinical problems. Similarities in characteristics between animal tumors 
and human tumors should serve as selection criteria for an animal model. The majority of 
transplantable leukemias in mice and rats show marked discrepancies with human leukemias. 
It should be noted that passage of a transplantable animal leukemia can be compared with the 
sequence of remissions and relapses in a single patient. In contrast to human leukemia, most 
transplantable leukemias in rodents show a very high proliferation rate. 1-5 As a consequence, 
many models do not show the degree of failure of normal hemopoiesis which is usually 
observed in late stages of human acute leukemia.6,7 
An animal model for human acute myelocytic leukemia (AML), the transplantable 
leukemia in the Brown Norway rat (BNML), has been extensively studied in our institute for 
many years. This leukemia has proven to share a great number of characteristics with those 
found in human AML so that its response to treatment can be employed in testing a variety of 
anti-tumor agents and various treatment modalities for clinical application.' ,8-11 
The L4415 WAG/Rij rat leukemia was introduced as a transplantable lymphocytic 
leukemia in our institute in 1976. 12,13 It was shown that L4415 leukemic cells distribute 
randomly in the femur marrow cavity after intravenous transfer. This is in contrast to 
myelocytic BNML cells which home preferentially near the endosteum of femoral bone 
marrow (BM) before they start dividingI2 intrathecally inoculated lymphocytic L4415 
leukemic cells show in comparison to the myelocytic BNML celis, a more pronounced 
leptomeningeal infiltration, mim.icking the pattern of leptomeningeal int1ltration observed in 
the respective human leukemias. 13 This paper describes the cell popUlation growth kinetics, 
immunophenotyping and the use of the model for chemo- and radiotherapy studies. 
2.2.3 MATERIALS AND METHODS 
Animals 
Inbred male W AGlRij (Wistar Albino Glaxo / Rijswijk) rats at 10-14 weeks of age were used 
(body weight, 200 to 250 g). The rats were bred at the SPF animal breeding facility of our 
institute and housed in plastic cages with water and food pellets ad IibitulII. 
Tlte LA415 rat leukemia 
The IA4151ymphocytic leukemia was induced in our laboratory by total body irradiation of a 
female WAGlRij rat with 0.5 MeV neutrons (dose; 5 cGy). Cytologically this leukemia is 
classified as a lymphocytic leukemia with accumulation of lymphoblasts in the Giemsa stain, 
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which are negative in the Graham Knoll, Sudan Black and Esterase stains, At autopsy. 
leukemic animals show enlarged lymph nodes (LN), thymus, spleen and liver and massively 
infiltrated BM. The major cause of death after inoculation of leukemic cells is significant 
enlargement and rupture of the spleen. The leukemia is ;n vivo passaged through intravenous 
(Lv.) inoculation. A large stock of the third passage has been prepared and stored in liquid 
nitrogen. 
Preparation of leukemic spleen cell suspensions 
Monocellular suspensions were obtained by mincing the enlarged spleens of end-stage 
leukemic animals and gently squeezing through a nylon gauze. The cells were washed and 
suspended in Hanks' buffered balanced salt solution (HBSS; Gibco Paisley, Scotland). The 
number of nucleated cells was counted, adjusted to the final cell concentration required and 
inoculated Lv. in a volume of 1 m1. 
Blood- and bone marrow suspensions 
For hematological follow-up during the experiments, peripheral blood samples were obtained 
by orbital punctures. The blood was collected in small plastic tubes containing ethane-
diamino-tetra-acetic acid (EDTA; British Drugs Houses Ltd., England) to prevent 
coagulation. When white blood cells (WBC) were prepared for immunophenotypic analysis 
the erythrocytes were lysed first (lysing buffer: 0.15 M NH4CI, Merck, Darmstadt; 0.01 M 
NaHC03, Merck; O.lmM EDTA, Merck). Subsequently the suspension was centrifuged, the 
pellet was resuspended in HBSS and the WEC were counted. 
BM cells were isolated by repeated flushing of the cavity of tibiae and femora with HESS. 
A single cell suspension was obtained by sieving the bone marrow through a nylon gauze. 
Cell counting 
BM- and peripheral \VBC were counted in TUrks' solution and erythrocytes in phosphate 
buffered saline (PBS; NPBI, Amsterdam, The Netherlands) in a BUrker hemocytometer. For 
platelet counting, peripheral blood samples were diluted in 'Diluid azide free' (7.83 gil NaCI, 
0.36 gil Na2EDTA, 0.28 gil KCI, 0.26 gil K2HP04, 2.35 gil NaH2P04; J. T. Baker, Deventer, 
The Netherlands) and counted in a Baker Diagnostics platelet analyzer (#810). 
Im11l1l11Ophenotypillg 
Single cell suspensions of BM, splenocytes or peripheral WEC in PBS/BSA (PBS, 1% BSA, 
Sigma, St. Louis, MO, U.S.A.; 0.01% NaN3, Merck, Darmstadt) were labeled with murine 
monoclonal antibodies (MCA's) directed to specific rat cell surface antigens (Table 2.2.1). 
Subsequently the cells were incubated with FITC-conjugated rat-ant i-mouse Ig (Jackson 
Laboratories, Maine, U.S.A.) and analyzed on a FACScall flow cytometer operating with a 
single argon (488 nm.) laser (Becton Dickinson, Mountain View, CA, USA). For data 
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analysis, the FACScan research software program Consort 30 (Becton Dickinson) was uficd, 
Specificity, origin and reference number of the MeNs used arc listed in Table 2.2.1. The OX-
814,15, OX_19 16,17 and OX-2718 hybridoma cell lines were kindly 
Table 2.2.1 Specificity of the Monoclonal Antibodies Used. 
MCA Specificity References 
OX-27 class I, BN rat (RT-l ,All) Jefferies et al,I8 
U9F4 class I, WAGlRij rat (RT-I ,Au) Stetetal. 21 
ER-13 class II, [Inl CRT-I.B) Stet et af.2O 
OX-19 CDS Mason el al. 16; Dallman et al. 17 
ER-2 CD4 Thomas et al,l9 
OX-S CD8 Barclay et af. 14; Brideau et al 15 
donaled by Dr. A. Williams (Oxford, U.K.). Hybridoma cell lines secreting MCA's ER_2 t9, 
ER_1320 and U9F42t were a generous gift of Dr. J. Rozing (IVVO-TNO, Leiden, The 
Netherlands), The Mark-l hybridoma was obtained from the American Type Culture 
Collection (Rockville, M.D.). All antibodies were produced intraperitoneally (Lp.) in BALB/c 
mice and purified over a protein A column (Dr. P. H. van def Meide, Dept. of Chronic 
Diseases, MBL-TNO, Rijswijk, The Netherlands). 
Growth characteristics 
Rats were inoculated with graded numbers of L4415 cells (Lv.) to define the correlation 
between leukemic cell dose and survival time. In treatment-efficacy experiments rats were 
given a fixed dose of leukemic cells, each group consisted of 8 rats." Every two or three days 
after injecting 106 L4415 cells, blood samples were taken and three rats were sacrificed and 
examined. Changes in peripheral blood cell counts, spleen- and liver weight and the size of 
other organs were recorded. 
Chemo- and radiotherapy 
Graded doses of cyclophosphamide (Cy; ASTA, Weesp, The Netherlands) were given ]0 
days after inoculation of ]06 L4415 cells. Cy was dissolved in 0.9% NaCI (NPBI, The 
Netherlands) and injected Lp. in a volume of about I ml. 
Total body irradiation (TBI), doses ranging from 0.0 Gy to 8.0 Gy, followed by syngeneic 
bone marrow transplantation (BMT) were given 10 days after injection of 106 L4415 
leukemia cells. The rats were irradiated unilateral in plastic cages, containing 8 animals at the 
same time, using a Philips X-ray generator (300 kV, 10 mAl at a dose rate of 48 cGy.min- t . 
Subsequent inoculation of 108 syngeneic BM cells Lv. was done on the same day. 
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Survival time assay 
This assay is based on the linear correlation between the number of leukemic cells inoculated 
and the survival time of the rats. 9-1 1 The anti-leukemic effect of the treatment used can be 
deduced from the increase of life span (ILS) compared to untreated leukemic control animals. 
The treatment inducing an ILS of 3.6 days corresponds with the survival time of animals 
given a 10-fold lower tumor load and is referred to as a I log cell kill (LCK). 
2.2.4 RESULTS 
2.2.4.a Growlh characteristics 
After inoculation of graded numbers (102 - 106) of L4415 cells in W AGlRij recipient rats, an 
inverse linear relationship was observed between the number of injected leukemic cells and 
the survival time (Figure 2.2.1). One log cell number corresponds with 3.6 days survival time. 
The median survival time in WAGfRij rats after 106 L4415 cell inoculation (i.v.) was 18 
days. All animals died of splenic rupture or severe pulmonary hemorrhage. At autopsy 
grossly enlarged liver, spleen, thymus and lymph nodes (LN) were found. Femoral bone 
marrow, normally dark red, turned yellowish-pink as a result of massive infiltration by 
leukemic lymphoblasts. 
40 
R2 = 0.994 
Number of L4415 cells Lv. 
Figure 2.2.1 Correlation between L4415 leukemic cell dose (Lv.) and survival time (11=8 rats per point). 
Logarithmic regression analysis results in a correlation coefficient of variation of 0.994 (R2). Vertical bars 
indicate S,B. 
Thirteen days after inoculation of 106 L4415 cells in male rats, the first changes in the 
recipient caused by leukemic cell proliferation were noticed. Thymus-, LN- (data not shown) 
and more conspicuously, liver- and spleen size increase. At the terminal stage, the spleen 
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even reaches 10 fold its original weight; liver weight increases from 10 to 20 grams (Figure 
2.2.2). 
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Figure 2.2.2 Increase in spleen and Ii\'er weight at various time points uncr inoculation of 106 L4415 cells Lv. 
(n=3 rats per point). Vertical bars indicate S.B. 
Reduced normal hemopoiesis caused by infiltration and proliferation oflcukemic cells in the 
BM cavity, results in severe thrombocytopenia from day 13 (Figure 2.2.3). As a consequence, 
pulmonary- and gastrointestinal hemorrhage are frequently found 
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Figure 2.2,3 Changes in peripheral WBC, platelet and erythrocyte counts at various time points after 
inoculation of 106 L4415 cells Lv. (n=3 rats per point), Vertical bars indicate S.E. 
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and the animals suffer from severe anemia. At the same time a sharp increase in the number 
of peripheral WBC is observed, mainly consisting of leukemic Iymphoblasts. 
2.2.4.h Immullophenotyping 
When BM, splenocytes and peripheral blood samples were taken from healthy and terminal 
stage leukemic animals for immullophenotypic analysis, remarkable changes in percentages 
of cells reacting with the various antibodies were found. This is a result of changes in the cell 
population-composition, because of L4415 infiltration, rather than changes in antigen 
expression itself. In the BM a shift of CD5 positive cells from 7.7 % in normal rats to 72.0 % 
in full blown leukemic animals was striking (Table 2.2.1; reacting with antibody OX_19 t6,17). 
Splenocytes and WBe of leukemic animals show a strong decrease in cells expressing class 
II, CD4 and CDS antigens (MCA ER_1320, ER_2t9 and OX_S t4,15, respectively) whereas an 
increase in CDS positive cells was observed (Figure 2.2.4), These three compartments are 
apparently heavily infiltrated with L4415 cells. Additionally, leukemic cells show a high 
expression ofWAGlRij rat-specific MHC class I (RT-l.A", MCA U9F4 21) and, as a control, 
no expression of BN rat-specific MHC class I (RT-l.An, MCA OX-27 18) antigens. Based on 
these data the L4415 can be classified as an acute leukemia originating from immature T-
cells. 
100 
8M peripheral blood spleen 
Monoclonal antibodies used 
Figure 2.2.4 Monoclonal antibody (MCA) reactivity in BM-, peripheral blood- and spleen cells of healthy and 
terminal L4415leukemic rats. MCA's used were specific for: BN class I, RT-1.An (OX-27), WAG/Rij class I, 
RT- LA II (U9P4), class IIlla], RT- LB (ER- 13), CDS (OX- t9), CD4 (ER-2) and CDS (OX-8; see Table 2.2. I). 
2.2.4.c Chemo- and radiotherapy 
Ten days after inoculation of 106 L4415 cells, rats were treated either with graded doses of 
Cy or with increasing doses of TBI followed by syngeneic BMT to investigate the in vivo 
cherno- and radiosensitivity of this lymphocytic leukemia. 
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Figure 2.2.5 In vivo sensitivity of L4415 leukemia to increasing doses of A: cyclophosphamide (Lp.) and B: x~ 
rays (TBI) followed by syngeneic BMT (108 cells Lv.). n=16 rats per point. Do is the dosage resulting in a 
surviving fraction of 0.37, N is the extrapolation number of the linear curve with the Y-axis. Single dose 
treatment was given 10 days after inoculation of 106 L4415 (Lv.). Survival time was translated into the 
surviving fraction ofL4415 cells (see text). Vertical bars indicate S,B. 
At relatively low dose Cy therapy, a strong anti-L44lS effect was observed which 
increased up to a dose of 100 mg Cy per kg body weight where a plateau was reached (Figure 
2.2.SA). From the increase of life span (ILS), it could be calculated that up to 6 logs of 
leukemic cells could be killed with a single injection of Cy. 
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TBI in the low dose range ('; 2.0 Gy) did not result in an ILS compared to unirradiated 
leukemic animals. Higher doses of X-rays (> 2.0 Gy) resulted in an antileukemic effect; a 2.9 
LCK was found when the leukemic recipients were exposed to 8.0 Gy (Figure 2.2.SB). As 
characteristics of the radiosensitivity of the L4415 leukemia, the dosage giving a surviving 
fraction of 0.37 (Do) was calculated to be 0.99 Gy with an extrapolation number (N) of 8.5. 
The single therapy regimens used did not result in treatment-related mortality. 
2.2.5 DISCUSSION 
A transplantable rat leukemia is presented which may serve as a relevant model for human 
ALL. 
Immunophenotyping of the BM, spleen and peripheral WBe of terminal leukemic 
W AGlRij rats shows that, taken into account that the BM and the spleen of the full blown 
leukemic animals consist of very few cells other than leukemic cells, L441S leukemia is 
characterized phenotypically as CDS+, CD4- and CD8-. Leukemic blast cells in the Giemsa 
stain are negative in the Graham Knoll, Sudan Black and Esterase stains,12 Taken together, 
the L4415 leukemia can be characterized as an acute lymphocytic leukemia of the immature 
T-cell type. 
After inoculation, the first signs of leukemia are found in the BM and the spleen which 
presumably are the organs where the L4415 cells lodge initially. Ten days after injection, 
changes in the spleen- and liver weight are observed. The enlargement of the spleen is often 
leading to spleen rupture. Assuming that the number of normal spleen and liver cells does not 
change significantly, this increase in weight is due to infiltration and rapid proliferation of 
leukemic cells.ID,lt Leukem.ic ceJIs rapidly proliferate and accumulate in the BM and as a 
consequence normal hemopoiesis is suppressed leading to severe thrombocytopenia and 
anemia. At the same time, drastic changes are observed in the peripheral blood, i.e. a rapid 
increase in peripheral WEC numbers. Most LN and the thymus are also enlarged to a great 
extend by massive infiltration with leukemic cells (data not shown). 
During the experiments reported here, no clinical signs of central nervous system (CNS) 
involvement are observed. However, from previous studies it appeared that after Lv. injection 
of L4415, clusters of leukemic cells were seen in the ventricles, Virchow-Robin spaces and 
pia mater in 23, 69 and 92 percent of the rats, respectively. In the spinal cord, epidural and 
subarachnoidal infiltration occurred in 100 and 36 percent of the animals respectively.13 
Apparently the animals die from systemic leukemia prior to the time that the deposits of the 
leukemia in the eNS cause neurological symptoms. 
Death is due to a combination of several factors. Severely depressed hemopoiesis quickly 
leads to severe thrombocytopenia and as a consequence bleeding occurs at various sites 
(gastrointestinal tract, respiratory tract, etc.). The infiltrated lungs often present serious 
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problems with respect to cardiovascular function and the massively infiltrated liver quite 
likely has an impaired fUIlCtiOll. Thus bleeding, spleen rupture and severely impaired organ 
functions are the main causes of death of the leukemic animals. 
After repeated inoculations of ill vitro lethally irradiated (20 Gy) lA415 cells into normal 
W AGlRij rats (Lp.), no beneficial effect is observed when these rats are challenged thereafter 
with viable leukemic cells compared to previously untreated control animals (data not 
shown), Thus unlike many virally induced leukemias the LA415 is non-immunogenic as is the 
Case for most human leukemias. 
In this study an inverse linear relationship was found between the log number of L4415 
leukemia cells inoculated and the survival time of the W AGlRij recipients. A reduction of 1 
log in leukemic cell dose results in a 3.6 days ILS. This relationship forms the basis for 
evaluating the efficacy of a variety of anti-ALL therapies to be tested in this model. 
Cyc1ophosphamJde and total body irradiation are included in most conditioning regimens 
for BMT in the treatment of leukemia. To study the chemo- and radiosensitivity of L4415 ill 
vivo, Cy or TBI were given to animals ten days after inoculation of 106 L4415 cells. 
Increasing doses of Cy result in increasing antileukemic effects with a maximum of 6 LCK 
when 100 mg per kg body weight is given. At this dose a plateau phase is reached which is 
uncommon for nlkylating drugs. So far, an explanation is lacking. Chemotherapeutical 
sanctuaries (e.g. the central nervous system) may contain leukemic ceUs which subsequently 
cause a relapse. TBI was followed by syngeneic BMT to prevent marrow aplasia. Low doses 
of X-rays ('; 2.0 Gy) seem to have no anti-lA415 effect, the survival time of the recipients 
remaining the same. The higher dose range ofTEI (> 2.0 Gy) results in a decreased surviving 
fraction of leukemic cells with a 2.9 LCK after the highest TBI dose studied, i.e. 8.0 Gy. As 
characteristics of the radiosensitivity of the L4415 leukemia, a Do of 0.99 Gy (dosage 
resulting in a surviving fraction of 0.37) with an extrapolation number of 8.5 were calculated. 
Based on the data reported on L4415 lymphocytic leukemia in this article 
(hepatosplenomegaly, lymphadenopathy, significantly reduced normal hemopoiesis, non-
immunogenicity and the cyclophosphamide- and radiosensitivity) and the previous findings 
on the distribution of the L4415 cells in the femoral bone marrow l2 and the pattern of 
leptomeningeal infiltration 13, the L4415 acute lymphocytic leukemia growing in the 
W AG/Rij rat has a number of characteristics in common with human ALL and may be 
regarded as a relevant pre-clinical model. Studies on different treatment modalities (e.g. 
chemo- and radiotherapy, interleukin-2 treatment and BMT, including 'graft-versus-
leukemia ') are currently being performed. 22 
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CHAPTER 3 
QUANTITATIVE STUDIES ON GRAFT-VERSUS-LEUKEMIA AFTER 
ALLOGENEIC BONE MARROW TRANSPLANTATION IN RAT MODELS FOR 
ACUTE MYELOCYTIC AND LYMPHOCYTIC LEUKEMIA * 
Ted C. Kloosterman I, Margret J.e. Tielemans l , Anton C.M. Martensl , 
Dirk W. van Bekkum l and Anton Hagenbeek l ,2 
ill1stitute of Hematology, Erasmus University Rotterdam, 2 Dept. of Hematology, 
The Dr. Dantel dell Hoed Cancer Center, Rotterdam, The Netherlands. 
3.1 SUMMARY 
The major shortcoming of present day treatment of in leukemia treatment with bone marrow 
transplantation (BMT) remains the relapse of leukemia, It has become clear that a graft-
versus-host reaction (GVHR) is accompanied by a graft-versus-leukemia reaction (GYLR) 
which may prevent a leukemia relapse. In two non-immunogenic rat leukemia models, Le. the 
Brown Norway acute myelocytic leukemia (BNML) and the W AG/Rij acute lymphocytic 
leukemia L4415, total body irradiation (TBI) was given to induce 'minimal residual disease' 
(MRD). Subsequently, it was attempted to evoke a GVLR by using syngeneic- or allogeneic 
BMT, with or without addition of graded numbers of lymphocytes. In both leukemia models 
the addition of high numbers of syngeneic lymphocytes to the syngeneic graft had no 
antileukemic effect. Allogeneic marrow grafts. which contain at the most 8% lymphocytes, 
only resulted in a GVLR when splenocytes were added, The therapeutic window was found to 
be narrow, i.e. in fully mismatched BMT the number of allogeneic splenocytes resulting in a 
significant GVLR (2-3 log leukemic cell kill) without inducing (lethal) acute GVHD was 
critical. Increasing the number of allogeneic spleen cells added to the allogeneic BM-graft 
induces lethal acute GVHD. Depletion of lymphocyte subsets showed that both CD4 and 
CDS positive cells are involved in the induction of GVHD. To date, our data indicate that the 
GVLR is an allogeneic effect, inseparable from GVHD. 
* BOlle Marrow Transp/alllalioJl1994; 14: 15-22, and lymphocyte sub,vel depletioll data. 
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3.2 INTRODUCTION 
Allogeneic BMT is being used with increasing frequency in the trcatment of patients with 
hematological disorders such as leukemia. 1 The success of BMT is limited by post-
transplantation complications. including GVHD and leukemia relapse. The intensity and 
incidence of GVHD is dependent on the extend of genetic disparity (major and minor 
histocompatibility complex antigens) between the donor and host2 ,3 as well as the quantity 
and quality of the lymphocytes present in the bone marrow (BM) graft.4 
Studies using animal models have shown that allogeneic T-cells in allogeneic BMT, which 
are the major contributors to GVHD,5 are held responsible for a reduction in the incidence of 
leukemia relapse compared with isologous/autologous BMT by inducing a graft-versus-
leukemia reaction (GVLR).6.7 Clinical data show that T-cell depletion (TCD) of allogeneic 
donor BM decreases the incidence of both acute and chronic GVHD but at the same time 
significantly increases the rate of leukemia relapse.8,9 Likewise, in a few cases the GVLR 
was shown to be abrogated by post-BMT GVHD prophylactic immuno-suppression 
(CsA).IO·t I The discontinuation of CsA at first signs of leukemia relapse induced complete 
hematologic and cytogenetic remission and these patients remain free of disease with a long 
follow up. Clearly, GVHD seems to be associated with the GVLR which eradicates the 
residual leukemic cells. Whether it will be possible to optimize the beneficial GVLR without 
increasing the risk of lethal GYHD remains to be seen. 
In some animal models, the GVLR can be separated from the GVHD reactivity l2,13 
leading to the speCUlation that GVL and GVH reactive cells are distinct. These preclinical 
data support the assumption that specific antigens are present on leukemic cells not shared by 
normal cells of the host. However, no leukemia-associated specific surface markers have been 
identified so far on human leukemic cells. Alternatively, the same cells may mediate both 
GVL and GVH reactions but quantitative differences in sensitivity of leukemic and normal 
cells could account for apparently distinct GVLlGVH reactions, inducing a 'threshold' effect. 
So far, no convincing clinical evidence has been reported on a GVLR separable from GVHD. 
To study GVL in animal models relevant to human leukemia, the experiments reported 
here were performed using the acute myelocytic leukemia (AML) growing in the inbred 
Brown Norway rat strain (BNML)14-16 and the L4415 acute lymphocytic leukemia (ALL) 
growing in the inbred WAGlRij rat strain. 17,18 Both leu'kemia models show a reproducible 
growth pattern after intravenous (Lv.) transfer. Survival time following Lv. inoculation is 
inversely related to the logarithm of the number of leukemic cells in the inoculum. This log-
linear relationship between leukemic cell load and survival time allows an estimation of the 
treatment-induced antileukemic effect, in terms of log leukemic eell kill (LCK), by recording 
prolongation of survival. Thus, these rat models offer the opportunity to compare the 
antileukemic effects of syngeneic and (fully mismatched) allogeneic BMT in the treatment of 
AML and ALL. Through the addition of graded numbers of spleen cells to the BM graft, Ihe 
64 
___________________ Qual/titative studies 011 GVL after BMT 
induction of various degrees of GVLR andlor GVHD and the feasibility of their separation 
were studied, 
3.3 MATERIALS AND METHODS 
Animals 
Inbred male BN, W AG/Rij (Wistar Albino Glaxo I Rijswijk) and PVG rats at 10-14 weeks of 
age (body weight: 200 - 250 g) were used in the experiments described. The rats were bred at 
the SPF animal breeding facility of our institute and housed in plastic cages with water and 
food pellets ad Ubitlllll. 
The BNML lIIodel 
The non-immunogenic BNML leukemia was induced in a female BN rat by 9,10-dimethyl-
1,2-benzanthracene (DMBA). It shows a slow, reproducible growth pattern upon i.v. cellular 
transfer within the BN strain and shares many characteristics with human acute (pro-) 
myelocytic leukemia: severe suppression of normal hemopoiesis, no specific leukemia-
associated antigens present, diffuse intravascular coagulation, response to chemotherapy, 
presence of cionogenic leukemic cells (in vitro and ill vivo; EDSO = 25 cells) and no evidence 
for a virus as an etiological agent. The leukemia is passaged by intravenolls (Lv.) cellular 
transplantation. The rat leukemia model for human AML has been described extensively. 14-16 
The L4415 lIIodel 
The L4415 lymphocytic leukemia was induced in a female W AG/Rij rat that received 5 cGy 
total body neutron irradiation (0.5 MeV). Immunophenotyping has shown that the relatively 
slowly growing, non-immunogenic L4415 is an immature T-cell leukemia (CD 4-, CD 8-, CD 
5+). The L4415 leukemia is passaged in vivo through (Lv.) cellular transfer, showing a 
reproducible growth pattern. L4415 leukemia has been described in detail before. 17 ,18 
Preparation of leukemia 01' normal spleen cell sllspensions 
Monocellular suspensions were obtained by mincing the spleens of end-stage leukemic or 
untreated animals and gently squeezing the suspension through nylon gauze. The cells were 
washed and suspended in Hanks' balanced salt solution (HBSS; Gibco Paisley. Scotland). The 
number of nucleated ceBs was counted and adjusted to the required cell concentration. 
Blood- (lnd bone marrow cell suspensions 
Peripheral blood (PB) samples were obtained by orbital punctures. The blood was collected in 
small plastic tubes containing ethane-diamino-tetra-acetic acid (EDT A; British Drugs Houses 
Ltd., UK) to prevent coagulation. When white blood cells (WBC) were prepared for 
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inmlllnophenotypic analysis the erythrocytes were lysed first (lysing buffer: 0.15 M NH4CI, 
Merck, Darmstadt; 0.01 M NaHC03, Merck; 0.1 mM EDTA, Merck). The suspension was 
then centrifnged, the pellet resnspended in HBSS and WBC counted. BM cells were isolated 
by repeated flushing of the cavity of tibhlC and femora with HBSS. A single cell suspension 
was obtained by sieving the BM through nylon gauze. Subsequently the cells were washed, 
counted and the ceH concentration adjusted. 
Cell cOIllltillg 
Nucleated cells were counted in Turks' solution and erythrocytes in phosphate buffered saline 
(PBS; NPBI, Amsterdam, The Netherlands) in a BUrker hemocytometer. For platelet 
counting, peripheral blood samples were diluted in 'Diluid azide free' (7.83 gil NaCI, 0.36 gil 
Na2EDTA, 0.28 gil KCI, 0.26 gil K2HP04, 2.35 gil NaH2P04; J. T. Baker, Deventer, The 
Netherlands) and counted in a Baker Diagnostics platelet analyzer. 
Total body irradiation 
Lethal total body irradiation (TBI, 8.5 Gy) was given 7 days after injection of 105 leukemia 
cells. The rats were irradiated unilaterally in plastic cages, containing eight animals at a time, 
using a Philips X-ray generator (300 kV, 10 rnA) at a dose rate of 48 cGy.min- l. Inoculation 
of 108 BM cells i.v. (BMT) +1- spleen cells was done the next day. 
11111nWlophcllOtypbig 
Single cell suspensions of splenocytes, BM cells or peripheral WBC in PBS/BSA (PBS, 
NPBI, Amsterdam, The Netherlands; 1% BSA, Sigma, St. Louis, MO, U.S.A.; 0.01 % NaN3, 
Merck, Darmstadt) were labeled with murine monoclonal antibodies (MCA's) directed to 
specific rat cell surface antigens (Table 3.1), or incubated with PBS/BSA serving as negative 
controls. Subsequently, the cells were incubated with FITC-conjugated rat anti-mouse Ig 
(Jackson Laboratories, Maine, U.S.A.) and analyzed on a FACScan flow cytometer operating 
with a single argon (488 nm) laser (Becton Dickinson, Mountain View, CA, USA). For data 
analysis, the FACScan research software program Consort 30 (Becton Dickinson) was used. 
The U9F4 and all OX hybridoma cell lines were kindly donated by Dr. D. Mason (Oxford, 
UK). Hybridoma cell lines secreting MCA's ER-2 and ER-13 were a generous gift of Dr. J. 
Rozing (IVVO-TNO, Leiden, The Netherlands). All antibodies were produced 
intraperitoneally (Lp.) in BALB/c mice and purified on a protein A column (Dr. P. H. van der 
Meide, Department of Chronic Diseases, MBL-TNO, Rijswijk, The Netherlands). 
Survival time assay 
This assay is based on the log-linear relation between the number of leukemia cells inoculated 
and the survival time of the rats. 15,16,18 The anti-leukemic effect of the treatment used can be 
calculated from the increase of life span (lLS) compared to untreated leukemic control 
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animals. An ILS of 4.0 days for the BNML and of 3.6 days for the L4415 model, equals a I 
log leukemic cell kill (LCK). 
Bioassay for residua/leukemia 
To detect residual leukemic cells in animals dying of acute GVHD, BM and/or spleen cell 
suspensions were prepared and lOS cells were inoculated in the tail vein (i.v.) of normal, 
syngeneic recipient rats. The proportion of leukemic cells in the inoculum can be derived 
from the survival time of the secondary recipients. As shown before, this assay allows the 
detection of very low numbers of residual leukemia cells (10-100) in the inoculum. 15.16 
Lymphocyte subset depletion 
To study the role of CD4 and CDS positive lymphocytes in the development of GVL and/or 
GVHD, these lymphocyte subsets were depleted from the spleen cell suspension added to the 
allogeneic marrow graft using MCA's (OX-19, ER-2 and OX-IS; Table 3.1, sectlon 3.4.5) 
and magnetic beads (Dynal@, Oslo, Norway). The Dynabeads® (M-4S0 sheep anti-mouse 
IgG) were coated with purified sheep polyclonal immunoglobulins (Ig) binding to all mouse 
immunoglobulins of the G subclasses (IgG), thus binding to the murine (IgG) MCA's used. 
Before use, the beads were washed in a large volume of PBS/BSA (PBS, NPBI; 1% BSA, 
Sigma; 0.01 % NaN3, Merck) and isolated using the magnetic particle concentrator (Dynal 
MPC®-6; 6 strong magnets). Subsequently, the beads were coated with the lymphocyte 
subset-specific MCA by adding 20 fig MCA to I mg of beads and incubated overnight at4°C 
oIl a rotating device. After two wash steps, removing the free MeA, the beads were added to 
single cell suspensions of splenocytes in a bead to CD4+ or CDS+ cell ratio of 10:1. The bead-
cell mix was incubated rotating for 1 hat 4°C. The CD4 or CD8 negative splcnocytes were 
isolated using the magnet and by removing the 'supernatant'. The depletion efficacy was 
verified by double staining and FACS analysis. 
Statistical Analysis 
Survival time analysis of rats from the different experimental groups was performed 
according to Peto ef al. t9,2D 
3.4 RESULTS 
3.4.1 SYllgelleic BMT ill the BNML model 
Seven days after inoculation of 105 BNML cells (Lv.), BN recipients were subjected to lethal 
total body irradiation (TBI: S.5 Gy, X-rays), and subsequently rescued with syngeneic BM 24 
hours later. The resulting increase in life span (ILS) compared with the leukemia-control 
group reflects the significant (1' = 0.001) anti-leukemic efficacy of the irradiation. TBI 
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induced a median ILS of 10 days reflecting a 2.5 log leukemic cell kill (LCK; Figure 3.1), 
with all rats finally dying from leukemia relapse. To estimate the residual leukemic cell load 
at the time of BMT, the survival time after the irradiation was monitored. The syngeneic 
BMT group survived 38.5 days post-TEl, indicating 103 leukemic cells survived (according 
to standard BNML growth curves), meeting the criteria for 'minimal residual disease' 
(MRD)15,16 
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Figure 3.1 BNML model studies: Survival curves of leukemic animals treated wilh syngeneic BMT +/-
splenocytes verslls the leukemia control group (1/ ::::8 rats per group), The rats were inoculated with 105 BNML 
cells (Lv.) 011 day 0, subjected to TDl (8.5 Gy X-rays) on day 7 and given syngeneic marrow ± splenocytes on 
day 8. All transplanted animals died of leukemia relapse; ( ) 105 BNML i.v.; ( ) + 
syngeneic BMT; ( ________ ,) + syngeneic BMT + 108 splenocytes. 
To evaluate whether syngeneic lymphocytes exert a possible anti-leukemic effect, 108 
syngeneic splenocytes were added to the syngeneic bone marrow graft since rat BM contains 
few T lymphocytes (5-8% positive staining on incubation with a CD 5 specific monoclonal 
antibody; Table 3.1) compared with human-BM (20-30%). This high number of lymphocytes 
did not result in differences in survival (or: time of death from leukemia relapse; Figure 3.1; P 
;:: not significant). 
3.4.2 SYllgelleic BMT illihe 1A41S lIIodel 
L4415 cells (l05) were inocula1ed at day 0 and subsequently TBI (8.5 Gy, X-rays) and 
syngeneic BMT (108 BM cells i. v.) were performed at day 7 and 8, respectively. TBI yielded 
a significant lLS (p = 0.001) correlating with 4.4 LCK (16 days median lLS: Figure 3.2). The 
median survival time of the rats receiving a syngeneic graft was 27 days post-TBI, indicating 
a residual leukemic cell burden of 103 cells (MRD). 
Addition of 108 W AGlRij splenocytes to the syngeneic BM inoculum did not influence 
the survival time compared with the transplantation of syngeneic BM alone (data not shown). 
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Thus, similar to the observation in the BNML model, no GVLR was observed in the rat ALL 
model in the syngeneic situation. 
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Figure 3.2 L4415 model studies: Survival curves of leukemic animals treated with allogeneic BMT +/-
splenocytes ~'ersflS the syngeneic BMT- and leukemia control groups (11 :::8 rats pcr group), The rats were 
inoculated with 105 L4415 cells (Lv.) on day 0, subjected to TBI (8.5 Gy X-rays) on day 7 and given syngeneic 
or allogeneic marrow ± splenocytes on day 8. All transplanted animals died of leukemia relapse but for the 
groups receiving 107 and 108 splenocytes; +107 : Three rats died of leukemia relapse, the five recipients with 
prolonged survival showed severe GVHD morbidity combined with hepalo-splenomegaly; +108 : All rats died 
of acute GVHD; ( ) 105 L44 15 Lv.; ( ) + syngeneic BMT; ( .....••••• .) + allogeneic BMT; 
( _____ ) + allogeneic BMT + 106 splenocytes; (_._._._._ .. ) + allogeneic BMT + 107 splenocytes; 
( •••••••• •• ,) + allogeneic BMT + 108 splenocytes. 
3,4,3 Allogelleic BMT illihe BNML model 
The WAG/Rij rat (RT-l.AU) was used for allogeneic BMT in the BNML model as a fully 
mismatched donor for the BN rat (RT-l.An). Recipient rats were injected with 105 BNML 
cells and irradiated at day 7 to induce a state of MRD. At day 8, syngeneic BMT or allogeneic 
BMT with or without graded numbers of allogeneic spJenocytes was given. Increasing 
numbers of allogeneic spleen cells were added to the allogeneic marrow graft to simulate the 
higher lymphocyte content in human, non T-cell-depleted) allogeneic marrow. The survival 
times of the syngeneic and allogeneic BMT groups were similar, indicating no additional 
antileukemic effect of the allogeneic BM graft (Figure 3.3). All rats died from leukemia 
relapse in the syngeneic BMT group. After allogeneic BMT one rat (out of eight) died from 
treatment-induced toxicity. 
Addition of 105 allogeneic splenocytes to the allogeneic BM graft resulted in an increase 
in the median survival time of the recipients of II days (2.8 LCK) compared with the 
syngeneic and al10geneic marrow only transplanted groups. AI1 rats died from leukemia 
relapse indicating a significant (p = 0.05) GVLR without the induction of acute lethal GVHD, 
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When higher numbers of allogeneic splcnocytcs were added to the allogeneic BM graft, 
Le. 106 splenocytes. this led to a reduction in the median survival time compared with the 
group receiving 105 allogeneic splenocytes and severe GVH-morbidity in five out of eight 
rats (Figure 3.3). At autopsy, these five animals showed signs of leukemia (hepato-
splenomegaly) and of GVHD (erythema, hair loss and diarrhea) both of which may have 
contributed to their death. Three rats died of leukemia without macroscopic signs of GVHD. 
The increase in survival compared with the syngeneic and allogeneic marrow only 
transplanted groups was not significant (NS). 
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Figure 3.3 BNML model studies: Survival curves of leukemic animals treated with allogeneic BMT +/-
splenocytes l'ersus the syngeneic BMT and leukemia control groups (11 =8 rats per group), The rats were 
inoculated with 105 BNML cells (Lv.) on day 0, subjected to TBI (8.5 Gy X-rays) on day 7 and given syngeneic 
or allogeneic marrow ± splenocytes on day 8. All transplanted animals died of leukemia relapse but for the 
group receiving 107 splenocytcs, ailihese rals died of acute GVHD; ( ) 105 BNML Lv.; ( ) 
+ syngeneic BMT; (_. __ .... _ .. ) + allogeneic BMT; ( _____ ) + allogeneic BMT + 105 splenocyles; 
(_._._._._ .. ) + allogeneic BMT + 106 splenocytes; ( .......... ,) + allogeneic BMT + 107 splenocytes. 
When 107 allogeneic splenocytes were added to the allogeneic marrow, all animals died of 
acute GVHD (Figure 3.3) without any macroscopic evidence of leukemia at autopsy. Six (of 
eight) rats died from acute GVHD whereas two animals showed a prolonged survival (death 
at days 49 and 67). They died from protracted GVHD. 
3.4.4 Allogelleic BMT illllze LA415 model 
After an initial inoculum of 105 L44lS cells, TBI (8.5 Gy) at day 7 induced MRD. 
Subsequent inoculation of allogeneic PVG rat (RT·l.AC) BM (l08 BM cells Lv. at day 8) 
caused a small ILS (3 days=0.8 LCK; p = NS) compared with syngeneic BMT. The addition 
of increasing numbers of PVG-splenocytes resulted in increasing antileukemic effects (Figure 
3.2). The 'maximum' GVLR (3.3 LCK, Le. 12 days median ILS compared with the syngeneic 
BMT group) was induced with 106 allogeneic spleen cells, leukemia relapse was the only 
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obvious cause of death. Therefore, as in the BNML model, a significant (I' = 0.003) GVLR 
could be induced without causing obvious GVHD. 
Addition of 107 splenocytes caused a more prolonged mediau survival time (22 days 
median ILS compared with syngeneic BMT=6.1 LCK (I' = 0.002)), but at the same time 
severe GVH-morbidity in the five rats dying at days 56 and 57 (Figure 3.2). At autopsy, these 
animals showed signs of both leukemia (hepatosplenomegaly) and GVHD (erythema, hair 
loss and diarrhea). The three rats dyiug at days 44, 45 and 48 showed no signs of GVHD and 
died of leukemia relapse. 
Finally, 108 PVG-splenocytes were added to the allogeneic BM graft resulting in a 100% 
incidence of lethal acute GVHD with a median survival time of 23 days after the time 
allogeneic BMT was applied (Figure 3.2). At autopsy there were no signs of recurrent 
leukemia. 
3.4.5 IlIIlIlrmoplzellotypillg 
To study the expression of class I and class II antigens and T-cell (sub)popuJations in normal 
rats, MCA's OX-27 (class I: RT-I.An),21 U9F4 (class I: RT_I.AU),22 ER-13 (class II: RT-
I.B),23 OX-19 (CD5),24 ER-2 (CD4)25 and OX-8 (CD8)26 were used (Table 3.1). 
Table 3.1 Specificity of the monoclonal antibodies (MeA's) used and antigen expression of splenocyles, BM 
cells and peripheral WBe of the recipient rat strains* 
BN WAG/Rij 
MeA's specificity spleen BM PB spleen BM PB 
OX-27 class I BN (RT_I.Afl)21 87.3 86.7 82.1 1.6 0.2 0.4 
U9F4 class I WAGlRij (RT_I.All)22 1.5 0.7 0.7 17.3 72.0 86.6 
ER-13 class II [Ial (RT-I.B)23 33.1 10.5 37.8 23.2 6.0 14.2 
OX-19 CD5; pan T-cells24 36.1 5.1 36.5 48.3 7.7 62.2 
ER-2 CD4; Thelperlinducer25 34.4 12.9 37.5 36.9 12.1 42.7 
OX·S CD8; T su ppressor/cytotox 26 10.8 1.8 7.7 22.0 3.9 22.4 
* Values are mean of 8 measurements and represent cell percentages positively reacting with the MeA's 
indicated 
Table 3.1 shows data of spleen, BM and peripheral blood nucleated cells of Ihe two rat 
strains labeled with these MeA's. As can be expected, most cells from the BN rat react with 
OX-27 and most cells from the WAGIRij rat wilh U9F4. Both these MCA's erosseeact with 
PVG c1ass-I antigens (RT-I.Ac; data nol shown). 
To establish the degree of chimerism in recipients of allogeneic marrow, peripheral blood 
samples were drawn at various time points. WBe were immunophenotyped for class I 
antigens using the MCA's OX-27 and U9F4. The mean (+f- S.D.) percentage positive cells of 
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the control rats versus recipients of allogeneic BM cells alone, clearly prove full donor 
chimerism at each time point investigated after allogeneic BMT (Figure 3.4). 
A B 
Control 25 46 62 86 106 Control 27 52 64 88 
(BN) rNAG) 
Days after BMT Days after BMT 
Figure 3.4 Inununophenotyping peripheral WBe of allogeneic transplanted rats (BM alone) at various time 
points post-BMT vers/ls untreated animals. Mean percentages positively reacting cells from 4 animals +/- S.D. 
ure represented: (A) \V AGlRij to BN BMT; all WBC show a high allogeneic and low ('background-level') 
recipient-class I expression. (B) PVG to WAGlRij BMT; all WBC show a high expression of both types class I 
(like normal PVG cells); (II1II) OX-27 (cia" I, BN); (EEl) U9F4 (class I, WAGlRij). 
3,4,6 Spleen and liver weights at autopsy 
Among the most characteristic symptoms of leukemia in both models, significantly increased 
spleen (> 8x) and liver weights (> 4x) are observed in rats during Ihe lerminal stages of 
leukemia development. In rats dying from acute lethal aVHD after allogeneic BMT, addition 
of Ihe highest number of allogeneic splenocyles, i.e. 107 WAG/Rij splenocytes in Ihe BNML 
model and 108 pya splcnocytes in the L4415 model, leads to normal or even reduced spleen 
and liver weights as observed al autopsy, i.e. 24 days after conditioning wilh TBl. Thus, in 24 
days the residual leukemia cells were not able to grow out and cause spleen- and liver 
enlargement, indicating a significant anti-leukemic effect in conjunction with acute aVHD. 
3.4,7 Residual leukemic cells ill aCllte GVHD 
To detect Ihe presence of small numbers of surviving leukemia cells in the BM or the spleen 
of recipient rats suffering from acute GVHD, the animals were sacrificed 24 hours before 
death was expected (as was observed in previous experiments). Spleen and BM cells were 
isolated and 108 cells were inoculated into untreated rats, Le. in BN and W AGlRij rats to 
assay for residual BNML and L44l5 cells, respeclively. Subsequently, in bOlh models the 
survival time assay revealed that leukemia cells were not present as none of the secondary 
recipienls died of leukemia (data nol shown). This suggesls Ihal acule (lethal) GVHD is 
accompanied by a significant GVLR, eradicating residual leukemia. 
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3.4.8 Depletioll of lymphocyte subsets 
Allogeneic BMT in the BNML model was used to study the depletion of CD4 and CDS 
positive lymphocytes from the added W AGlRij spleen cells and the effect on GVL andlor 
GVHD induction. The BMT 'setting' (leukemia dose, TBI and BMT) was similar to the one 
described earlier. 
After the 'one step' lymphocyte depletion procedure, double staining and FACS analysis 
showed that about a two log depletion of both the CD4+ and CDS+ subsets of the splenocytes 
was achieved (CD4: from 3S.1 % to 0.1 %; CDS: from 22.7% to 0.5%). Assuming that 40% of 
the un separated W AGlRij spleen cells are CD4+ and 20% CDS+ (Table 3.1), the number of 
CD4- or CDS- splenocytes added to the allogeneic BM graft were adjusted, i.e. 60% and SO% 
of the number of un separated lymphocytes, respectively. Unfortunately, in this experiment we 
did not observe a GVLR when either 105 unseparated, 6x 104 CD4 depleted or 8x 104 CD8 
depleted W AGlRij lymphocytes were added to the allogeneic marrow graft. All these 
recipient rats died of leukemia relapse with similar survival times as the rats receiving 
allogeneic marrow only (median survival 42-45 days; data not shown). Therefore, we can not 
draw any conclusions from the depletion of CD4 or CDS positive lymphocytes as regards the 
GVLR. 
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FJgure 3.5 Selective depletion of allogeneic spleen cell populations in the BNML model. Survival curves of 
leukemic animals treated with allogeneic BMT + allogeneic splenocytes l'erSI(S the allogeneic marrow only 
transplanted group (11 :::8 rats per group). The rats were inoculated with 105 BNML cells (Lv.) on day 0, 
subjected to TBI (8.5 Oy X-rays) on day 7 and given allogeneic marrow ± splenocytes on day 8. All rats 
transplanted with allogeneic marrow only or allogeneic marrow + 6x 106 CD4-depleted splenocytes died of 
leukemia relapse. The groups receiving 107 unseparated splenocytes or 8x 106 CDS-depleted splenocytes died of 
acute graft-versus-host disease (OVHD); ( ) + allogeneic BMT: ( ) + allogeneic BMT + 107 
unseparated splenocytcs; ( ________ .) + allogeneic BMT + 6x 106 CD4-depleted splenoeytes; (- - _) + 
allogeneic BMT + 8xl06 CD8-depleted splenocytes. 
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Adding 107 unseparated allogeneic spleen cells to the allogeneic marrow graft induced 
acute lethal GVHD in seven out of eight recipient rats with a median survival time of 30.5 
days. One animal unexpectedly survived till day 80 and died of an unknown cause (Figure 
3.5). The addition of 6xlO6 CD4 depleted lymphocytes did not induce evident GVHD. Seven 
out of eight rats died from leukemia relapse with a median survival time of 50 days. similar to 
the rats transplanted with allogeneic marrow only. One rat died at day 24 from BMT-related 
complications. However, 8xlO6 CD8 depleted lymphocytes did induce lethal acute GVHD in 
seven out of eight rats, but with an eight days prolongation of median survival time (38.5 
days). One rat died at day 86 of an unknown cause (Figure 3.5). These data indicate that both 
CD4 and CD8 positive allogeneic lymphocytes are involved in the induction of GVHD, the 
CD4+ lymphocytes being the major contributors and the CD8+ cells responsible for an 
additional effect. 
3.5 DISCUSSION 
The involvement of immunocompetent donor T-cells in the GVLR is well established both in 
animal modcls6,7 and in O1ao.8,9 It is not clear whether the mechanisms of the GVLR arc 
separable from those operative in GVHD. Evidence has been reported for at least two 
elements of the GVLR; one that is dependent on the presence and the intensity of GVHD27 
and the other operating without clinically overt GVHD.2B,29 Thus, the latter would allow 
enhancing the GVLR while minimizing GVHD. In this way a more safe and complete 
eradication of leukemia cells still present after conditioning might be achieved. However, to 
determine whether this can be accomplished, a better understanding of the mechanisms of the 
GVLR and its mediators is warranted. The present paper describes our studies on the GVLR 
in the BNML and the L4415 rat leukemia models using syngeneic and allogeneic BMT with 
and without the addition of graded numbers of splenocytes. 
In both models, the survival times of the animals receiving syngeneic BMT indicated a 
residual leukemic cell load of 103 cells. Addition of high numbers of mature syngeneic 
lymphocytes to the marrow inoculum did not change the leukemia growth pattern or the 
survival of the recipient rats. These data indicate that high numbers of syngeneic lymphocytes 
do not induce a GVLR. 
To study GVL after allogeneic BMT in the BNML model, the W AG/Rij rat was applied as 
a fully mismatched donor. Transplantation in MRD of allogeneic BM alone did not induce a 
GVLR. Addition of graded numbers of W AG/Rij splenocytes to the inoculum induced an 
increase in the survival time of the recipient rats which was 'maximaP (without inducing 
severe GVHD) with 105 spleen cells. This significant increase in survival time reflects a 2.8 
log leukemia cell kill. Higher numbers of allogeneic splenocytes caused the induction of acute 
lethal GVHD. 
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For GVL studies in the ALL rat leukemia model, the PVG rat was used as a mismatched 
donor. Transplantation of allogeneic BM without splenocytes added to the graft induced a 
small GVLR (0.8 LCK), which may be caused by different alloreactivity (donor-host 
combination) as observed in the BNML model where no GVLR was observed after marrow 
only grafting. The survival time was further increased when 106 PVG spleen cells were added 
to the BM graft with a significant GVLR (3.3 LCK) without clinically evident GVHD. 
Addition of 107 allogeneic lymphocytes induced severe GVHD, but a significantly prolonged 
survival time corresponding with a 6.1 log leukemic cell kill. The GVHD induced 2.8 extra 
logs of leukemia cell kill compared with 106 additional splenocytes (6.1 Vel'SIlS 3.3 LCK, 
respectively). Thus, in this situation, the GVLR induced a significantly stronger antileukemic 
effect compared with TBI (4.4 LCK). Further increased numbers of allogeneic splenocytes in 
the graft induced acute lethal GVHD and significantly reduced life span. 
Immunophenotyping the \VBC of the recipient rats given an allogeneic BMT, clearly 
showed that they were full donor chimeras. Autopsy revealed that acute lethal GVHD was 
accompanied by a significant GVLR. To study the possible presence of residual leukemia 
cells in the animals suffering from acute GVHD, BM and spleen cells were isolated just 
before their expected death and subsequently transferred in high numbers to untreated 
recipients. As these rats did not die from leukemia, apparently no leukemic cells were present 
in the inoculum. Thus, the acute lethal GVHD at the same time exerts a strong anti-leukemia 
activity. 
The median survival time after (syngeneic) BMT indicates a residual leukemia cell load of 
103 BNML or L4415 cells, respectively. In both leukemia models a significant GVLR 
(approximately 3 log leukemia cell kill) without signs of GVHD can be induced using 
allogeneic BMT, with a critical number of additional allogeneic splenocytes. Nevertheless 
these animals all die from leukemia relapse; no cures were observed. As the first symptoms of 
GVHD become evident 8-10 days after allogeneic BMT, the GVLR is probably not 
operational instantly after BMT. Once evoked, the GVLR may have a continuing 
antileukemic effect resulting in an increase in the survival time which, using our criteria to 
calculate antileukemic effects oCinstant-effecf treatment, reflects a 3 log leukemia cell kill. 
Apparently, the leukemia cell elimination by the GVLR could not keep lip with the rate of 
leukemia cell proliferation, ultimately leading to leukemia relapse. 
The data show that syngeneic BMT serves as a model for human autologous BMT. 
Transplantation of allogeneic rat BM alone induces neither a significant GVLR nor GVHD 
and therefore resembles human allogeneic (pan-) T-cell depleted BMT, the addition of critical 
numbers of alJogeneic lym.phocytes to the marrow graft evokes a significant GVLR andlor 
acute lethal GVHD, serving as a model for full marrow grafting in humans. To date, we have 
not been able to separate the GVLR from GVHD. In the experiments discussed here, 
unseparated T-cell populations (splenocytes) have been added to the marrow graft. Several 
reports mention the in vitro induction of cytotoxic T lymphocytes specific for MHC-matched 
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allogeneic leukemia Of nonleukemia cells Of lysing both leukemic and non-leukemic target 
cells,30,3t and their correlation to the GVLR in vivo in a murine modc1.32 
In our first attempt to deplete lymphocyte subsets from the added allogeneic splenocytes, 
we were unable to induce an evident GVL effect without GVHD. Nevertheless, our 
preliminary data on the 'two log' CD4+ and CD8+ lymphocyte depletion in the BNML model 
indicate that the depletion of CD4+ cells completely eradicated the induction of GYHD. 
When CD8+ lymphocytes were depleted it was observed that the incidence of GYHD was 
100%, but that death due to GYHD was postponed in all recipient rats. These results are in 
agreement with experimental data reported by Truitt et a1. and Sykes et a1. They have shown 
that CD4+ T-cells playa critical role in causing GYHD in fully mismatched murine strain 
combinations, and that CDS+ T-cells given alone do not cause acute GVHD.33-35 Moreover, 
it was proven in these murine models that CD4+ cells can contribute to GVL effects.33 A 
promising clinical trial of selective donor CD8+ cell depletion (HLA-identical sibling BMT 
for CML in chronic phase) demonstrated a reduction in, but not absence of, GVHD, whereas 
leukemic relapse rates were low. 36,37 Further studies using the rat models will reveal whether 
the addition of graded numbers of certain (MHC-mismatched) lymphocyte subpopulations to 
the marrow graft, e.g. CD4+ Of CDS+ celis, may induce a wider therapeutic window. 
How do the GVL-results relate to the current clinical experience? Mathematical model 
computations based on the relapse rate of leukemia patients with or without GVHD suggest 
that the GYLR associated with GYHD produces one extra log leukemic cell kill which 
increases the cure rate from 40 to 90% or, in other words, decreases the leukemia relapse rate 
from 60 to 10%.38 The higher LCK induced by the GYLR in the rat models may be caused by 
the fact that donor and recipient are fully mismatched versus the MHC matched 
transplantations performed in patients. As calculated in human HLA-matched allogeneic 
BMT with full marrow, the GYLR only induces a one log leukemia cell kill together with 
significant (lethal) GYHD. Therefore in acute leukemia it is advisable to use T-cell depletion 
which eliminates death from GVHD 16 and seek other means to achieve additional leukemia 
cell kill, such as intensification of the conditioning regimen or treatment with low-dose 
chemotherapy after BMT39 
Furthermore, transfusions of donor leukocytes in patients showing leukemia relapse 
(chronic myelocytic leukemia) after allogeneic BMT to induce a GYLR have recently been 
reported. The majority of patients had complete hematologic and cytogenetic remission 
persisting 28-91 weeks.40,41 The value of alternative strategies reported are currently being 
explored and include; (I) the infusion of interleukin-2 (IL-2) post-BMT to induce a 
GVLR,42,43 (2) an improved GYL effect of ill vitro IL-2 activated syngeneic BM prior to 
BMT and followed by IL-2 trcatment,43 and (3) combination of allogeneic lymphocyte 
infusion and IL-2 administration post_BMT44 Studies of the nature of lymphocyte (sub) 
popUlations and cytoklne involvement in GVLR and GVHD in response to major and/or 
minor histocompatibility complex antigens in allogeneic BMT are essential to develop 
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therapeutic approaches further. Controversial reports on the application of IL-2 therapy in 
cancer treatment promoted us to initiate IL-2 therapy studies post allogeneic BMT in the rat 
models. Experiments in the BNML model clearly show a GVL effect (without GVHD) of 
low-dose IL-2 administration and induction of acute lethal GVHD when high dose IL-2 
therapy is used after allogeneic BMT45 These data show that the rat leukemia models are 
suitable tools for further GVLR/GVHD studies. Currently, several possible treatment 
strategies to optimize the GVLR without the induction of severe GVHD are under 
investigation. 
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CHAPTER 4 
IN VITRO RESISTANCE OF THE BROWN NORWAY RAT ACUTE 
MYELOCYTIC LEUKEMIA (BNML) TO LYMPHOKINE-ACTIV ATED KILLER 
ACTIVITY* 
Koos F. Gaiserl. Ted C. Kloosterman I. Anton C.M. Martens l and Anton Hagenbeekl,2 
1 Institllte of Applied Radiobiology and Immunology TNO. Rijswijk. The Netherlands. and 2 
The Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlal1ds 
4.1 SUMMARY 
In ill vivo allogeneic bone marrow transplantation studies with the Brown Norway (BN) rat as 
recipient and the W AG/Rij rat as allogeneic donor a significant graft-versus-Ieukcmia (OVL) 
effect is observed. Studies were performed to investigate whether Iymphokine activated killer 
(LAK) cells playa role in this GVL effect. Splenocytes from W AG/Rij and BN rats were 
activated ill v;,ro by recombinant human interleukin-2 (rhIL-2) for 5-6 days. The cytolytic 
activity of these LAK celJs was tested on four rat solid tumor cell lines, Le. an urethra 
carcinoma, a rhabdomyosarcoma and two lung tumors and on leukemic cells derived from the 
BN rat acute myelocytic leukerrtia (BNML) and the W AG/Rij acute lymphocytic leukemia 
(L4415). The panel of target cells also included the murine cell lines P815 and Y AC. Both 
W AG/Rij and BN LAK cells were not capable of lysing the leukerrtic cells in contrast to 
significant cytolytic activity on the rat solid tumor cell lines. P815 and YAC. BNML cells 
showed to be resistant to lysis by I'uman NK cells. Phenotypical analysis of the rat LAK 
popUlation revealed a decrease in the CD4/CD8 ratio compared to the unstimulated 
splenocyte population. Rat LAK cells displayed no antibody-dependent cellular cytotoxicity 
(ADCC) on the leukerrtic cells. whereas JL-2 stimulated human peripheral blood cells showed 
moderate ADCC activity on the leukemic cells. To investigate whether cytokines playa role 
in lysis of leukemic target cells. graded numbers of LAK cells and leukemic cells were co-
cultivated for seven days in an agaI'~based colony culture system. This resulted in moderate 
suppression of leukemic colony formation. From the current ill vitro studies it appears that the 
graft-versus-leukemia observed in ill vivo allogeneic bone marrow transplantation studies is 
probably not due to a direct leukemic cell kill by LAK cells. 
* Leukelllia 1993; 7: 736-741. 
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4.2 INTRODUCTION 
To prevent severe graft-versus-host disease (GVHO) after allogeneic bone marrow 
transplantation, as part of the therapy in hematologic malignancies, T-cell depletion of the 
marrow graft has proved to be effective. 1 However, the successful prevention of GVHD is 
accompanied by an increased risk of graft failure and leukemia relapse: i.e. the graft-versus-
leukemia (GVL) effect is reduced.2-4 There is controversy on whether the GVL effect can be 
separated from the GVHD effect. T-cells are considered major effectors in both reactions,5-7 
although LAK cells and NK cells may also have a role in the GVL reaction 8 ,9 
Interleukin-2, a 15-kDa glycoprotein, is a major growth factor for T-cells. It also is 
required to generate Iymphokine-activated killer (LAK) activity. 10 These cells are able to lyse 
a variety of tumor cells with limited effect on normal cells. This lytic activity is not restricted 
to solid tumors, but also acute lymphocytic leukemia (ALL) and acute myelocytic leukemia 
(AML) blasts are reported to be susceptible to the lytic activity of autologous and allogeneic 
LAK cells ill vitro II-IS Clinical studies confirm these preclinical results for solid 
tumors l6.17 and acute Ieukemias,18,19 
The rat leukemia model (Brown Norway rat acute myelocytic leukemia, BNML) used as a 
relevant model for human acute myelocytic leukemia in this study, has been described in 
detail elsewhere (origin, classification, transplantation procedure, growth characteristics, 
etc.).20,21 In the past years this experimental leukemia has served as a model to study the 
detection and treatment of lminimal residual diseasel.22-24 III vivo results showed a GVL 
effect after allogeneic bone marrolV transplantation (BMT) with 105 allogeneic spleen cells 
added to the graft.25 
The aim of the experiments reported here was to investigate whether GVL activity could 
be induced ill vitro by LAK cells and, if so, to establish the phenotype of these effector cells. 
4.3 MATERIALS AND METHODS 
BNMLcel/s 
BNML cell suspensions were made from spleens of full-blown leukemic rats. Spleens were 
minced with scissors and suspended through a nylon sieve in Hanks buffered salt solution 
(HBSS) to obtain monocellular suspensions. 
The LT12 ill vitro BNML cel/lille 
An ill vitro growing cell line of the BNML was established,26 based on culturing BNML cells 
in the presence of a stromal layer. Ultimately BNML cells were capable of autonomous 
growth. The promyelocytic nature of the BNML cells was retained. Most of the ill vitro 
assays presented here are performed with this ;n vitro growing cell line. 
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Splenocyte isolation 
The spleens from WAGlRij and BN rats (age 12-20 weeks) were removed aseptically, minced 
with scissors and passed through a nylon sieve. Mononuclear cells were obtained after 
centrifugation on lymphocyte separation medium (Organon Technika Corporation, Durham, 
NC, USA). Cells recovered from the interface were washed twice in HBSS and counted prior 
to use, 
Gelleration of LAK cells 
To remove monocytes and macrophages, fresh spJenocytes were incubated in plastic culture 
flasks for I hour at 3TC in RPMI-I640 medium supplemented with 10% heat-inactivated 
fetal calf serum (FCS, Seromed, Biochrom Berlin, Germany). Plastic-non-adherent cells were 
collected and cultured for five to seven days in RPMI-1640 medium containing 1000 U/mi 
recombinant human interleukiu N 2 (rhIL-2; Eurocetus, Amsterdam), 0.5 J.tM 2-mercapto-
ethanol, O.S /lM indomethacin (Sigma, St.Louis, USA) and 100 U/ml of penicillin at an 
optimal cell density of 2-3 x 106 cells/ml. 
Target cells 
A panel of target cells was used to determine lytic activity of the effector cells. RI, a 
'VAGlRij rat rhabdomyosarcoma; RUe-II, a BN rat urethra carcinoma; L37, a moderately 
differentiated squamous cell lung carcinoma (W AG/Rij) and L44, an anaplastic lung 
carcinoma (BN). These W AG/Rij and BN tumor cell lines were selected to circumvent 
differences in species and strain between target and effector celJs as is the case with P8IS and 
Y AC. As leukemic cell targets the BN acute myelocytic leukemia (BNML), its ill vitro 
growing subline LTI2 and the WAG/Rij acute lymphocytic leukemia (L44IS) were used. 27 
The widely lIsed P8IS, an NK-resistant mouse mastocytoma and YAC, an NK-sensitive 
Moloney virus induced lymphoma, were used as controls. 
Assay for cell-mediated cytotoxicity 
Cytotoxicity was determined in a standard 4 hour SICr-release assay. For the labeling I x 106 
target cells were incubated with 100 /lCi of Na2SICr04 (Amersham, UK) for 60 minutes at 
37'C. After washing, the target cells were added at a concentration of 2 x 103 cells/well to 
various numbers of effector cells. Effector to target ratios were SO:I, 2S:I, 12:1 and 6:1. All 
experiments were performed in triplicate in 96-well round-bottomed microtiter plates. 
Incubation was then performed at 3TC for 4 hours. Supernatants were harvested with a 
Skatron harvesting system and counted in a gamma counter. Spontaneous and maximal 
release of chromium were determined by incubating target cells in medium alone or with 10% 
detergent, respectively. 
The percentage of specific lysis was calculated by the following equation: 
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Experimental release - Spontaneous release 
Lysis (%) = ------------------------------------------------------- x 100 
Maximal release - Spontaneous release 
Arifibody·depellderif cellular cytotoxicity (ADCC) 
Human peripheral blood lymphocytes (PBL) were cultured for 7 days in the presence of 
Epstein-Barr virus (EBV)-transformed B-celllines, allogeneic PBL and 25 U/ml rhIL-2 
yielding a population of cells comprising 56% CD3+ , 42% CD16+ and 34% yo+ cells. Also a 
human NK clone was used as effector cell. ADCC was determined in a 4h 51Cr-release assay 
using P815 target cells. Before the 4 h incubation, rabbit anti-P815 serum (1:1000) was 
added. Further procedure for determining cytotoxicity was identical as described under cell-
mediated cytotoxicity. 
Proliferation of LT12 cells 
LTl2 cells (1.5 x 106 per flask) were incubated for 48 h in medium containing 0, 10 or 20 % 
conditioned supernatant. Conditioned medium was obtained from cultures of W AG/Rij 
splenocytes in the presence of 25 Gy y-rays irradiated BN splenocytes. Likewise BN 
splenocytes were cultured with irradiated W AGlRij splenocytes. Conditioned supernatants of 
both cultures were harvested after 72 h. For the proliferation assay, cells were incubated in 
microtiter plate wells in triplicate at a cell concentration of 4 x lOS cells/well in the presence 
or absence of conditioned medium. Each well was pulsed with 9.25 kBq of 3H-thymidine for 
4 h. The wells were harvested on to filter paper and thymidine incorporation was measured by 
liquid scintillation counting. 
Clonogenic assay 
The activity of LAK cells on the ill vitro colony formation of LT12 cells was determined by 
cocultivating LAK cells with LT12 cells in agar at varying effector/target ratios for 7 days. 
Plating efficiency was calculated as (the nnmber of LT 12 colonies counted/total number of 
LT12 cells plated) x 100%. 
The surviving fraction was calculated by the following equation: (plating efficiency in the 
presence ofLAK cells)/(plating efficiency in the absence ofLAK cells) x 100. 
Antibodies for phellot),pillg of LAK cells 
Fresh spleen cell suspensions and cultured IL-2 stimulated splenocytes were immuno-
phenotyped using a panel of monoclonal antibodies (MCA's): ERl3 (anti-class II [Ia], RT-
l.B), OXl9 (anti-CDS), ER2 (anti-CD4), OX8 (anti-CD8), OX39 (anti-IL-2 receptor), ERl5 
(macrophages/monocytes). 
All OX hybridoma cell lines were kindly donated by Dr. A. Williams (Oxford, UK). 
Hybridoma cell lines secreting MCA's ER-2, ER-13 and ER-15 were a generous gift of Dr. J. 
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Rozing (IVVO-TNO, Leiden, The Netherlands). All antibodies were produced 
intraperitoneally (Lp.) in BALB/c mice and purified using a protein A column (Dr. P.H. van 
der Meide, ITRI-TNO, Rijswijk). 
Cell suspensions in PBSIBSA (PBS; 1% BSA, Sigma, St.Louis, MO, USA; 0.01% NaNJ, 
Merck, Darmstadt) were incubated for 45 m.in. at 4°C with optimal concentrations of the 
specific MeA, then washed twice in PBS/BSA and incubated with fluorescein~isothiocyanate 
(FITC)-conjugated rat-ant i-mouse immunoglobulin (lg) antibody (Jackson Laboratories, 
Maine, USA). 
Analysis was performed on a FACScan flowcytometer with a single argon (488 nm) laser 
(Becton Dickinson, Mountain View, CA, USA), 
Table 4.1 Lytic activity of WAGlRij LAK cells and BN LAK cells on a panel of target cells 
a. WAGlRij LAK cells 
Err ratio P81S YAC RIM RUC-U LTl2 L37 L44 BNML 
L441S 
6 6.0±0.9 7.3±1.9 14.0±3.3 4.6±Q.7 0.2±Q.1 1.0 0.0 0.0 0.0 
12 9.3±1.4 11.0±2.S 24.6±4.S 6.4±Q.8 0.6±Q.3 0.0 1.0 0.0 0.0 
2S 17.9±2.3 18.4±3.3 37.3±S.S 1O.4±1.0 1.8±Q.6 17.0 8.0 2.0 0.0 
SO 29.7±3.7 27.9±4.S 47.7±S.7 16.t±l.S 3.t±0.7 38.0 31.0 4.0 0.0 
II 11 7 7 7 10 1 1 1 4 
b. BN LAK cells 
Elf ratio P8tS YAC RIM RUC-IT LTl2 BNML L44tS 
6 t2.3±1.4 14.7±5.3 2.5±1.5 2.S±I.S 0.0 0.0 0.0 
t2 21.3±2.2 21.7±6.0 5.0±2.0 S.O±O.O 0.0 1.0 0.0 
2S 33.3±3.S 31.0±7.t 9.0±2.0 8.5±Q,5 0.0 1.0 0.0 
SO 44.7±4.6 43.7±7.4 t6.S±3.S 13.S±Q.S 0.0 1.0 0.0 I, 6 3 2 2 4 1 2 
Lytic activity is expressed as percentage 51Cr-release (mean ± standard error of the mean); Err ratio, effector to 
target cell ratio; fI, number of experiments, 
4.4 RESULTS 
4.4.1 Cell mediated cytotoxicity 
Percentage of specific lysis of the different targets by LAK cells are shown in Table 4.1. LAK 
cells from both WAGlRij and BN rats showed very low or no cytotoxicity to LTl2 cells in a 
4h 51Cr-release assay, Even an overnight incubation did not result in any lysis of LT 12 cells, 
Results obtained with fresh BNML and L4415 cells are identical to that obtained with LTl2 
cells. All other non-leukemic target cells were lysed to various degrees by these LAK cells. 
Thus, the lack of cytolytic activity on the leukemic cells is not due to defective activity of the 
LAK cells, but due to insusceptibility of the leukemic cells. 
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4.4.2 Phellotypical allalysis 
To study the phenotype of the cytolytic lymphocytes, FACScan analysis was performed. 
Results of these assays are showed in Table 4.2. In the W AGIRij LAK cell populations, a 
shift in the CD4/CD8 ratio from 1.96 (in the unstimulated splenocytes) to 0.37 (in the LAK 
cells) is observed. For BN LAK cells, this ratio shifted from 3.09 to 1.54. The percentage of 
cells that express the IL-2 receptor increased from 2.7 to 22.6% and from 5.1 to 15.6% for the 
WAGIRij and BN LAK populations, respectively. The percentage of macrophages in these 
populations was reduced, as could be expected since the LAK cells are generated from non-
adherent cells. No remarkable changes in the percentages of the other cell subpopulations 
were observed. 
Table 4.2 Immunophenotype of WAGlRij and BN normal spleen and LAK population 
MeA's Target WAGIRij BN 
Spleen LAK Spleen LAK 
ER-13 class II [Ia] 18.9 19.7 33.9 39.9 
OX-19 CD5 (pan T) 53.3 53.7 36.1 37.3 
ER-2 CD4 (Th) 40.1 18.4 34.4 27.1 
OX-8 CD8 (Ts I Tel 26.7 54.2 12.0 19.8 
ER-15 macr I mono 14.7 7.9 10.5 ND 
OX-39 IL-2 receptor 2.7 22.6 5.1 15.6 
CD4/CD8 ratio 1.96 0.37 3.09 1.54 
Data are expressed as mean percentage of the total cell population; ND, not determined; maer, macrophages; 
mono, monocytes. 
4.4.3 Antibody depelldellt cellular cytotoxicity (ADCC) 
The susceptibility of BNML and LTi2 cells to NK-mediated cytotoxicity and ADCC was 
investigated. Cells of the human NK clone 472 do not lyse PSIS, BNML and LTI2 cells. In 
an ADCC assay, only the PSIS cells were lysed. IL-2 stimulated human PBL (yielding 56% 
CD3+, 42% CDI6+, 34% yo+ cells) do not lyse BNML or LTi2 cells, whereas 55% lysis of 
P815 cells was achieved. Up to 30-36% lysis of the leukemic cells is obtained in an ADCC 
assay with these human PBL as effector cells (Table 4.3), which was clearly effector-cell dose 
dependent. The results of the 51Cr release assay showed no cytotoxic activity of the rat LAK 
cells on the leukemic cells. The ability of W AGIRij and BN LAK cells to perform ADCC on 
LT12 cells has also been tested in a 5ICr release assay. There was no substantial lysis of the 
L Ti2 cells. 
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Table 4.3 ADCC activity of IL-2 stimulated human PBL, human NK clone 472 and rat LAK cells 
Effector Err ratio Specific Lysis (%) 
P815 LTl2 BNML 
medium anli-PSIS medium anti-P8IS medium anti-P8I5 
human PBL I 2 73 0 2 0 7 
3 10 79 2 8 0 10 
9 32 82 5 19 5 21 
27 55 88 4 36 I 30 
human NK I 0 42 0 0 
clone 472 3 0 49 0 0 
9 0 61 0 0 
27 I 69 0 0 
WAG 6 0 0 
LAK cells 12 0 0 
25 29 I I 
50 42 68 2 3 
BN 6 6 12 I 0 
LAKceils 12 14 21 0 0 
25 23 39 0 0 
50 41 60 I I 
anti-PSIS, polyclonal rabbit anti-P8IS serum; PEL, peripheral blood lymphocytes; Err ratio, effector to target 
cell ratio. 
4.4.4 Effect of IVAG/Rij or BN Sllpematallt 011 the growth of LT12 cells 
In stead of leukemia cell kill, leukemia growth suppression by soluble growth inhibiting 
factors could be involved in the GVL effect observed after allogeneic BMT. This situation 
was simulated in vitro by co-cultivation of either W AGlRij spiellocytes with irradiated (25 
Table 4.4 Influence of various supernatants on the growth of LTI2 cells 
Supernatant Growth 
Type % (v/v) Celtslflask (x 106) cpm 
Control 0 7.5 37036 
10 6.5 38953 
20 9.5 41748 
BN" 10 7.0 462t4 
20 7.5 44682 
WAGlRijb 10 5.0 46174 
20 7.5 48288 
1.5 x 106 cellslflask were incubated and cultuned for 2 days. 3H-Thymidine incorporation in 4 x 105 cells during 
4 h was determined. Supernatants were obtained from 72 h cocultivations of BN splenocytesa with irradiated 
\V AGlRij splenocytes, or the other way aroundb. 
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Oy) BN spleen cells or BN spleen cells together with irradiated W AOlRij splenocytes. As a 
result of the allogeneic stimulation, the supernatants of these cultures might contain cytokines 
with growth inhibiting activity. Addition of up to 20% supernatant to the cell cultures did not 
result in growth inhibition of LTl2 cells as is indicated by equal cell numbers and 3H-
thymidine incorporation in control and test groups (Table 4.4). 
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Figure 4.1 Effect ofLAK cells on survival of LTl2 cells after cocultivation for 7 days in agar. Each data point 
represents the mean of three experiments. The bar indicates the standard error of the mean. Each data point is 
calculated relative to the corresponding control group. Err ratio; effector to target cell ratio; --0--, 200 
LT 12 cells/dish; - - • - ~ , 2000 LT 12 cells/dish. 
4.4.5 Agar colollY assay 
Since no cell kill could be measured in a 4 h 5lCr-release assay and no leukemia growth 
suppression was induced by (20% v/v) supernatants of allo-stimulated splenocytes, LAK and 
LT12 cells were cocultured in agar for 7 days. This agar colony assay would allow the 
detection of an indirect cell kill or a leukemia growth suppressing effect of cytokines 
produced by the LAKcells. Increasing Err ratios induce a decrease in LT12 colony formation 
with a maximal reduction of 50% at a ratio of 50: I (Figure 4.1). 
4.5 DISCUSSION 
In several in vitro studies it has been demonstrated that some but not all human acute 
myelocytic and lymphocytic leukemias are susceptible to lysis by autologous andlor 
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allogeneic LAK cells. 1l~15 These results have been confirmed in clinical studies. 18,19 Other 
reports suggest that LAK cells can mediate a GVL reaction,8,9 
Since a GVL reaction could be induced in the BNML model after allogeneic BMT and the 
BNML model is a relevant model for human AML j experiments were performed using this 
model to study the role of LAK cells in GVL, 
As indicated by the 4h 5lCr-release results, fresh BNML cells and the ill vitro growing 
subline LT12 are not susceptible to lysis by syngeneic or allogeneic LAK cells, while, in 
contrast, WAG/Rij and BN solid tumor cells and P815 and YAC are lysed, Although 
W AGlRij and BN LAK cells displayed a different pattern of cytotoxic activity on the various 
target cells, no allo-elTect could be distinguished i.e, W AGlRij LAK cells were not in all 
cases more cytotoxic on BN target cells than were BN LAK cells. Neither were BN LAK 
cells more cytotoxic on all W AG/Rij target cells than were W AGlRij LAK cells, Human NK 
cells were not capable of killing BNML and LTl2 cells either. Only moderate lysis of BNML 
and LTI2 cells is performed by stimnlated human PBL in an ADCC assay, 
Immuflophenotypic analysis of the normal spleen and IL-2 activated spleen popUlations 
showed a preferential presence of CD8-positive cells over CD4-positive cells in the activated 
population. The percentage of cells expressing the IL-2 receptor was also increased. These 
phenomena occurred in both BN and W AG/Rij populations. 
Little is known about the mechanism of LAK-mediated cytotoxicity. Adhesion of effectors 
to targets may be critically important,28 although the nature of the target antigens needed foJ' 
lysis by LAK cells still remains to be elucidated, Apparently, lack of expression of adhesion 
molecules on BNML and LTl2 cells Illay be the cause of their resistance to lysis, LTI2 and 
BNML cells were shown to be negative for expression of ICAM-I (Unpublished data of K. 
Smits et aI., Dept. of Pathology, Leiden University), So far, it is not clear whether the iI/ vivo 
GVL effect observed in the BNML model after allogeneic BMT is the result of direct cell 
killing by NKILAK cells, Lymphokines produced by these cells could also be involved, To 
study this phenomenon, L Tl2 cells were cultured in the presence of supernatant of LAK 
cultures. Addition of up to 20% supernatant did not result in any growth inhibition (data not 
shown). Due to differences in medium requirements of LT12 and LAK cells, it was 
impossible to increase the percentage of supernatant above 20%. This might be the reason 
why we could not demonstrate any growth inhibition. 
11/ vitro IL-2 stimulation of peripheral blood lymphocytes results in the production of 
Iymphokines like tumor necrosis factor alpha, This or other Iymphokines could be responsible 
for the decreased survival of LTI2 cells after co-cultivation in agar for 7 days with LAK 
cells, 
In summary, in the current study it was investigated whether GVL activity could be 
induced ill vitro by LAK cells. No direct cell killing was observed, it was therefore concluded 
that the BNML and LTl2 cells are LAK-resistant. Yet a significant GVL effect is observed in 
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ill vivo BMT studies when 105 W AG/Rij splenocytes are added to the allogeneic marrow 
graft in BN rats suffering from minimal residual leukemia. 25 
The results of these ill vitro studies suggest that if LAK cells do playa role in the in vivo 
observed GVL reaction, this effect is most probably not due to direct leukemia cell killing by 
LAK cells. Another lymphocyte subset that can be involved in the observed GVL effect is the 
cytotoxic T -lymphocyte subset. Modulation of this subset might enable us to control and 
improve the GVL effect. 
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INTERLEUKIN-2 THERAPY AFTER ALLOGENEIC BONE MARROW 
TRANSPLANTATION FOR ACUTE MYELOCYTIC LEUKEMIA * 
Studies in a relevant Rat Model for AML 
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1 Illstitllte of Hematology, Erasmlls Ulliversity Rotterdam, 2 F. Hoffmanll-La Roche Ltd., 
Basle, Switzer/and, 3Dept. of Hemato-Oncology, The Dr. Dalliel dell Hoed Cancer Center, 
Rotterdam, The Netherlands 
5,1 SUMMARY 
One of the major problems in the treatment of leukemia with BMT remains leukemia relapse. 
It has generally been established that allogeneic BMT, compared with autologous BMT, gives 
rise to a graft-versus-Ieukemia reaction (GVLR), usually associated with GVHD. To explore 
a possible role for post BMT immunotherapy, recombinant human IL-2 therapy has been 
studied in the Brown Norway acute myelocytic leukemia (BNML), a rat leukemia model 
relevant for human AML. The antileukemic efficacy of rhIL-2 therapy is studied applying 
different doses of rhIL-2 after syngeneic or allogeneic BMT. RhIL-2 treatment post syngeneic 
BMT, showed a small, borderline significant GVLR. Repeated rhIL-2 treatment after 
allogeneic BMT resulted either in no significant antileukemic effect or in letha) GVHD when 
'low' or 'high' doses were administered, respectively. An intermediate dose, however, induced 
a significant GVLR without Ihe induction of (lethal) GVHD. Transplantation of allogeneic ral 
BM, which contains only a few lymphocytes, does not result in a significant GVLR or GVHD 
and thus resembles human HLA matched allogeneic T-cell depleted (TCD) BMT. In 
conclusion, from Ihe rat studies presented il appears that the GVLR lost by TeD of the 
allogeneic graft, may be more than fully compensated by IL-2 treatment post allogeneic TeD 
BMT. 
* Bone Marrow Transplantation 1994; 14: 965-973. 
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5.2 INTRODUCTION 
One of the major problems of present leukemia treatment remains the incidence of leukemia 
relapse, even after high dose marrow ablative chemoradiotherapy and BMT. A possible 
approach to improve leukemia free survival is the application of immunotherapy to eradicate 
MRD. 
To augment the immune response against MRD, IL-2 treatment has been introduced after 
intensive chemotherapy or following autologous BMT. To date, IL-2 has only rarely been 
given to humans following allogeneic transplantation because of fear of accelerating GVHD. 
Although GVHD is accompanied by a profound antileukemic effect (graft-versus-leukemia; 
GVL), it bears the risk of significant morbidity and even mortality. 
IL-2 is critical for the activation and proliferation of T lymphocytes. It has been 
considered, therefore, to play an important role in acute GVHD. However, the role of IL-2 as 
an effector molecule of GVHD induced damage has been difficult to establish. Serum JL-2 
levels are not increased in acute GVHD, whereas increases in IL-2 receptor (IL-2R) levels 
have been observed. I The significance of this observation is doubtful because many cell types 
have JL-2 receptors and anti JL-2R MCA therapy provides only transient benefit in steroid 
resistant GVHD.2 IL-2 can be administered safely after T-cell depleted allogeneic or 
autologous marrow grafting without causing or accelerating GVHD.3 In these settings, IL-2 
can only be directly implicated in causing a 'GVH like' syndrome when high doses of JL-2 are 
administered simultaneous with syngeneic or allogeneic lymphokine activated killer (LAK) 
cells4 Even then, much of the JL-2 toxicity is probably mediated through the induction of 
other inflammatory cytoldnes such as IL-l and TNF5 
There are a number of reports of phase IIII studies indicating that IL-2 is tolerated 
following chemotherapy or autografting in doses which produce substantial 
immunomodulation6~8 JL-2 infusions increase both CD3+ and CD3- LAK cell function and 
the effector lymphocytes generated can destroy clonogenic leukemia precursor cells ill vitro. 
There is also a considerable increase in LAK cell secretion of cytokines such as IFNyand 
TNFu which may have additional antileukemic activity.9 
The first clinical trials applying JL-2 after autologous BMT in the treatment of AML are 
encouraging. Various trials employing IL-2 after autologous BMT have been reported to 
assess definitively the effect, if any, on the relapse rate and the biological mechanisms that 
might be involved.IO,11 
Case reports give evidence on the existence of GVL in man post allogeneic BMT, which 
could be enhanced by IL-2 treatment without augmenting GVHD. 12 In addition, GVL was 
induced by inoculation of allogeneic lymphocytes following initial transplantation with T 
lymphocyte depleted allografts. The GVL effect could be significantly augmented by 
concomitant administration of a short course of low dose IL-2 in a murine leukemia model,13 
Further studies on IL-2 administration after allogeneic BMT in patients at high risk of relapse 
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seem warranted, especially because IL-2 production is very low during the first 2 years post 
BMT.14 
Here we report on IL-2 therapy in an animal model relevant to human leukemia, i.e. the 
Brown Norway acute myelocylic leukemia (BNML) growing in Ihe inbred BN ral slrain. IS-17 
This leukemia model shows a reproducible growlh paUern upon Lv. cellular transfer. Ii has 
been used extensively for optimizing BMT conditioning treatment regimens and was found to 
have predictive value for the clinical outcome of new therapeutic approaches. 15 ,17 Survival 
time following i.v. inoculation is inversely related to the number of leukemia cells in the 
inoculum. This log-linear relationship between leukemia cell load and survival time allows an 
accurate calculation of the therapy induced antileukemic effect, in terms of LCK, by 
monitoring the prolongation of the survival time. The BNML model, in combination with the 
W AG/Rij rat as a fully mismatched donor, has proven to be highly informalive in 
GVLlGVHD studies. IS We have shown thai syngeneic BMT serves as a model for 
aUlologous BMT. The addition of critical numbers of allogeneic lymphocytes to an allogeneic 
marrow graft induced significant GVL andlor acute lelhal GVHD, appearing to be a realislic 
model for HLA matched full marrow grafting in humans. However, transplantation of 
allogeneic rat BM alone, which contains only 5~8% lymphocytes, induces neither GVL nor 
GVHD and Iherefore resembles human HLA matched allogeneic T-cell depleled BMT. 
Thus, this rat model offers the opportunity to quantitatively estimate the antileukemic 
effect of IL-2 therapy in minimal residual leukemia, both after syngeneic and allogeneic 
BMT. 
5.3 MATERIALS AND METHODS 
Animals 
Inbred male BN recipient rats and W AGlRij (Wislar Albino Glaxo I Rijswijk) donor rats al 
10-14 weeks of age (body weighl 200 - 250 g) were used in the experiments described. The 
rals were bred al and supplied by the SPF animal breeding facility of the Medical Biology 
Laboratory (MBL)-TNO (Rijswijk, The Nelherlands) and housed in plastic cages with waler 
and food pellets ad libitum. 
BNML lIIodel 
The BNML leukemia was induced in a female BN rat by 9,IO-dimelhyl-l,2-benzanlhracene 
(DMBA). Ii shows a slow, reproducible growlh pattern upon Lv. cellular transfer within the 
BN strain and has many characteristics in common with human acute (pro~) myelocytic 
leukemia: severe suppression of normal hemopoiesis, diffuse intravascular coagulation, 
response to chemotherapy as in human AML and the presence of clonogenic leukemia cells 
(ill vitro and in vivo; ED50 = 25 cells), The leukemia is passaged by Lv. cellular 
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transplantation. The rat leukemia model for human AML has been described extensively. t5-17 
To study allogeneic BMT, the WAG/Rij rat was used as a fully mismatched donor. 
Preparation of cell suspensions 
BNML (spleell) cells. Monocellular suspensions were obtained by mincing the enlarged 
spleens of end stage leukemic animals and gently squeezing the suspension through nylon 
gauze. The cells were washed and suspended in HBSS (Gibco, Paisley, UK). The number of 
nucleated cells was counted in Tiirks' solution using a BUrker-type hemocytometer and 
adjusted to the final cell concentration required for Lv. transfer. 
Peripheral blood. PB samples were obtained by orbital punctures. The blood was 
collected in small plastic tubes containing EDT A (Sigma, SI. Louis, MO, USA) to prevent 
coagulation. When PBL were prepared for immunophenotypic analysis the erythrocytes were 
lysed first (lysing buffer: 0.15 M NH4Cl, Merck, Darmstadt, Germany; 0.01 M NaHC03, 
Merck; 0.1 mM EDT A, Sigma). The suspension was then centrifuged, the pellet resuspended 
in HBSS and PBL counted. 
Bone marrow. BM cells were isolated by repeated flushing of the cavity of tibiae and 
femora with HBSS. A single cell suspension was obtained by sieving the BM through nylon 
gauze. Subsequently the cells were washed, counted and the cell concentration adjusted. 
High dose cllemoradiotherapy 
Eleven days after Lv. inoculation of 107 BNML cells, leukemic animals carrying 
approximately 109 BNML cells were subjected to CY treatment (ASTA, Weesp, The 
Netherlands) and 7.0 Gy X-rays TBI the next day (day 12). CY was dissolved in 0.9% NaCI 
(Merck) and injected Lp. in a volume of approximately 1 ml. The rats were irradiated 
unilaterally in plastic cages, containing eight animals at a time, using a Philips X-ray 
generator (300 kY, 10 mAl at a dose rate of 48 cGy/min. This high dose chemoradiotherapy 
conditioning regimen induces a state of minimal residual disease (MRD) in which few BNML 
cells reside in the recipient rats. Subsequently, the rats were rescued with syngeneic or 
allogeneic BM (108 BM cells Lv.) after TBI (day 12). 
Recombinant /uanan IL-2 
IL-2 (rhIL-2; Proleukin® recombinant human des-alanyl-I, serine-125 human interleukin-2) 
was supplied by EuroCetus (Amsterdam, The Netherlands). The doses applied are expressed 
in international units (IV). Each vial of lyophilized Proleukin was reconstituted with 1.2 ml 
MilliQ-water, the resulting clear solution contained 18 x 106 IV (I mg) Proleukin per ml. 
Dilutions were prepared using 5% D-glucose (Merck), 1 % rat serum. IL-2 was inoculated s.c. 
which prolongs the semm activity compared with Lv. administration. 19 The post BMT rhIL-2 
immunotherapy was applied on days 15-19 and on days 22-26, twice daily, according to 
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different dose regimens, Thus, each animal received two separate courses of rhIL-2 for 5 
days, each given the indicated dose (e.g. 130,000 IV) twice daily (2x130,000 = 260,000 IV 
rhIL-2/day). 
Sun/ivai time assay 
This assay is based on the log-linear relation between the number of leukemia cells inoculated 
and the survival time of the rats. 15,17 The antileukemic effect of the treatment used can be 
deduced from the increase of life span (ILS) of the treated group compared with the untreated 
leukemia control group (11=10 rats/group). A treatment iuducing an ILS of 4.0 days 
corresponds with the extra survival time of animals with a to-fold lower leukemia cell load 
and is referred to as a 1 LCK. In addition, gross pathology (e.g. spleen and liver weight, BM 
smears) will confirm the cause of death (GVHD, take failures, leukemia). 
Imnlllllophellotypillg of peripheral blood lymphocytes (PBL) post BMT 
Chimerism. Single cell suspensions of PBL in PBSIBSA (PBS (NPBI, Amsterdam, The 
Netherlands); 1% BSA (Sigma); 0.01% NaN3 (Merck» were labeled with murine MCA's 
directed to the BN (OX_27 20) or the WAG/Rij inbred rat strain (U9F4 2t) specific class I Ag 
(RT-l.An or RT-l.Au, respectivcly), or incubated with PBS/BSA serving as negative 
controls, Subsequently. the cells were incubated with FITC-conjugated rat anti-mouse Ig 
(Jackson Laboratories, Maine, USA) and analyzed on a FACScan flow cytometer operating 
with a single argon (488 nm) laser (Becton & Dickinson, Mountain View, CA, USA). For 
data analysis, the FACScan research software program Consort 30 (Becton & Dickinson) was 
used. 
Lymphocyte subsets. Single cell suspensions of PBL were labeled and subsequently 
analyzed as described above. The results obtained were compared with values observed in 
untreated control rats. The murine MCA's used were ER-2 22, OX-19 23, OX-8 24 and OX-39 
25 specifically recognizing CD4, CDS, CD8 and CD2S, respectively. Other MCA's used were 
specific for MHC class II Ag ([Ia]: RT-l.B; ER_l)26, NK cells (anti-NKR-Pl; 3.2.3.)27, 
macrophages and monocytes (EDl)28 and the BNML (RmI24)29 
The OX hybridomas and the U9F4 hybridoma were kindly donatcd by Dr. D. Mason 
(Oxford, UK), the hybridoma cell lines secreting MCA's ER-2 and ER-13 were generous gifts 
from Dr. J. Rozing (lVVO-TNO, Leiden, The Netherlands). The ED-l and Rml24 
hybridomas were obtained from Dr. C.D. Dijkstra (Department of Cell Biology and 
Immunology, Medical Faculty, Free University, Amsterdam, The Netherlands) and Dr. R.J. 
Johnson (John Hopkins University, Baltimore, MD), respectively. The antibodies were 
produced Lp. in BALB/c mice and purified on a protein A column (Dr. P.H. van del' Meide, 
Immunosciences, BPRC-TNO, Rijswijk, The Netherlands). The 3.2.3 Ab was a generous gift 
from Dr. W. Chambers (Pittsburgh Cancer Institute, Pittsburgh, PAl. 
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Statistical Analysis 
Survival time analysis of rats from the different experimental groups was performed 
according to Peto et a/. 30 Animals dying from other causes than leukemia were censored in 
the statistical analysis. 
5.4 RESULTS 
S.4.1 1L-2 therapy post syngeneic BMT 
The increase of life span (ILS) of the animals receiving syngeneic BMT compared with the 
leukemia control group reflects the antileukemic effect of the conditioning regimen; 60 mg/kg 
CY Lp. and 7.0 Gy TBI (X-rays) induced a median ILS of 14.5 days, representing a 3.6 LCK, 
with all rats dying from leukemia relapse as judged by gross pathology (e.g. significantly 
enlarged spleen and liver; Figure 5.1). The syngeneic BMT group showed a median survival 
time (MdST) of 30.0 days post BMT, indicating a residual leukemia cell load after high dose 
chemoradiotherapy of approximately 2xlO5 cells (deduced from standard BNML growth 
curves). 
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Figure 5.1 rhIL-2 treatment post syngeneic BMT. Survival curves of rats treated with syngeneic BMT ± rhIL-2 
therapy (2x 130,000 IU/day s.c. for 2x5 days) versl/s the leukemia control group (11 =10 rats per group). The rats 
were inoculated with 107 DNML cells (Lv.) on day 0 and subjected to CY (Lp.; 60 mg/kg) and subsequently to 
TBI (7 Oy X-rays) and BMT (108 BM cells Lv.) on days t I and 12, respectively. All animals died of leukemia 
relapse; ( _____ .) 107 BNML Lv.; ( ) + syngeneic BMT; ( ___ ) + syngeneic BMT + 
2x 130,000 IU JL-2 daily. 
To study the antileukemic effect of rhIL-2 in animals with residual leukemia after 
syngeneic BMT, high dose rhlL-2 therapy (2xI30,000 IV rhIL-2/day) was applied. This 
immunotherapy regimen induced an ILS of 7 days compared with animals receiving 
syngeneic BM only, with all rats dying from leukemia relapse (Figure 5.1). Since the 
mechanism(s) of the rhlL-2 induced antileukemic effect remains unclear, the term log 
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leukemic cell kill (LCK) should not be applied. Thus, high dose Proleukin treatment 
(2x I 30,000 IV/day for 10 days) induced a borderline significant antileukemic effect (p=0.03), 
although the survival range of both groups totally overlapped. 
In a second experiment, the ILS induced by the same high dose IL-2 therapy after 
syngeneic BMT was not significant (NS; I day) and all recipient rats died of leukemia relapse 
(data not shown), Thus, due to for example minor biological variations between the rats, high 
dose rhIL-2 therapy after syngeneic BMT induces either a borderline significant or no 
antileukemic effect. 
5.4.2 IL-2 therapy post allogeneic BMT 
The lack of alloreactivity after transplantation of allogeneic BM alone, often observed in 
rodent models, can be explained by the presence of very low numbers of lymphocytes in the 
marrow (5-8%) compared with human BM (20-30%). We therefore consider the 
transplantation of allogeneic rat marrow alone as a model for HLA matched, T-cell depleted 
alJogeneic BMT in humans and the transplantation of a graft with additional numbers of 
splenocytes to induce GVL andlor GVHD as a model for full marrow grafting. t8 
5.4.2.a Dose-findillg 
Two (of ten) recipients of allogeneic BM died during the aplastic phase (day 32) caused by 
transplantation related complications (sepsis), The remaining eight animals in this allogeneic 
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Figure S.2A Dose-finding rhIL-2 treatment post allogeneic BMT. Overall survival curves of leukemic rats 
treated with allogeneic BMT ± rhIL-2 therapy (2x26,OOO, 2x52,OOO or 2x 104,000 IU/day s.c. for 2x5 days) 
l'ersl/S the leukemia control group and syngeneic transplanted animals (II =10 rats per group). The rats were 
inoculated with 107 BNML cells (i.v.) on day 0 and subjected to CY (i.p.; 60 mglkg) and subsequently to TBI (7 
Gy X-rays) and GMT (l08 BM cells Lv.) on days II and 12, respectively; ( _____ ) 107 BNML Lv.; 
( ) + syngeneic BMT; ( ) + allogeneic BMT; (_._._._._.) + allogeneic BMT + 2x26,OOO IU 
IL-2 daily; ( ________ ) + allogeneic BMT + 2x52,OOO IU IL-2 daily; ( ___ ) + allogeneic BMT + 
2xl04,000 IU IL-2 daily. 
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BMT group died from leukemia relapse with a MdST of 52 days, compared with the 
syngeneic BMT group, with an ILS of 10 days (Figure 5.2). Thus, in this particular 
experiment, allogeneic BM alone induced a significant (p=0.02) GVL effect correlating with 
2.5 LCK without the induction of overt GVHD. 
After allogeneic BMT, different doses of rhIL-2 were administered to study whether the 
antileukemic activity could be increased without the induction of severe GVHD. In the group 
receiving 2x26,OOO IV rhIL-2/day, all animals died of leukemia relapse with a MdST of 55.0 
days. Thus the ILS compared with the group transplanted with allogeneic BM only, is NS 
(Figure 5.2A). When 2x52,000 IV rhIL-2 were administered, one rat died of BMT related 
complications (day 29), two rats 'lied of GVHD (alopecia, erythema, diarrhea, hunched 
posture and severe cachexia: days 39 and 41; Figure 5.2A) and seven rats died of leukemia 
relapse with a MdST of 57.0 days (ILS was NS; Figure 5.2B). The addition of 2xI04,000 IU 
rhIL-2 led to death due to GVHD in six rats (days 30, 45, 46, 53, 59 and 61; Figure 5.2A) 
without signs of leukemia at autopsy. Four rats in this group died of leukemia relapse with a 
MdST of 69.5 days (Figure 5.2B). Compared with the recipients of allogeneic BMT only, an 
additional ILS of 17.5 days was induced, Thus, rhIL-2 post allogeneic BMT up to 2x52,000 
IV/day does not significantly change the life span, When 2x 104,000 IV/day are administered, 
a high incidence of GVHD mortality is observed (60%). The rats dying of leukemia relapse 
however, show a significant prolongation in survival compared with allogeneic BMT alone 
(p=O.OOO I). 
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Figure S.2D Dose-finding rhIL-2 treatment post allogeneic BMT. Leukemia-free survival curves of leukemic 
rats treated with allogeneic BMT ± rhlL~2 therapy (2x26,000, 2xS2,OOO or 2x 104,000 IU/day s.c. for 2xS days) 
versus the leukemia control group and syngeneic transplanted animals (11 =10 rats per group). Animals dying 
from transplantation related complications or OYHD are excluded from the graph. The rats were inoculated with 
107 BNML cells (Lv.) on day 0 and subjected to CY (Lp.; 60 mglkg) and subsequently to TBI (7 Gy X-rays) and 
BMT (108 BM cells Lv.) on days 11 and 12, respectively; ( _____ ) 107 BNML i.v.; ( ) + 
syngeneic BMT; ( ) + allogeneic BMT; (_._._._._.,) + allogeneic BMT + 2x26,OOO IU IL-2 daily; 
( ________ .) + allogeneic BMT + 2xS2,OOO IU IL-2 daily; ( ___ ) + allogeneic BMT + 2x104,OOO IU IL-2 
daily. 
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SA.2.b Optimal dose 
As is usually seen after BMT in the BNML model, in this experiment, the allogeneic 
(W AGlRij to BN) BM alone does not induce a significant antileukemic effect compared with 
syngeneic marrow (ILS=2 days) and all rats died from leukemia relapse (MdST=44; Figure 
5.3). 
To study the antileukemic efficacy and/or GVHD induction of an intermediate dose of 
rhIL-2 derived from the dose-finding study, 2x78,000 IU/day were administered post 
allogeneic BMT in the same schedule as was mentioned earlier. Two (of ten) rats died of 
transplantation related complications (days 23 and 26; aplasia). None of the animals showed 
signs of acute GVHD, one animal survived longer than 150 days and was considered to be 
cured of leukemia. As regards the animals evaluable for dying from leukemia (8 of 10), this 
rhIL-2 immunotherapy regimen induced a MdST of 69.5 days and an ILS of 25.5 days 
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Figure 5.3 Optimal dose rhIL-2 treatment post allogeneic BMT. Overall survival curves of leukemic rats 
treated with allogeneic BMT ± rhIL-2 therapy (2x78,OOO IV/day s.c. for 2x5 days) ~'ers/{s the leukemia control 
group and syngeneic transplanted animals (Ii =10 rats per group). The rats were inoculated with 107 BNML cells 
(L .... ) on day 0 and subjected to CY (Lp.; 80 mglkg) and subsequently to TBI (7 Gy X-rays) and BMT (l08 BM 
cells L .... ) on days II and 12. respecti ... ely. One animal sur ... i ... ed longer than 150 days and was considered to be 
cured of leukemia; ( _____ ) 107 BNML L .... ; ( . ) + syngeneic BMT; ( ) + allogeneic 
BMT: (_._._._._ . .) + allogeneic BMT + 2x78,OOO IV JL-2 daily. 
(correlating with 6.4 LCK) compared with allogeneic BMT alone (Figure 5.3). Thus, the 
inlermediate dose of rhIL-2 after allogeneic BMT induced a highly significant antileukemic 
effect compared with the group treated with allogeneic BM alone (p=0.OO2), without inducing 
significant GVHD. 
The results of syngeneic and allogeneic transplanted animals with or without rhIL-2 
therapy post BMT are summarized in Table 5.1. 
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Table 5.1 RhIL-2 therapy after syngeneic or allogeneic BMT 
Treatment 
(fl = 10 rats) 
Calise of death 
BMT-related GVHD Leukemia 
complications 
107 BNML (Lv,) 
+Syngeneic BMT 
° ° +2x 130,000 IV IL-2/day 0 0 
+AlIogeneic BMT I 2 0 
+AlIogcneic BMT II 0 0 
+2x 26,000 IU IL-21day 0 0 
+2x 52,000 IV IL-2/day 1 2 
+2x 78,000 IV IL-2/day 2 0 
+2x 104,000 IV IL-2/day 
° 
6 
2 
ILS == increase of life span; NS == not significant 
I Compared with syngeneic transplanted animals 
10 
10 
10 
8 
10 
10 
7 
7 
4 
Cllre 
° 0 
° 0 
0 
0 
1 
° 
2 Compared with allogeneic DMT I (= dose-finding experiment) 
3 Compared with allogeneic BMT II (= optimal dose experiment) 
5,4,2.c lmmrmophellotypillg of PBL post BMT 
MdSTili days 
Overall Leukemia-free 
sun'imf slIn'ival 
27.5 27.5 
42,0 42,0 
49,0 49,0 
46,5 52,0 
44,0 44,0 
55,0 55,0 
54.5 57,0 
63,5 69,5 
60,0 69,5 
Significance 
lLS 
1'=0,03 1 
1'=0,02 1 
NS I 
NS2 
NS2 
p == 0.002 3 
I' = 0,0001 
To study the engraftment of allogeneic BM with and without post BMT rhIL-2 treatment and 
a possible shift in lymphocyte (sub)populations in the PB during and after rhIL-2 
administration, PB samples were obtained during the dose-finding experiment. PBL were 
isolated from blood samples taken weekly (from day 24 onwards) from two animals per 
experimental group receiving syngeneic or allogeneic marrow without post BMT treatment or 
treated with the highest dose ofrhIL-2 studied, Le, 2x I 30,000 IV rhIL-2/day or 2x104,000 IV 
rhIL-2/day, respectively, 
1. Chimerism after allogenek BMT. Immunophenotyping of PBL from rats not receiving 
rhIL-2 treatment after allogeneic BMT on days 24, 31 and 38 clearly indicated full donor 
chimerism (;'95% U9F4+ cells), Analysis of PBL from the same rats on days 45, 52 and 59 
showed an increasing percentage of cells positively reacting with the MeA specific for the 
recipient rat strain and concomitantly, a decreasing percentage of U9F4+ cells reflecting 
leukemia relapse (confirmed by Rml24 labeling), Labeling PBL of rats receiving rhIL-2 
treatment (2xI04,000 IV rhIL-2/day) after allogeneic BMT, showed full donor chimerism up 
to day 59, In these two rats no BNML cells could be detected til! day 52; at day 59 one of 
these rats showed 5,0% Rm124+ cells, indicating leukemia regrowth (data not shown). 
2. Lymphocyte subsets. The PBL isolated were concomitantly immunophenotyped to 
define possible changes in percentages of lymphocyte (sub)type(s) induced by the rhIL-2 
treatment, using MeNs specific for macrophagesl monocytes, NK cells and BNML cells, and 
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for the expression of class II, CD4, CDS, CDS and CD2S. During or after the rhIL-2 treatment 
post syngeneic BMT, no differences in MCA labeling of PBL could be detected comparing 
animals either or not treated with rhIL-2. During high dose rhIL-2 treatment after allogeneic 
BMT (day 24), an increase in the percentage macrophages! monocytes and CDS+ cells was 
observed compared with allogeneic BMT alone (from 13.1% to 24.7% and from 23.1% to 
44.6%, respectively), which disappeared immediately after rhIL-2 administration (day 31). 
No significant changes in expression of the other Ag studied were observed. All experimental 
groups showed a sharp increase in the percentage RM124+ cells upon leukemia relapse (from 
S 1.0 to 20.0-45.0%; data not shown) 
5,5 DISCUSSION 
Controversial experimental data on IL-2 therapy post BMT have been reported. In syngeneic 
BMT in mice it has been postulated that the marrow graft should be activated with IL-2 (ex 
vivo) and IL-2 therapy should be initiated immediately after BMT to induce a syngeneic 
GVLR.31 The mechanism of this approach is unknown and was observed to be transient. On 
the other hand, a maximal antileukemic effect of IL-2 therapy in minimal residual leukemia 
after murine syngeneic transplantation (unstimulated BM) was reported when IL-2 was given 
2-3 weeks after BMT32 
In allogeneic BMT the addition of low doses of IL-2 during the first week of a murine 
GVHD could enhance the severity and mortality seen in a class I disparate, but not in a class 
II disparate GVHR presumably mediated by CD4+ cells.33 Augmentation of GVHD induced 
by recombinant IL-2 was observed both in MHC disparate rats34 and mice mismatched for 
minor histocompatibility Ag. 35 In contrast, a different group reported not to aggravate GVHD 
with IL-2 doses able to induce allospecific cytotoxic T lymphocytes (CTLs), using a different 
murine minor histoincompatibility model,36 IL-2 is produced only within the first 2 days of a 
GVHR by the engrafted murine CD4+ T-cells,37 coinciding with the induction phase of the 
GVHR.38 It appears that IL-2 production plays a critical role in the early development of 
acute GVHD most likely by facilitating the development of donor-anti-host CTLs39 
The role of ll.,-2 in GVHD has recently become even more controversial. It was found in 
murine models that administration of high doses of IL-2 at the time of infusion of T -ceIJ 
depleted syngeneic BM (to delay GVHD-related mortality) together with fully MHC 
mismatched allogeneic BM and allogeneic spleen cells, further reduces lethal GVHD, 
promotes alloengraftment and maintains the GVL.40,41 However, initiation of IL-2 
administration at later time points, e.g. day 7 post BMT. can exacerbate GVHD.4! Further 
studies using mouse models for leukemia revealed that in fully MHC mismatched 
transplantation. early ll.,-2 treatment selectively inhibits the GVHD-producing CD4 activity, 
but does not inhibit the antileukemic effects of CD8+ T_cells.42 ,43 Using an allogeneic murine 
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BMT model in which both GVL and GVHD were CD4-dependent, IL-2 treatment inhibited 
GVHD but not the antileukemic effects of CD4+ cells43 These findings suggest that the 
inhibitory effect ofIL-2 is directed against a limited subset or function of CD4+ T-cells and 
that GVL and GVHD can be mediated through different CD4 mechanisms43 
The resuits obtained from the experiments described here indicate that the high dose of 
rhIL-2 applied post syngeneic BMT (2x130,000 IV/day for 2x5 days) induces a borderline 
significant or no antileukemic effect. The difference in the results obtained is most probably 
caused by slight biological variations between the experimental rats. Even though the dose of 
rhIL-2 applied was 1.25 times higher than the highest dose studied after allogeneic BMT, the 
treatment was well tolerated but no significant antileukemic effects could be observed. Higher 
doses of rhIL-2 after syngeneic BMT may induce a more pronounced antileukemic effect but 
were not studied in these experiments. 
Dose-finding of rhIL-2 therapy post allogeneic BMT in the BNML model (resuiting in full 
donor chimeras) revealed that doses up to 2x52,000 IV/day for 2x5 days did not induce a 
significant antileukemic effect. However, the dose of 2x52,000 IV Proleukin did induce 
deaths caused by GVHD (20%). After the rhIL-2 dose of 2x104,000 IV, 60% of the recipients 
died from GVHD. Nevertheless, the prolongation in the life-span of rats dying from leukemia 
indicated a highly significant antileukemic effect without signs of treatment induced toxicity. 
To study whether this significant antileukemic effect could be obtained without the induction 
of severe GVHD, the intermediate dose of 2x78,000 IV rhIL-2 was applied. The resuits 
clearly demonstrate that the intermediate Proleukin dose post allogeneic BMT induced the 
same median survival as was observed for animals dying from leukemia after 2xl04,OOO IV 
rhIL-2. In the dose-finding experiment, the allogeneic BM graft alone induced a GVL effect, 
resulting in an ILS of 10 days. As a resuit, the prolongation in survival induced by the rhIL-2 
therapy compared with allogeneic BMT alone was less than in the experiment where the 
optimal dose of rhIL-2 was employed. In both experiments the ILS, compared with the 
syngeneic transplanted groups, was 27.5 days and the MdST was 69.5 days. Thus, a strong 
antileukemic effect could be induced in recipient rats with a relatively high leukemia cell load 
using 'the optimal dose' rhIL-2 (2x78,000 IV/day) post allogeneic BMT, without inducing 
evident GVHD. The GVLR induced by allogeneic marrow alone (dose-finding) is usually not 
observed and was, in this experiment, probably caused by biological variations in the rats. A 
higher allogeneic reactivity of the marrow lymphocytes may explain GVHD induction when 
2x52,000 IV rhIL-2/day were administered in the dose-finding experiment compared with the 
absence of GVHD when 2x78,000 IV rhIL-2/day were applied in the 'optimal dose' 
experiment. These preclinical exercises demonstrate a dose-effect relationship: too low doses 
of IL-2 exert no effect, too high doses cause lethal GVHD and intermediate doses induce a 
significant GVLR without 'clinical' GVHD. Thus, when the recipient shows a high level of 
donor chimerism, the administration of IL-2 after allogeneic BMT may serve as a remission 
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induction therapy at leukemia relapse, in analogy with donor leukocyte transfusions.44 .45 
Therefore, phase I studies are warranted. 
The mechanism of the IL-2 induced antileukemic effect observed remains unclear. The 
'optimal dose' rhIL-2 applied after allogeneic BMT is well tolerated and the MdST after the 
rhIL-2 treatment is 43.5 days. According to the standard growth curves of BNML this reflects 
less than 103 residual BNML cells at day 26 compared with the 2x 105 residual leukemia cells 
at day 12 after the conditioning regimen (calculated using the MdST after syngeneic BMT; 
see Results section 'IL-2 therapy post syngeneic BMT'). This could mean that the induced 
ILS has been caused by a direct antileukemic effect which reduced the leukemia cell load 
another 2 logs in stead of the expected more than 4 logs increase in 14 days. In that case, a 
prolongation of the rhIL-2 treatment could have increased the cure rate. A different 
explanation could be a rhIL-2 induced leukemia growth suppression which is slowly fading 
after the treatment is stopped and finally results in leukemia relapse. Thus, the log leukemic 
cell kill (LCK) terminology should not be applied for the rhIL-2 induced antileukemic effects 
observed. 
How does the 'optimal dose' of rhIL-2 applied in the experiments reported here relate to 
those administered to patients post BMT? Clinical trials report on a maximum tolerated chIL-
2 'induction' dose of 3.0x106 U/m2/day (Roche) post autologous BMTW Because 2.3 units of 
Roche rhIL-2 equals 6 IU, calculating the dosages from these trials in international units 
reveals 7.Sx106 IU IL-2/m2/day. Given the body surface area of an adult male of 70 kg to be 
2 m2, this correlates with 2.2x105 IU IL-2/kg/day. Thus the 'optimal dose' that was used after 
allogeneic BMT in the rat model was (2x7S,000 IU1250 g/day = 6.2x105 IU/kg/day) 2.S times 
higher than llsed in the clinical studies. This comparison does not imply that, given our 
preclinical data on allogeneic BMT in the rat, the dose of rhIL~2 administered in patients after 
autologous BMT should be increasec!. It is simply meant to indicate that IL~2 regimens, both 
applied in rat and in humans, are of the same order of magnitude. Moreover, the 'tight' 
titration curve for antileukemic versus GVH effects in the rat model indicates that the dosing 
of IL~2 should be done with great caution and for each donor~recipient combination the 
optimal dose may be different. 
As described, PBL were studied for the expression of rat strain specific class I Ag 
(chimerism). Concomitantly, these cells were immunophenotyped using MCA's specific for 
macrophages/monocytes, NK cells and BNML cells, and for the expression of class II, CD4, 
CDS, CDS and CD25 to study possible changes in percentages of lymphocyte (sub)type(s) 
induced by the rhIL-2 )reatment. During high dose rhIL-2 treatment after allogeneic BMT 
(day 24: 2xlO4,OOO IU rhIL-2/day), an increase in macrophages/monocytes and CDS+ cells 
was observed compared with allogeneic BMT alone. No significant changes in expression of 
the other Ag studied were observed. The increased percentage of CD8+ cells is in agreement 
with our studies on the ill vitro rhIL-2 incubation of rat splenocytes.46 During or after the 
rhIL-2 treatment post syngeneic BMT no differences in MCA binding of PBL could be 
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detected compared with animals not treated with rhIL-2. These preliminary results indicate 
that macrophages/monocytes and CDS+ lymphocytes may playa role in the antileukemic 
effects observed after high dose rhIL-2 treatment after allogeneic BMT. 
Concerns have been raised whether IL-2 therapy could accelerate the growth of residual 
leukemia cells. Human in vitro and murine ill vivo (immunosuppressed fiU/fiU mice as a model 
for human leukemia cell growth) data indicated that lL-2 does not promote the proliferation 
and growth of human acute leukemia cells of myeloid and lymphoid origin,47 However, more 
recently, relapses were reported after ll.,-2 treatment of AML patients in CR, where the IL-2R 
a chain was detected on the surface of leukemia cells from such patients during relapse.48 
Similarly, in vitro proliferation of many human leukemia blasts in the monocytic lineage 
(FAB M4 and M5) was stimulated by IL-2, which was significantly correlated with the 
expression of the lL-2R p chain49 
Using the rat model for AML, resembling human promyelocytic leukemia (FAB-M3), no 
expression of the IL-2R p chain was detectable (CD25: MCA OX-39 25) and no growth 
stimulation of the BNML cells could be induced by rhIL-2 inoculations in vivo (data not 
shown). However, preliminary results in a rat model relevant for human acute lymphocytic 
leukemia (L4415; an immature T-cell leukemia growing in the WAGlRij rat),50 have shown 
that rhlL-2 therapy (2x I 30,000 IVlday, 2x5 days) significantly stimulates the growth of these 
IL-2 receptor bearing leukemia cells. Inoculation of 107 L4415 cells Lv. into untreated 
WAGlRij rats on day 0 resulted in an MdST of 29.5 days, administration of 2x I 30,000 IV 
rhlL-2/day for 2x5 days s.c. (days 4-S and days 11-15), reduced the life span to 23.5 days 
(p=0.02). These results lead to the conclusion that in human leukemias which express the IL-
2R (0: and/or p chain), IL-2 treatment might lead to acceleration of the regrowth of residual 
leukemia cells and should therefore be applied with great caution. 
Using the BNML model, we have previously shown that the addition of critical numbers 
of allogeneic lymphocytes to the allogeneic graft, as a model for full marrow grafting in 
humans, induced a maximal GVLR of 2-3 LCK without symptoms of overt GVHD. 18 Further 
increased numbers of additional allogeneic splenocytes induced acute lethal GVHD. 
However, transplantation of allogeneic BM alone usually induces neither GVL nor GVHD, 
resembling human allogeneic, HLA-matched T-cell depleted BMT. Even though the 
mechanism(s) remain(s) unclear, in our rat model optimal IL-2 therapy after 'allogeneic T-cell 
depleted BMT' generates an antileukemic effect (the 25.5 days lLS correlates with 6.4 'LCK') 
which makes up for the loss of GVL after T-cell depletion (maximally 2-3 LCK). 
Therefore, further IL-2 therapy studies in animal models to optimize the observed 
antileukemic effects or even inducing cures in minimal residual leukemia are needed. To 
elucidate the controversial data reported in the literature, future studies should include 
variation of the IL-2 treatment schedule (Le. further increased doses of rhIL-2 post syngeneic 
BMT. different timing of treatment initiation, prolongation of optimal dose treatment and 
additional rhlL-2 maintenance treatment after allogeneic BMT), combination therapy with 
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other cytokines and the possible synergistic antileukemic effect of donor lymphocytes and JL-
2 therapy. 
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CHAPTER 6 
GRAFT-VERSUS-LEUKEMIA IN RAT MHC-MISMATCHED BONE MARROW 
TRANSPLANTATION IS MERELY AN ALLOGENEIC EFFECT* 
Ted C. Kloosterman I , Anton c'M. Martens I , Dirk W. van Bekkum I and Anton 
Hagenbeekl,2 
1 Institute oj Hematology, Erasmus University Rotterdam, 2 Department of Hematology, 
The Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. 
6.1 SUMMARY 
One of the major problems in the treatment of leukemia with bone marrow transplantation 
(BMT) remains leukemia relapse. It has been clearly shown that graft-versus-host disease 
(GVHD) is accompanied by a graft-versus-Ieukemia reaction (GVLR) which reduces the 
incidence of leukemia relapse, To date, discussion is still going on as to whether GVHD and 
GVLR are either two different reactions or are exerting their effects through the same 
mechanism(s), In two rat leukemia models, namely the Brown Norway acute myelocytic 
leukemia (BNML) and the W AG/Rij acute lymphocytic leukemia L4415, total body 
irradiation (TBl) was given to induce a state of so-called minimal residual disease (MRD). 
Subsequently, it was attempted to evoke a GVLR distinct from GVHD by using semi-
allogeneic hybrid-ta-parent or parent-ta-hybrid BMT, with or without the addition of graded 
numbers of lymphocytes. In both leukemia models applying hybrid-to-parent BMT, the 
addition of high numbers of semi-allogeneic lymphocytes to the semi-allogeneic graft had no 
antileukemic effect. In parent-ta-hybrid BMT, the grafts sharing their alloantigens with the 
leukemia cells did not induce an antileukemic effect, irrespective of the number of 
lymphocytes present in the graft or the induction of evident GVHD. When the parental graft 
was histoincompatible with the leukemia cells, transplantation of bone ll1alTOW alone induced 
a significant increase in life span (ILS) correlating with 2.8 log leukemia cell kill (LCK). 
Addition of graded numbers of histoincompatible splenocytes to the graft further inereased 
the antileukemic effect (maximally correlating with 4.0 LCK) without signs of obvious 
GVHD or, with higher numbers of splenocytes, induced acute lethal GVHD. Thus, the results 
indicate that the GVLR observed post MHC mismatched BMT in these rat leukemia models 
for ALL and AML are mere allogeneic effects, inseparable from GVHD. 
*/1/ press (Bone Marrow Transplantation) 
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6.2 INTRODUCTION 
In the treatment of hematological malignancies such as leukemia, allogeneic bone marrow 
transplantation (BMT) is being used with increasing frequency.I.2 The success of BMT is 
limited by post-transplantation complications such as graft-versus-host disease (GVHD) and 
leukemia relapse. The GVHD incidence and intensity is dependent on the extend of genetic 
disparity (major and minor histocompatibility complex antigens) between the donor and 
h08t3.4 as well as the quantity and quality of the lymphocytes present in the bone marrow 
(BM) graft. 5 
Studies applying animal models have shown that allogeneic T-cells in allogeneic BMT, 
which are the major contributors to GVHD,6 are held responsible for a reduction in the 
incidence of leukemia relapse compared with isologous/autologous BMT, inducing a graft-
versus-leukemia reaction (GVLR).7-9 
Clinical data show that the magnitude of the GVLR correlates with GVHD severity. 10, I I T-
cell depletion (TCD) of allogeneic donor BM decreases Ihe incidence of both acule and 
chronic GVHD but at the same time significantly increases the rate of leukemia relapse. 12,13 
Likewise, in a few cases the GVLR was shown 10 be abrogaled by post BMT 
immunosuppression using cyclosporine A (esA) to prevent GVHD,14,15 The discontinuation 
of esA at first signs of leukemia relapse induced complete hematologic and cytogenetic 
remission. Clearly, GVHD seems to be associated with the GVLR which eradicates residual 
leukemic cells. The question remains whether these two reactions are separable or whether it 
will be possible to oplimize the beneficial GVL effecls without increasing Ihe risk of lethal 
GVHD. 
In some animal models, the GVLR can be separated from apparenl GVHD I6-18 leading to 
the speculation Ihal GVL and GVH reactive cells are distinc!. These preclinical dala support 
the assumption that specific antigens (Ag) present on leukemic cells, are not shared by normal 
cells of the host. However, no leukemia associated specific surface markers have been 
identified on human leukemic cells. Alternatively, the same cells may mediale both GVL and 
GVH reactions, but quantitative differences in sensitivity between leukemic and normal cells 
could account for apparently dislinct GVUGVH reactions. including a 'Ihreshold' effec!. To 
date, no convincing clinical evidence has been reported on a GVLR separable from GVHD. 
To study GVL in animal models relevant to human leukemia, experiments were performed 
applying Ihe Brown Norway ral acule myelocylic leukemia (BNML) 19-21 and the L44l5 
acute lymphocytic leukemia growing in the inbred WAG/Rij rat slrain.22,23 Bolh leukemia 
models show a reproducible growth pattern upon intravenous (Lv.) transfer. The log-linear 
relationship between leukemia cell load and survival time allows an accurate calculation of 
Ihe treatment induced anlileukemic effecl, in terms of log leukemic cell kill (LCK), by 
recording prolongation of survival. 
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Recent reports on our studies employing these rat models have shown that syngeneic BMT 
serves as a model for human autologous BMT (no GVLlGVH induction)9 Transplantation of 
allogeneic MHC mismatched rat BM alone, containing just 5N 8% lymphocytes. induced 
neither a significant GVLR nor GVHD and therefore resembles human allogeneic HLA-
matched T-cell depleted BMT. The addition of critical numbers of (unseparated) allogeneic 
Splcllocytes to the allogeneic marrow graft evoked a significant GVLR in both models 
correlating with 2-3 LCK, without inducing overt GVHD. Acute lethal GVHD was induced 
when further increased numbers of lymphocytes were added? Thus, transplantation of 
allogeneic rat marrow and splenocytes serves as a model for full marrow grafting in humans. 
Subsequently, using the BNML model, studies on interleukin-2 (!L-2) administration post 
BMT have illustrated the capacity of optimal dose IL-2 therapy, after transplantation of 
allogeneic marrow only. to induce a significant antileukemic effect (correlating with 6.4 
LCK) without the induction of 'clinically' evident GVHD?4 The administration of higher 
doses of IL-2 induced acute (lethal) GVHD. Therefore, we concluded that the GVLR lost by 
T-cell depletion of the allogeneic graft, may be more than fully compensated by optimal IL-2 
treatment after allogeneic T-cell depleted BMT. 
To date, we have not been able to separate the GVLR from GVHD. To assess whether the 
in vivo observed GVLR is a specific antileukemic reaction or a secondary effect of GVHD, 
e.g. mediated by increased cytokine levels, semi-allogeneic BMT was studied. Semi-
allogeneic hybrid-to-parent BMT does not lead to GVHD since the hybrid (FI(WAGlRij X 
BN) or FI) lymphocytes will recognize the parental (P) Ag as 'self', but high numbers of 
hybrid (FI) lymphocytes may induce a specific antileukemic effect. Semi-allogeneic P-to-FI 
BMT does induce GVHD, generating the opportunity to study the antileukemic effects of 
GVHD inducing lymphocytes, either or not sharing their major histocompatibility complex 
(MHC) Ag with the leukemia cells. 
6.3 MATERIALS AND METHODS 
Animals 
Inbred male BN, WAGlRij (Wistar Albino Glaxo / Rijswijk) and FI(WAG/Rij x BN) rats at 
10-14 weeks of age (body weight: 200 - 250 g) were used in the experiments described. The 
rats were bred at and supplied by the (specified pathogen free) animal breeding facility of the 
Medical Biology Laboratory (MBL)-TNO (Rijswijk, The Netherlands) and housed in plastic 
cages with water and food pellets ad libitum. 
BNML lIIodel 
The BNML leukemia was induced in a female BN rat by 9,IO-dimethyl-I,2-benzanthracene 
(DMBA). It shows a slow, reproducible growth pattern upon Lv. cellular transfer within the 
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BN rat strain and shares many characteristics with human acute (pro-) myelocytic leukemia: 
severe suppression of normal hemopoiesis, diffuse intravascular coagulation, response to 
chemotherapy, presence of clonogenic leukemic cells (in vitro and in vivo; EDSO = 2S cells) 
and no evidence for a virus as an etiological agent. The leukemia is passaged by i. v, cellular 
transplantation. The rat leukemia model for human AML has been described extensively,19-21 
IA415 model 
The L441S lymphocytic leukemia was induced in a female WAO/Rij rat by O.S MeV total 
body neutron irradiation (dose; S cOy). Immunophenotyping has shown that the relatively 
slowly growing, non-immunogenic L441S is an immature T-cell leukemia (CD4-, CD8-, 
CDS+). The L441S leukemia is in vivo passaged by Lv. cellular transfer, showing a 
reproducible growth pallern. L441S leukemia has been described in detail before. 22,23 
Preparation of cell suspensions 
BNML or normal spleen cells. Monocellular suspensions were obtained by mincing the 
enlarged spleens of end stage leukemic animals or the spleens of untreated rats, and gently 
squeezing the suspension through nylon gauze. The cells were washed and suspended in 
Hanks' balanced salt solution (HBSS; Gibco, Paisley, UK). The number of nucleated cells 
was counted in TUrks' staining solution (0.005% Crystal Violet, 1 % acetic acid, in H20) 
using a BUrker-type hemocytometer and adjusted to the final cell concentration required. 
Peripheral blood (PH) samples were obtained by orbital punctures. The blood WllS 
collected in small plastic tubes containing ethylene-diaminctetra-acetic acid (EDTA; Sigma, 
S!. Louis, MO, USA) to prevent coagulation. When peripheral blood lymphocytes (PBL) 
were prepared for immunophenotypic analysis the erythrocytes were lysed first (lysing buffer: 
O.IS M NH4CI, Merck, Darmstadt, Oermany; 0.01 M NaHC03, Merck; 0.1 mM EDTA, 
Sigma). The suspension was then centrifuged, the pellet resuspended in HBSS and the PBL 
counted. 
Bone marrow cells were isolated by repeated flushing of the cavity of tibiae and femora 
with HBSS. A single cell suspension was obtained by sieving the BM through nylon gauze. 
Subsequently the cells were washed, counted and the cell concentration adjusted. 
Total body irradiation 
To reduce the leukemia cell load and induce a state of so called 'minimal residual disease' 
(MRD; few leukemic cells survive the conditioning regimen21 ), lethal totnl body irradiation 
(TEl, 8.5 Gy) was applied. The rats were irradiated unilaterally in plastic cages, containing 
eight animals at a time, using a Philips X-ray generator (300 kV, 10 mAl at a dose rate of 48 
cOy.min- l . Subsequently, the rats were rescued by the inoculation of 108 BM cells +/- spleen 
cells (Lv.). 
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Chimerism: Immrmophellotyping of PBL post BMT 
Single cell suspensions of PBL, washed and resuspended in PBS/BSA (PBS, NPBI, 
Amsterdam, The Netherlands; 1% BSA, Sigma; 0.01 % NaN3, Merck) were labeled with 
murine monoclonal antibodies (MCA's) directed to the BN (OX-27 25) or the WAGfRij 
(U9F4 26) inbred rat strain specific cell surface Ag (RT-I.An and RT·I.Au, respectively), or 
incubated with PBSIBSA serving as negative controls. Subsequently, the cells were incubated 
with FITC-conjugated rat anti-mouse Ig (Jackson Laboratories, Maine, U.S.A.) and analyzed 
on a F ACScan flow cytometer operating with a single argon (488 nm) laser (Becton 
Dickinson, Mountain View, CA, USA). For data analysis, the FACScan research software 
program Consort 30 (Becton Dickinson) was used. 
The OX-27 and U9F4 hybridoma cell lines were kindly donated by Dr. D. Mason (Oxford, 
U.K.). The antibodies were produced intraperitoneally (Lp.) in BALB/c mice and purified on 
a protein A column (Dr. P.H. van der Meide, Immunosciences, BPRC-TNO, Rijswijk, The 
Netherlands). 
Survival t;,ue assay 
. This assay is based on the log-linear relation between the number of leukemia cells inoculated 
and the sllIvivai time of the rats.21 ,27,20 The antileukemic effect of a particular treatment can 
be deduced from the increase of life span (ILS) of the treated group compared with the 
untreated leukemia control group (11=8 rats/group). A treatment inducing an ILS of 4.0 days 
corresponds with the extra survival time of animals with a IO-fold lower leukemia cell load 
and is referred to as a I LCK. In addition, gross pathology (e.g. spleen and liver weight, bone 
marrow smears) will confirm the cause of death (GVHD, take failures, leukemia). 
Statistical Analysis 
Survival time analysis of rats from the different experimental groups (11=8 rats), was 
performed according to Peto et aPS,29 
6.4 RESULTS 
6.4.1 Fl-to-parellt BMT ill the BNML model 
BN rats were inoculated with 105 BNML cells on day 0, subjected to total body irradiation 
(TBI, 8.5 Gy X-rays) on day 7 and subsequently given a BMT on day 8. 
The 17 days ILS observed after syngeneic BMT compared with the leukemia control group 
indicates the significant (p=O.OOI) antileukemic effect of the TBI, reflecting 4.3 log leukemic 
cell kill (LCK; Figure 6.1). To estimate the residual leukemic cell load at the time of BMT, 
the survival time after the irradiation was monitored. The median survival time (MdST) of 
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Figure 6.1 FI to BN BMT, Survival curves of leukemic animals treated with semi-allogeneic BMT ± 
splenocytes versus syngeneic BMT and leukemia control groups (II =8 rats pcr group). The rats were inoculated 
with 105 BNML cells Lv. on day 0, subjected to TBI (8,5 Gy X-rays) on day 7 and to BMT (108 BM cells ± 108 
splenocytes Lv.) on day 8. All transplanted rats died of leukemia relapse; ( ) 105 BNML Lv.; 
___ ) + syngeneic BMT; ( ...... " ...... ) + Pi BMT; ( _____ ) + FI BMT + 108 PI splenocytes, 
syngeneic transplanted animals was 43 days post-TBI, indicating that 102 leukemic cells 
survived the conditioning regimen (according to standard BNML growth curves), meeting the 
criteria for MRD20,21,27 
Transplantation with hybrid rat strain (Pl) marrow induced a 3 days increase in the MdST 
compared with the rats transplanted with syngeneic marrow (p=not significant: NS). To 
evaluate the possible induction of an antileukemic effect of high numbers of semi-allogeneic 
lymphocytes, 108 FI splenocytes were added to the FI marrow graft because rat BM contains 
few T-Iymphocytes (S-8% CDS+ cells)9 This high number of FI splenocytes did not induce a 
significant difference in survival (MdST~S2 days), compared with transplantation of 
syngeneic or FI BM alone. All transplanted groups (1l~8 rats) died of leukemia relapse 
(Figure 6.1). 
6.4.2 FI-Io-parenl BMTin Ihe LA415 model 
W AGlRij rats were inoculated with 106 lA41S cells at day 0, TBI and BMT were performed 
at days 7 and 8, respectively. TBI followed by syngeneic BMT yielded a significant ILS 
(p~O.OOI) indicating 3.6 LCK (13 days median ILS: data not shown). The MdST of the rats 
receiving a syngeneic graft was 24 days post-TBI with all rats dying of leukemia relapse, 
indicating a residual leukemic cell load of 5xl03 cells. 
Transplantation of FI marrow did not induce a significant decrease in MdST (28.S days: 
data not shown) compared with syngeneic BMT. Two (of eight) recipient rats died of aplasia 
whereas the other six animals died of leukemia relapse in the same range as the syngeneic 
transplanted group. Addition of 108 F 1 splenocytes to the semi-allogeneic marrow inoculum 
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did not change the survival time compared with the recipient rats receiving semi-allogeneic 
BM only. All rats died from leukemia relapse. Thus, similar to the observation in the BNML 
model, no antileukemic effect could be observed in the rat ALL model after semi-allogeneic 
BMT ± high numbers of F 1 lymphocytes. 
6.4.3 Chimerism after FI.to.parent BMT 
control 
(BN) 
27 52 64 88 
Days alter BMT 
Figure 6.2 Immullophenotyping PBL of semi-allogeneic transplanted animals (PI to BN BMT; BM only) at 
various timepoints post BMT versus untreated BN rats. Mean percentages positively reacting cells from 4 
animals ± S,D. are represented. After BMT, all PBL show a high expression of both types parental class I Ag (as 
in FI rats); (I11III) OX-27 (class I, BN); dl]) U9F4 (class I, WAGIRij). 
To establish the state of chimerism in recipients of F 1 marrow, peripheral blood samples were 
drawn from four recipient rats at various time points after BMT. PBL were immuno~ 
phenotyped using the rat strain specific class I MeA's QX·27 (RT.I.An)25 and U9F4 (RT· 
I.AU)26 The mean (+1- S.D.) percentage positive cells of the control (P) rats versus recipients 
of PI BM cells alone, clearly illustrate full donor chimerism at each timepoint investigated 
after FI·to·P BMT both in the BNML model (Figure 6.2) and the L4415 model (data not 
shown). 
6.4.4 Growth characteristics oft/Ie BNMLaf!d L441S lellkemia if! FI rats 
Fl rats were inoculated Lv. with graded numbers of BNML and L4415 cells to define the 
correlation between leukemic cell dose and survival time. 
The growth of BNML in FI rats is accompanied by severe paralysis. Histological 
examination revealed growth of leukemia cells in all marrow compartments but limited in 
spleen and liver. Leukemia outgrowth from the vertebral bones led to compression of 
peripheral nerves, leading to the observed paralysis. First symptoms of paralysis of the front 
limbs were observed only 20 days after the inoculation of 107 leukemic cells, four days later 
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all rats were totally paralyzed and were therefore sacrificed. Since no reproducible dose-
survival relation could be established for BNML growing in the hybrid rat strain, BNML was 
not further used in the parent-to-FI transplantation studies. 
40 
R2= 0.958 
Number of L4415 cells i.v. 
Figure 6.3 Correlation between L4415 leukemic cell dose inoculated (Lv.) in FI(WAGfRij x BN) rats and 
survival time (11 =8 rats per point). Logarithmic regression analysis results in a correlation coefficient of 
variation ofO.958 (Rl). Vertical bars indicate S,E. 
Graded numbers of lA415 cells induced death of leukemia in all recipients. A significantly 
enlarged spleen (;;'5 g) frequently with spleen rupture, an increased liver weight (;;,20 g), 
gastrointestinal and pulmonary hemorrhage and enlargement of thymus and lymph nodes 
were prominent features at autopsy. The lA415 leukemia growth in FI rats developed similar 
to that observed in the W AG/Rij rat strain23 with a slightly slower growth pattern. As is 
shown in the correlation between the number of L4415 cells inoculated in the F I and the 
survival time, I log leukemia cells correlates with 4.3 days in life span (Figure 6.3). 
6.4.5 Parent-to-Fl BMT illihe lA415 lIIodel 
To evaluate the antileukemic efficacy of transplanted lymphocytes either sharing their Ag 
with the leukemia cells or expressing allogeneic MHC Ag, the L4415 acute lymphocytic 
leukemia growing in the FI(WAG/Rij x BN) has been used as a recipient of BN or W AG/Rij 
BMT. 
6.4.5.a BN-Io-FJ BMT 
FI rats were inoculated with 106 L4415 cells on day O. Since the L4415 leukemia growth 
pattern in the hybrid rat strain is slightly slower, irradiation of the leukemic animals was 
postponed till day 14 and the BM graft was given on the same day. TBI followed by 
syngeneic (FI) BMT induced a significant ILS (15 days: p=0.002) indicating 3.5 LCK 
(Figure 6.4). The MdST of the rats receiving a syngeneic graft was 21 days post TEl with all 
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rats dying of leukemia relapse, indicating that 4xl06 cells leukemic cell survived the 
conditioning regimen. 
Transplantation of BN marrow induced a MdST of 47 days (Figure 6.4), hence an ILS of 
12 days (correlating with 2.8 LCK) compared with the animals receiving a syngeneic graft 
(p;0.002). Addition of ]OS (or ]06: data not shown) parental splenocytes to the marrow graft 
increased the MdST 17 days (corresponding with 4.0 LCK) compared with syngeneic BMT, 
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Figure 6.4 BN to F I BMT. Survival curves of leukemic animals treated with semi- allogeneic BMT ± 
splenocytes versus syngeneic BMT and leukemia control groups. The groups receiving syngeneic BM and semi-
allogeneic BM+ to7 splenocytes existed of 6 recipient rats. All other groups consisted of 8 recipients. The rats 
were inoculated with 106 L4415 cells Lv. on day 0 and subjected to TBI (8.5 Gy X.rays) and BMT (l08 BM 
cells ± splenocytes Lv.) on day 14. One rat from the group transplanted with BN marrow only was censored 
(dying of aplasia on day 29). The rats died from leukemia relapse but in the group receiving lO7 splenocyles, all 
rats died from acute GVHD; ( ) lO6 L4415 Lv.; ( ) + syngeneic BMT; ( .......... ,) + BN 
BMT; ( _____ ) + BN BMT + 105 splenocytes; (_._._._._ .. ) + BN BMT + 107 spienocytes. 
with all rats dying from leukemia relapse. The highest dose of additional splenocytes studied 
i.e. ]07 cells, reduced the MdST compared with the other groups receiving BN BMT (40 
days), with all animals dying of acute GVRD (Figure 6.4). The observed signs of severe 
GVHD were red ears, paws and snout, hair loss, diarrhea, cachexia and a hunched 
appearance. At autopsy, no macroscopic evidence for leukemia regrowth was observed. 
6.4.S.h. IVAGIRij-to-FI BMT 
As was shown in the BN to Fl transplantation, the residual leukemia cell load after the 
delayed radiotherapy and subsequent syngeneic BMT was relatively high. To further reduce 
the leukemia cell burden, the conditioning and BMT were performed 7 and 8 days after the 
inoculation of ]06 L4415 cells, respectively. The significant (p;0.001) ILS induced by the 
irradiation and syngeneic BMT compared with the leukemia control group was 10 days (2.3 
LCK; Figure 6.5). The MdST of the syngeneic (Fl) transplanted group was 41.5 days (34.5 
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days post-TBI) reflecting a residual leukemic cell load of 2x103 with all rats dying from 
leukemia relapse. 
Transplantation of WAGlRij marrow resulted in a MdST of 42 days, the addition of 106 
(or 107: data not shown) W AG/Rij splenocytes to the parental marrow graft reduced the 
MdST to 38 days (Figure 6.5). All rats died from recurrent leukemia. The transplantation of 
FI rats with WAGlRij marrow with the highest dose of additional spleen cells studied, i.e. 
108 splenocytes, resulted in a MdST of 37.5 days with all rats dying with symptoms of severe 
GVHD. At autopsy, four of eight rats were found to have normal liver and spleen weights, 
whereas the other rats (4/8) showed significant enlargement of the spleen and liver, indicating 
leukemia regrowth concomitant with GVHD. Thus, no antileukemic effect could be observed 
after the addition of high numbers of semi-allogeneic splenocytes sharing their MHC Ag with 
the leukemic cells, even when lethal GVHD was induced. 
An additional 'control' group of F I rats was transplanted with BN marrow supplemented 
with 105 BN splenocytes to reproduce the significant antileukemic effect observed in the 
previous experiment, applying the postponed conditioning regimen. Once more a significant 
(p=0.003) ILS could be observed compared with the syngeneic transplanted group (12 days; 
correlating with 2.8 LCK), with all rats dying of leukemia relapse (Figure 6.5). 
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Figure 6.5 WAGfRij to FI BMT, Survival curves of leukemic animals treated with semi-allogeneic BMT ± 
splenocytes verslls syngeneic BMT and leukemia control groups (11 =8 rats per group), The rats were inoculated 
with 106 L4415 cells Lv. on day 0, subjected to TEl (8.5 Oy X-rays) on day 7 and to BMT (108 BM cells ± 
splenocytes Lv.) on day 8. The rats died from leukemia relapse but in the group receiving 108 spienocytes, all 
rats died from acute OVHD; ( ) 106 L4415 Lv.; ( ) + syngeneic BMT; ( _________ .,) + 
WAGlRij BMT: ( _____ ) + WAGlRij BMT + 106 sptenocytes: ( •. _._._._ . .) + WAGlRij BMT + 108 
splenocytes; ( __ _ ) + BN BMT + 105 splenocytes. 
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6.4.6 Chimerism afterparellt-to-FI BMT 
Peripheral blood samples were drawn from four recipient rats at various time points after 
parental BMT to establish the state of chimerism. PBL were immunophenotyped using the rat 
strain specific MeA's (OX-27 25 and U9F4 26). The mean (+/- S.D.) percentage positive cells 
of untreated control (Fl) rats versus recipients of parental strain BM cells alone, clearly 
indicate full donor chimerhm at each timepoint investigated after semi-allogeneic BMT, both 
after transplantation with BN marrow (Figure 6.6) and WAGlRij marrow (data not shown). 
control 27 57 86 117 
(FI(WAGlRij x BN)) 
Days after BMT 
Figure 6.6 Immunophenotyping PBL of semi-allogeneic transplanted animals (BN to FI DMT; BM only) at 
various timepoinls post BMT toerSf/S untreated PI rats. Mean percentages positively reacting cells from 4 
animals ± S.D. are represented. After BMT, all PBL show a high expression of BN class I Ag and low 
('background level') of WAGIRij class lAg; (II) OX-27 (class I, BN); ([]]) U9F4 (class I, WAGlllij), 
6.S DISCUSSION 
To date the pathophysiological mechanism of the GVLR has not been well defined. The 
involvement of immunocompetent donor T-cells in the GVLR is well established, both in 
animal models7,8 and in man. 12,13 It is not clear whether the mechanisms of the GVLR are 
separable from those operative in GVHD. Evidence has been reported about at least two 
elements of the GVLR; one that is dependent on the presence and the intensity of GVHD30 
and the other one operating without clinically overt GVHD. t8,3t The latter would allow 
enhancing the GVLR while minimizing GVI-ID. In this way a more safe and complete 
eradication of leukemic cells still present after the conditioning regimen may be achieved. 
However, to determine whether this can be accomplished, a better understanding of the 
mechanisms of the GVLR and its mediators is warranted. 
Using the BNML and the L4415 rat leukemia models, we have previously shown that the 
addition of critical numbers of allogeneic (MHC mismatched) unseparated lymphocytes to the 
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allogeneic graft, as a model for human allogeneic HLA matched full marrow grafting, 
induced a maximal GVLR correlating with 2-3 LCK without symptoms of obvious GVHD.9 
Further increased numbers of additional allogeneic splenocytes induced acute lethal GVHD. 
Using the BNML model, studies on administration of IL-2 post BMT have shown that 
optimal IL-2 therapy after 'allogeneic T-cell depleted BMT' generates an antileukemic effect 
correlating with 6.4 LCK, which makes up for the loss of GVL after T-cell depletion24 
Higher doses of IL-2 after allogeneic BMT induced acute lethal GVHD. The present paper 
describes our studies on GVL and GVHD in the BNML and L4415 rat leukemia models using 
semi-allogeneic hybrid-to-parent and parent-to-hybrid BMT with and without the addition of 
graded numbers of spienocytes. 
In both models, the survival time of leukemic BN and W AG/Rij rats treated with 
syngeneic BMT indicated a state of MRD after the conditioning regimen (l02 and 3xlO5 
residual leukemia cells, respectively). Neither the transplantation of hybrid strain marrow 
only nor the addition of high numbers of semi-allogeneic splenocytes to the Fl graft 
significantly changed the life span of the recipient rats compared with the rats given a 
syngeneic marrow transplant. Thus, these data indicate that hybrid-to-parent BMT, even when 
high numbers ofFllymphocytes are present in the graft, did not induce GVL. 
Since the BNML caused severe paralysis before antileukemia effects could be evaluated in 
the hybrid rat strain, parent-to-F I BMT was not further studied using the BNML model. 
L4415 leukemia was shown to have a similar growth pattern in the hybrid rat strain as in the 
parental rat strain. Thus; the hybrid rat that shared half of the alloantigens with the parent-
type tumor cells was immunologically incapable of rejecting the L4415 leukemia cells. This 
model permitted the generation of GVHD in a hybrid recipient by using either parent as a 
donor whereby the GVHD producing effector cells were either histocompatible or 
incompatible with the leukemia cells. 
Syngeneic BMT after delayed TBI in FI rats carrying L4415 leukemia, indicated a 
relatively high residual leukemia cell load (4x106 cells). Nevertheless, transplantation of BN 
marrow only resulted in a significant ILS compared with syngeneic BMT. Addition of critical 
numbers (l05 or 106) ofBN splenocytes further increased the survival time (correlating with 
4.0 LCK) without inducing GVHD, whereas higher numbers of parental lymphocytes induced 
acute lethal GVHD. 
To induce MRD, the hybrid strain recipients of L4415 leukemia were subjected to TBI on 
day 7. The MdST (post TBI) of rats given a syngeneic marrow transplant indicated a residual 
leukemia cell load of 2x 103 cells. Transplantation of W AG/Rij BM ± the addition of high 
numbers of parental splenocytes (up to 107) did not induce an antileukemic reaction 
compared with syngeneic BMT, and all rats died from leukemia relapse. The addition of 108 
WAG/Rij splenocytes induced acute GVHD. At autopsy, 50% of these recipients showed 
leukemia specific characteristics such as hepatosplenomegaly, indicating that the leukemia 
growth was not hampered by GVHD. In the same experiment, a group of recipient F 1 rats 
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was transplanted with BN marrow and 105 additional splenocytes. Again, these rats were 
shown to have a significantly increased life span compared with the syngeneic transplanted 
rats, without 'clinical' signs of GVHD. These data indicate that semi-allogeneic lymphocytes 
sharing their alloalltigens with the leukemia cells are not capable to induce an antileukemic 
effect, even when they do induce acute GVHD. Thus, the GVL effects observed after MHC 
mismatched allogeneic BMT in these rat models for leukemia are mere allogeneic effects, 
confirming results of Tutschka et al. 32 
These results seem to be in contrast with several reports mentioning the in vitro induction 
of cytotoxic T-lymphocytes (CTLs) specific for allogeneic leukemia cells or nonleukemic 
cells, or lysing both leukemic and nonleukemic target cells,33,34 and their correlation to the 
GVLR if! vivo in a murine mode1.35,36 These observations were made in studies on MHC 
matched, minor histocompatibility Ag mismatched transplantations, whereas we have studied 
MHC misnmtched BMT. Though the reports on allogeneic MHC matched leukemia specifiC 
CTLs are promising, their role in the GVL effects observed in vivo still has to be proven. As 
the higher reactivity of MHC mismatched lymphocytes seems to be logical (greater disparity), 
it still needs to be confirmed that the in vitro 'leukemia specific' CTLs are capable to exert 
their effect in vivo through that same leukemia specific pathway. For ill vivo application, the 
cell numbers need to be largely expanded and the specificity could be lost. Even when these 
cells are able to induce an evaluable in vivo antileukemic effect, this may turn out to be an 
alloreaction of minor histocompatibility Ag mismatched lymphocytes, comparable to the 
'threshold' effect exerted by MHC mismatched lymphocytes. Nevertheless, the 'threshold' 
effect induced by minor histocompatibility mismatched lymphocytes probably reveals a wider 
therapeutical window compared with MHC mismatched lymphocytes. 
In fact, donor buffy coat transfusions in patients with chronic myelocytic leukemia 
showing leukemia relapse after HLA matched allogeneic BMT have recently been reported to 
induce a GVLR. The majority of patients had complete hematologic and cytogenetic 
remission persisting 28-91 weeks37,38 but most of these patients also developed acute or 
chronic GVHD which responded well to immunosuppression without losing its antileukemic 
efficacy.39,40 These data confirm that minor histocompatibility mismatched lymphocytes are 
capable of inducing a significant GVLR, often accompanied by controllable GVHD. 
Further studies on the nature of lymphocyte (sub-) populations and cytokine involvement 
in GVLR and GVHD in response to major- and/or minor histocompatibility complex Ag in 
allogeneic BMT are essential to further develop and refine therapeutic approaches. Currently, 
several possible treatment strategies to optimize the GVLR without the induction of severe 
GVHD, e.g.IL-2 therapy after T-cell depleted allogeneic BMT24, are encouraging. 
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CHAPTER 7 
SUMMARY AND GENERAL DISCUSSION 
7.1 INTRODUCTION 
Allogeneic hone marrow transplantation (BMT) transfers both hemopoietic stem cells and 
alloreactive donor lymphocytes. The latter are capable of responding to host antigens, leading 
to a form of adoptive immunotherapy (Chapter I), The antileukemic effect mediated by 
immunocompetent donor celJs is known as the graft-versus-leukemia (OVL) effect and has 
been well characterized in animals. 1-3 In humans, the presence of the GVL reaction has been 
supported by indirect evidence that relapse rates are significantly higher after transplantation 
of T-cell depleted allogeneic donor bone marrow (BM)4-6 and autologouslisologous grafts5 
compared 'with allogeneic. 'full' marrow transplantation. The occurrence of graft-versus-host 
disease (GVHD) after BMT is associated with lower relapse rates,4-8 and patients with a 
relapse of leukemia may enter remission when GVHD follows the withdrawal of 
immunosuppression (Chapter 1)9-11 
Leading investigators in the field of experimental and clinical BMT for leukemia have 
expressed the opinion that elucidation of the nature of the GVL effect and its therapeutic 
exploitation should be one of the highest priorities among attempts to improve cure 
rates.1,12,13 An issue which has not yet been finally resolved is whether GVL independent of 
GVHD can be documented and whether clinical approaches to amplify GVL without GVHD 
can be developed, Although several experimental data as well as a recent analysis from the 
International Bone Marrow Transplant Registry (illMTR) suggest that some of the GVL 
effects observed may be independent from GVHD, identification of leukemia-specific 
effector cells and leukemia-specific target molecules that may serve as antigens for donor-
type T lymphocytes have not yet been clearly documented,I4 
7.2 GVL IN THE RAT LEUKEMIA MODELS 
Transplantable leukemias growing in animals, preferentially inbred rodent strains, offer the 
opportunity to reproducibly manipulate initial leukemia cell dose and intervene in leukemia 
growth, Animal leukemias are relevant when they share many characteristics with human 
leukemias, e,g, specific homing, low antigenicity and sensitivity to drugs and radiation, The 
studies reported here were performed with the acute myelocytic leukemia (AML) 
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transplantable in the inbred Brown Norway rat strain (BNML)t5-t7 and the L44l5 acute 
lymphocytic leukemia (ALL) transplantable in the inbred W AGlRij rat strain. t8.t9 Both 
leukemia models show a reproducible growth pattern upon intravenous (Lv.) transfer. 
Survival time following Lv. inoculation is inversely related to the logarithm of the number of 
leukemic cells in the inoculum. This log-linear relationship between leukemic cell load and 
survival time allows an accurate estimation of the treatment-induced antileukemic effect, by 
recording prolongation of survival. As opposed to many other experimental rodent leukemias, 
one of the many characteristics which these rat leukemias have in common with human 
leukemia is that they seem to be non-immunogenic (Chaptcl' 2). 
GVHD 
Mortafity 
MorbIdity 
Subclinical GVHD 
GVL 
No measurable 
anltlleukemlc effect 
Manipulation of the Inoculum 
and/or treatment of recipient 
GVL 
Figure 7.1 Schematic representation of the hypothesis that GVL (within the therapeutical window) = 
subclinical GVHD. Different susceptibility to the donor lymphocytes between leukemic and normal cells causes 
the 'threshold'~cffecl which may lead to the confusion that GVL and GVHD are two different reactions; T-W, 
therapeutic window. 
We showed that it was not possible in these leukemias to induce an antileukemic effect 
with syngeneic (Chapter 3) or semi-allogeneic (Fl to parent; Chapter 6) BMT. Since the 
transfer of fully MHC-mismatched allogeneic marrow does (normally) not induce GVL or 
GVHD, the transplantation of allogeneic BM in the rats resembles human allogeneic HLA-
matched T-cell depleted BMT (Chapter 3). The addition of increasing numbers of allogeneic 
spleen cells. as a source of lymphocytes, to the BM graft induces GVL and. at higher 
numbers, lethal acute GVHD. Thus, the transplantation of allogeneic rat marrow with 
additional splenocytes serves as a model for 'full' marrow grafting in man. In these models the 
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same cells seem to induce/mediate both GVL and GVH reactions, but quantitative differences 
in sensitivity of leukemic and normal cells appear to account for a 'threshold' effect, leading 
to a measurable GVL effect before GVHD becomes evident. The GVL effect further 
increases beyond the 'threshold' with increasing spleen ceB numbers, but concomitantly 
GVH-morbidity emerges. The therapeutic window was found to be narrow, the resulting 
increase in life span correlates with 2-3 log leukemic cell kill. Therefore we hypothesize that 
GVL, within the therapeutical window, is merely a subclinical GVH reaction (Figure 7.1). 
Nevertheless, a significant GVL effect without the induction of overt GVHD could be 
observed when critical numbers of allogeneic splenocytes were added to the marrow graft 
(Chapter 3). Unfortunately, the separation of the GVL from GVHD could no longer be 
achieved after a microbiological change of the rat intestinal microflora. However, the results 
are in concert with data reported by other investigators who used partially depleted BM. 
Results of their studies suggest that there may be an 'optimal' number of T-cells residing in 
the allogeneic graft, reducing the incidence and severity of GVHD to tolerable levels while 
preserving a GVL effect20·22 
7.3 DEPLETION OIl LYMPHOCYTE SUBSETS 
It is generally accepted that T-cells are the major contributors to the GVL effect and to 
GVHD. Assuming that there is not only a quantitative effect of allogeneic T-cells on GVL 
andlor GVHD but also a qualitative difference between the T-cells, an approach to prevent 
GVHD different from reducing the T-cell numbers may be depletion of a specific lymphocyte 
subset. In an attempt to separate the observed GVL and GVHD inducing capacity, 
lymphocyte subsets were depleted from the allogeneic spleen cells prior to transplantation 
into leukemic rats using the BNML model (Chapter 3). Lymphocyte depletion was 
performed with monoclonal antibodies (MCA's) specific for CD4 and CD8, and magnetic 
beads coated with a MCA binding the Fc of the CD4 or CD8 specific murine MCA's. The one 
step, two log depletion of CD4 or CD8 positive cells, was cumbersome but feasible. 
Subsequently, the CD4 or CD8 negative fractions of splenocytes were added to the marrow 
graft, correcting for the percentages of CD4 and CD8 negative cells present in the 
unseparated spleen cell suspension. 
It was clearly shown that the depletion of CD4+ cells completely prevented GVHD. When 
CD8+ lymphocytes were depleted from the spleen cell suspension, the incidence of lethal 
GVHD was still 100%, but the progression of the disease was reduced in all recipient rats. 
Unfortunately, in the experiment adding CD4 depleted or CD8 depleted splenocytes to the 
allogeneic marrow graft, no evident GVL effect could be observed in the rats receiving the 
critical dose of unseparated allogeneic spleen cells normally inducing the maximal GVL. 
Therefore we can not deduce any conclusions on the depletion of CD4 or CD8 positive cells 
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as regards the GVL effect. Attempts to obtain prove of a pivotal role of CD4+ T -cells in the 
GVL effect failed because of the inability to reproduce the separation of GVL and GVHD 
(see above). In view of the close linkage of GVHD aud GVL, it seems nevertheless very 
likely that CD4+ T -cells are also responsible for the autileukemic effect. 
Our conclusions are in agreement with experimental data reported by Truitt et al. and 
Sykes et a!. They have shown that CD4+ T-eells playa critical role in causing GVHD in fully 
mismatched murine strain combinations, and that CDS+ T-cells given alone do not cause 
acute GVHD.23-25 Moreover, it was proven in these murine models that CD4+ cells can 
contribute to GVL effects23 It was reported by Korngold et a!. that both CD4+ and CDS+ T 
lymphocytes playa crucial role in GVHD in mice. It appears that the T-cell subset involved 
was dependent on the MHC or mH antigen differences between donor and recipient.26 In 
some mH antigen disparate strain combinations both subsets appear to be equally involved,27 
A promising clinical trial of selective donor CDS+ cell depletion provided information on T-
cell subsets mediating GVHD and GVL in man (HLA-identical sibling BMT for CML in 
chronic phase). This study demonstrated a reduction in, but not absence of, GVHD, whereas 
leukemia relapse rates were low.28 ,29 When relapse rates remain low with adequate follow-
up, CDS depletion of the allogeneic marrow graft or addition of CD4+ cells to the T-cell 
depleted graft seems to be favorable in the clinical setting (HLA-matched BMT) compared 
with depletion of all T -cells or CD4 depletion of the marrow graft. 
7.4 GVL AND LAK ACTIVITY 
Some authors have described an association between NK activity and GVHD,30-32 and donor 
NK cells or LAK cells have been implicated as effectors of GVHD. 
Other studies indicated that NK cells and LAK cells may playa role in the GVL 
reaction.5,33,34 These cells are able to lyse, most efficiently in the presence of IL-2, a variety 
of tumor cells with limited effect on normal cells. This lytic activity is not restricted to solid 
tumors, but also acute lymphocytic leukemia (ALL) and acute myelocytic leukemia (AML) 
blasts are reported to be susceptible to the lytic activity of autologous and allogeneic LAK 
cells in vitro. 35-39 Clinical studies confirm these preclinical results for acute leukemias.40,41 
Other studies suggest that in AML, but not in ALL, the LAK cell compartment may playa 
role in the clinical course and overall outcome of the disease.42 
We investigated whether lymphokine activated killer (LAK) cells playa role in the GVL 
effect observed in our rat models after allogeneic BMT (Chapte,' 4). Splenocytes from 
W AG/Rij and BN rats were activated ill vitro by recombinant human interleukin-2 (rhIL-2). 
The W AG/Rij and BN derived LAK cells were not capable of lysing the rat leukemia cells in 
contrast to significant cytolytic activity on the rat solid tumor cell lines. To reveal whether 
LAK cytokine production could mediate leukemic cell lysis, graded numbers of LAK cells 
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and leukemic cells were co-cultivated. This resulted in moderate suppression of leukemic 
colony formation. Thus, in the fat model, the GVL effect observed in allogcllcic BMT is most 
probably not due to a direct antileukemic effect of LAK cells. These results are in concert 
with our T-cell depletion data indicating that GVHD (and GVL) effects were abolished by the 
depletion of CD4+ cells. 
It was shown recently that acute GVHD may serve to increase the lytic activity of NK 
cells but does not result in increased numbers of LAK precursors. LAK precursor frequencies 
are below normal during the first two months after BMT, a finding not previollsly recognized 
from bulk culture LAK studies. The role of LAK effectors in GVL may rather involve the 
degree of cellular activation than the number of cells activated.43 
7.5 GVL EFFECTS INDUCED BY IL-2 
Numerous reports both on preclinicaI24,44-51 and clinical studies52-55 have stressed the 
importance of JL-2 in GVL effects and GVHD. 
To explore a possible increase in the GVL effect without aggravating lethal GVHD by 
post-BMT immunotherapy, IL-2 administration has been studied in the BNML model 
(Chapter 5). The results indicated that animals with minimal residual leukemia treated with 
high doses of JL-2 post syngeneic BMT (equivalent to human autologous BMT), showed a 
small, borderline significant antileukemic effect. Future studies on the addition of syngeneic 
lymphocytes, either or not activated with IL-2 in the presence of irradiated BNML cells, to 
the BM graft combined with high dose JL-2 therapy, will reveal whether IL-2 administration 
after autologous BMT may lead to antileukemic effects. A recent report mentioned an 
alternative beneficial procedure for IL-2 therapy and autologous BMT. Transplantation of 
BM autografts activated by culture in IL-2 followed by administration of IL-2 represents a 
novel approach in an attempt to combine ex vivo purging and post-transplant ill vivo 
immunotherapy. Initial clinical results have suggested its feasibility. 56 
Table 7.1 The rat as a model for human allogeneic BMT 
Rat model 
Full marrow 
Full marrow + splenocytes (A) 
Full marrow + IL-2 (B) 
Human equivalent 
T-cell depleted BMT 
Full marrow 
T-cell depleted BMT + IL-2 
Log leukemic cell kill (LCK) in the BN1vIL model: 
(A) 2-3 
(B) 6.4 
GVL 
+ 
+++ 
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Repeated IL-2 treatment initiated 3 days after allogeneic BMT in the BNML model, 
resulted either in no significant antileukemic effect Of in lethal GVHD when 'low' or 'high' 
doses were administered, respectively. An intermediate dose (2x78,OOO IU/day) of 
Proleukin® however, induced a significant antileukemic effect amounting to an increase in 
life span correlating with 6.4 log leukemic cell kill (LCK) without the induction of GVHD 
(Chapter 5). We have shown that the maximal GVLR (without overt GVHD), induced by the 
addition of critical numbers of lymphocytes to the allogeneic graft, corresponds with a 2-3 
LCK. Therefore, it appears that the GVLR lost by T-cell depletion of the allogeneic graft, 
may be more than fully compensated by IL-2 treatment post allogeneic T-cell depleted BMT 
(Table 7.1). Thus, our data show that a major contribution of IL-2 treatment to the GVL 
effects after allogeneic T-cell depleted BMT may be feasible, significantly widening the 
therapeutic window of clinical allogeneic BMT. 
In studies with transplantable leukemia in mice, Sykes et al. observed that after 
transplantation of fully MHC mismatched BM and additional allogeneic lymphocytes, early 
IL-2 treatment (initiated on the day of BMT) selectively inhibits GVHD induced by CD4+ 
cells, but does not affect the antileukemic effects of CD8+ T_cells24•51 In BMT, using 
different mouse combinations, in which both GVL and GVHD were CD4 dependent, IL-2 
treatment inhibited GVHD but not the antileukemic effects of CD4+ cells51 These findings 
suggest that the inhibitory effect of IL-2 is directed against a limited subset or function of 
CD4+ T-cells and that GVL and GVHD can be mediated through different CD4 mechanisms. 
Finally, these authors have shown that the type of CD4 activities mediating GVHD is 
determined by the particular histoincompatibilities between donor and host,25 and that IL-2 
preserves CD4 as well as CD8 mediated GVL effects. 57 However, initiation of IL-2 
administration at later time points, e.g. day 7 post BMT, can exacerbate GVHD. 48,49 
Confirmation of these complicated interactions have to be awaited before the implications for 
clinical practice can be evaluated. 
In conclusion, after syngeneic BMT of leukemic rats it remains dubious whether lL.-2 may 
lead to a GVL effect. Further studies on the addition of syngeneic lymphocytes combined 
with high dose IL-2 treatment will solve this question. The data of Sykes et al. point to the 
GVHD suppressive effects without losing the GVL efficacy of immediate IL-2 administration 
in allogeneic 'full' marrow grafting. They have shown that this response to IL-2 is highly 
dependent on the timing of administration and the degree of histoincompatibility between the 
donor and recipient. Nevertheless, this approach seems to bear a high risk of GVHD. Our data 
indicate that IL-2 therapy post allogeneic T-cell depleted BMT provides a significantly wider 
therapeutical window compared with allogeneic 'full' marrow grafting. Moreover, promising 
results of a phase II study, using low dose IL-2 after allogeneic T-cell depleted BMT for 
hematologic malignancies, were recently published.55 Thus, a randomized controlled trial of 
IL-2 immunotherapy after allogeneic (HLA-identical), T-cell depleted BMT for leukemia is 
warranted. 
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7.6 GVL EFFECT; LEUKEMIA-SPECIFIC OR MERELY AN ALLOGENEIC REACTION? 
To date, discussion is still going on whether the GVL effect and GVHD are two different 
reactions or that both effects are caused via the same mechanism(s), Both the T-cell subset 
depletion studies and the IL-2 therapy studies have so far failed to prove a distinct GVL 
reaction apart from GVHD. Both reactions are highly dependent on the histocompatibility of 
the donor and the recipient. Even when they are MHC-matched, the minor histocompatibility 
complex antigens may lead to both GVL and GVH reactions. 
Using the BNML and the L4415 rat leukemia, it was attempted to evoke a GVLR distinct 
from GVHD by using semi-allogeneic hybrid-to-parent or parent-to-hybrid BMT (Chaptet· 
6). Firstly, in hybrid-to-parent transplantation, no GVHD can be induced. Similarly, the 
addition of large numbers of lymphocytes to the hybrid marrow graft did not induce a GVL 
effect. 
In parent-to-hybrid BMT, the grafts sharing their alloantigens with the leukemia cells did 
not induce an antileukemic effect, irrespective of the number of lymphocytes present in the 
graft or the induction of (lethal) GVHD. When the parental graft was histoincompatible with 
the leukemic ceils, transplantation of bone marrow alone induced a significant increase in life 
span. Addition of critical numbers of histoincompatible splenocytes to the graft further 
increased the antileukemic effect without obvious signs of GVHD. The antileukemic effect of 
BM only might be explained by the fact that the leukemic cells are the exclusive cells being 
completely mismatched to the donor lymphocytes compared with the haploidentical recipient 
cells, increasing the GVLlGVHD 'threshold'. Higher numbers of splenocytes induced acute 
lethal GVHD. The results provide the most compelling evidence that the GVL effect, 
observed post MHC-mismatched BMT in these rat leukemia models for ALL and AML, are 
mere allogeneic effects, un separable from GVHD. These data again point at a quantitative 
difference in sensitivity of leukemic and normal cells accounting for apparently distinct 
GVLlGVH reactions, confirming our earlier (Chaptel' 3) hypothesized 'threshold' effect. 
Another approach to separating the beneficial from the harmful effects of allogeneic T-
cells comprises the in vitro expansion and cloning of donor T -cells that specifically react to 
host leukemia celis, but that do not recognize non-malignant recipient cells. It has been 
demonstrated that leukemia 'specific' CTL lines and clones could be generated from the 
peripheral blood of MHC identical siblings of patients with leukemia, which do not recognize 
non-malignant cells from the same patient ill vitro.58 ,59 The specific recognition of some 
leukemias/lymphomas by effector cells might be explained by the expression of so called 
fusion proteins, encoded for by gene rearrangements as a result of chromosomal 
translocations. Well known examples are BCR-ABL, as a result of the translocation t(9;22) in 
Philadelphia chromosome (Phi) positive CML and ALL, the E2A-PBX protein associated 
with t(I;19) in pre-B cell ALL, PML-RAR after t(l5;17) in acute promyelocytic leukemia 
(PML) and DEK-CAN in t(6;9) AML60-62 The AML cells used to stimulate the 'specific' 
133 
Chapter 7 
CTL clone exhibited the chromosomal translocation t(8;16). Nevertheless, the specificity was 
not associated with this translocation since the other AML samples recognized by the CTL 
clone did not display t(8;16).59 To explore the possibility of clinical application of donor-
derived CTL lines directed against the leukemic cells from patients who relapsed after 
allogeneic BMT, Falkenbnrg et aJ. performed a pilot study using eight donor-recipient 
combinations.63 In five of these cases, the CTL Hnes showed reactivity with the leukemic 
cells, but not with the IL-2-stimnlated lymphocytes from the same individual, iIlustratiug a 
'relative specificity' for leukemic cells. However, this does not exclude possible reactivity 
with antigens expressed on the target organs of GVHD. 63 It can be imagined that slich 
leukemia 'specific' T -cells are quite rare in normal peripheral blood. Their separation from T-
cells that do induce GVHD, subsequent in vitro cloning and expansion may be impractical in 
the setting of BMT.64 
A less sophisticated hut, so far, more applicable method is the administration of donor 
buffy coat cells to induce remission in patients whose CML and AML had relapsed after 
allogeneic BMT65-73 Although details of the protocols varied, it has been shown that 
unseparated allogeneic buffy coat mononuclear cells have a striking capacity to destroy CML 
ill vivo. Even though acute GVHD occurred in a high percentage of the patients (grade II-IV 
in 51 %), mortality was directly attributed to GVHD in only one patient (= 2.2%). A 
retrospective comparison of the disease free survival reported in these studies, with the results 
of a second BMT shows that both the relapse rate and therapy-induced mortality are 
substantially lower with buffy coat infusions.74,75 It appears that the GVL reaction is more 
effective in chronic-phase CML than in other hematologic malignancies Of advanced CML. 
However, retrospective analyses do support the presence of a GVL effect in non-Hodgkin's 
lymphoma 76 and the acute leukemias.5,69 Thus, further studies in these hematologic disorders 
are needed to reveal the feasibility of reliably inducing leukemia remission with donor buffy 
coat infusions, without the induction of severe (lethal) GVHD. 
7.7 FUTURE PROSPECTS 
Ongoing studies will disclose whether it will be possible to optimize the currently used 
culture, stimulation and cloning techniques to obtain leukemia specific CTL lines, 
preferentially for each single patient (in remission), on such short notice that residual 
leukemia can be eliminated before the number of proliferating target cells exceeds the limits 
of 'immunotherapy'. Newly discovered cytokines and cytokine-therapy studies will 
continuously improve our knowledge on and insight in the necessities of ex vivo lymphocyte 
culturing, stimulation and cloning, and the prevention of anergy andlor apoptosis once these 
ceBs are retransplanted. 
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In the meantime, appropriate follow-up of the patients already treated, together with 
further studies on the administration of donor buffy coat lymphocytes to CML patients and 
patients with acute leukemia in relapse after allogeneic BMT will strive to improve this 
approach, Until now, only Drobyski et a1.67 have attempted to administer a 'standard' number 
of donor T -cells. Complete molecular remissions were reported with as few as 0.34 x 108 
cells/kg whereas some patients receiving far larger doses showed no response. It will be 
important to establish a 'threshold' dose of effectors, in combination with the degree of 
histoincompatibility, to administer a sufficient number of cells to induce a remission but as 
few as possible to limit the risk of severe GVHD.77 
Currently, a new exciting approach to explore a wider therapeutic window of GVL is 
being studied. Transducing cells with the Herpes Simplex thymidine kinase (HSV-tk) gene 
makes these cells susceptible to destruction by ganciclovir, not affecting non-transduced cells. 
The drug will be phosphorylated by HSV-tk to its monophosphate derivative, which finally 
will be phosphorylated to ganciclovir-triphosphate, a competitive inhibitor of DNA 
synthesis,78 resulting in selective cell death of HSV-tk expressing cells. The approach has 
been proven highly efficient in the treatment of transfected (experimental) tumor cells.79 To 
apply the antileukemic effect of GVHD without adverse effects of GVHD, HSV-tk 
expressing donor T -cells may be added to the allogeneic (T-cell depleted) marrow graft to 
induce GVL and/or GVHD. GVHD will be held within tolerable limits by the application of 
ganciclovir, selectively killing the multiplying lymphocytes causing GVL and GVHD. This. 
approach may allow the induction of significant GVL without inducing lethal GVHD. Crucial 
in the preclinical development (BNML and L44l5 leukemia models) of this 'suicide gene' 
treatment will be the efficacy of donor lymphocyte HSV-tk gene transfection, efficient 
lymphocyte depletion of the allogeneic graft to prevent uncontrollable GVHD and the optimal 
timing of the immediate abrogation of the GVL/GVH reaction to maximally benefit from its 
anti-leukemic effect. 
In the ongoing development of new drugs for the treatment of human diseases, compounds 
may emerge which further improve the treatment of leukemia. As a striking example, dinaline 
(4-amino-N-(2'-aminophenyl)benzamide) was initially described as a potent anticonvulsive 
agent80 The drug and its acetylated form acetyldinaline (ACD) have been shown to be 
immunosuppressive81 and highly effective against slowly growing experimental tumors82 and 
the BNML.83 In this rat model, ACD shows an exceptional sparing effect on normal 
hemopoiesis and unlike most others drugs when given post-BMT, ACD does not jeopardize a 
(syngeneic) marrow graft. Optimal anti-leukemic efficacy is obtained after repeated daily oral 
administration for a prolonged period of time, inducing an 8 log leukemic cell kill with less 
than a 1 log normal stem cell kill.84 ,85 Preliminary results indicated that a brief ACD 
treatment after allogeneic BMT plus high numbers of splenocytes, reduced the incidence of 
acute lethal GVHD from 100% to 37.5% while its antileukemic efficacy (5 log leukemic cell 
kill) is preserved. Further studies in the BNML model are therefore warranted on the efficacy 
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of ACD as an anti~leukemic. immunosuppressive and marrow ablative conditioning agent, 
which may allow reduced doses of total body irradiation, and on its efficacy in eradicating 
minimal residual leukemia and GVHD in the post-BMT period. Currently, ACD phase-I 
clinical studies are being conducted. 
7,8 FINAL REMARKS 
Returning to the title of this thesis, as concerned to the clinical applicability of GVL, the 
following can be concluded. We hypothesize that the GVL effects without evident symptoms 
of GVHD, observed in our rat models as well as in the reported experimental and clinical 
studies, are mere subclinical graft-verstls-host effects. These GVL effects are occasionally 
interpreted as a distinct reaction, misled by the quantitative differences in sensitivity of 
leukemic and normal cells for the allogeneic lymphocytes, accounting for a 'threshold' effect 
(Figure 7.1). 
The intensity of the GVL effect induced in MHC-compatible allogeneic BMT varies 
among different leukemias and donor-host strain combinations in mice.86 Similarly, it was 
shown that human leukemic cells show an extreme variability in their al1ostimulatory 
capacity and that HLA-DR expression plays a central role in determining leukemic allo-
recognition. 87 Therefore one can imagine that it is impossible to standardize allogeneic BMT 
in man. Since it seems that acute GVHD is easier to prevent than to treat once it is 
established,88 it is strongly discouraged to deliberately induce GVHD for its GVL effect until 
reliable strategies for the abrogation of GVHD are developed. However, an exception should 
be made for BMT in the treatment of CML, in which a limited T-cell depletion (one-log 
instead of two log) of the marrow graft seems to be optimal. Optimization of the treatment pre 
and post allogeneic T-cell depleted, HLA identical BMT should be the objective for future 
studies to further reduce relapse rates in the treatment of leukemia. The studies in the BNML 
model indicate that ACD treatment in conjunction with the current conditioning regimen. or 
even in combination with reduced doses of TBI, seems to be the pre-BMT treatment of 
choice. Apart from the optimal conditioning regimen, T-cell depleted HLA-identical BMT 
and post-BMT IL-2 therapy may be the best approach to reduce the incidence of acute 
leukemia and CML relapse to date. At molecular recurrence of leukemia (PCR), donor buffy 
coat transfusions (± 1-2 x 108 mononuclear cells/kg) should be administered, followed by 
ACD treatment when symptoms of severe GVHD are observed. Studies on the application of 
lymphocytes carrying suicide genes,89 will allow the deliberate induction of GVL without 
risking the detrimental effects of GVHD in the near future. 
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7.1 INTRODUCTIE 
Met een donor (allogene) beenl11erg transplantatie (BMT) worden zowel bloedvormende 
stamcellen aJs alloreaktieve lymfocyten getransplanteerd. Deze laatste soort cellen zijn in 
staat om te reageren tegen ontvanger-antigenen (o.a. aanwezig op leukemie cellen), hetgecn 
leidt tot cell vorm van immunotherapie (Hoofdstuk I), Het antileukemische effect 
gemedieerd door deze immullocompetente cel1en staat bekend ais de transplantaat-tegen-
leukemic reaktie (graft-versus-leukemia; GVL) en is goed gekarakteriseerd in proefdieren,l-3 
In de mens is het bestaan van een GVL reaktie indirect aangetoond door cen hogere incidentie 
van leukemic recidief fla transplantatie van T-cel gedeplcteerd allogeen4-6 of autoloog 
(patient-eigen) beenmerg (BM)5 in vergelijking met een ongedepleteerd allogeen 
transpiantaat. Het opt red en van een transplantaat-tegen-gastheer/ontvanger ziekte 
(omgekeerde afstotingsreaktie: graft-versus-host disease; GVHD) na BMT is geassocieerd 
met eeo lagere incidentie van leukemie recidief,4-8 patienten met een dergelijk leukemie 
recidief kunnen in remissie komen wanneer een immunosuppressieve behandeling gestopt 
wordt (Hoofdstuk 1).9-" 
Vooraanstaande onderzoekers in het veld van experimentele en klinische BMT in de 
behandeling van leukemie menen dat de opheldering van het mechanisme van de GVL reaktie 
en haar therapeutische bruikbaarheid een zeer hoge prioriteit heeft am de genezingskansen te 
verhogen7 . t2.t3 Onduidelijk is nag of GVL onafhankelijk van GVHD verloopt en of het 
klinisch mogelijk is de GVL reaktie te optimaliseren zonder GVHD te indnceren. Hoewel 
experimentele gegevens alsook een recente analyse van de Internationale Beenmerg 
Transplantatie Registratie (llMTR) snggereren dat sommige van de GVL reakties los zouden 
staan van GVHD, zijn leukemie-specifieke effector cellen of leukemie-specifieke target 
moleculen die zouden kunnen dienen ais antigenen voor donor T~lymfocyten nag niet 
duidelijk beschreven. t4 
7.2 GVL IN DE RATTELEUKEMIE MODELLEN 
Transplanteerbare proefdier-leukemiecn, bij voorkeur groeiend in inteeit knaagdierstammen, 
bieden de mogeJijkheid reproduceerbaar de initiele hoeveelheid leukemie cellen te bepalen en 
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de Jeukemiewgroei te kunnen manipuieren. Proefdier-Ieukemieen zijn relevant wanneer zij 
veel gemeen hebben met humane leukemieen, zoals specifieke groeilokaties, ceo lage 
antigeniciteit en gevoeligheid voar cytostatica en/of bestrating. De hier beschreven studies 
zijn uitgevoerd met de acute myeloide leukemie (AML) transplanteerbaar in de inteelt Brown 
Norway rattestam (BNML),15-17 en de L4415 acute Iymfatische leukemie (ALL) 
transplanteerbaar in de inteelt WAGlRij rattestam. 18,19 Beide leukemiemodellen hebben een 
reproduceerbaar groeipatroon na intraveneuze (Lv.) toediening van leukemiecellen. De 
overlevingstijd oa Lv. inoculatie is omgekeerd evenredig gerelateerd aan het aaotal 
leukemiecellen dat is toegediend. De lineaire correlatie tussen de hoeveelheid leukemiecellen 
en de overleving maakt ceo nauwkeurige berekening van het antileukemische effect van ceo 
toegepaste behandeling mogelijk door de toename in de overlevingstijd te bepalen. In 
tegenstelling tot vele andere experimentele knaagdier leukemieen, zijn deze ratteleukemieen 
net als humane leukemieen niet immunogeen (Hoofdsfuk 2). 
GVHD 
Manaliteit 
Marbfditeft 
SubkUnlsche GVHD 
GVL 
Geen meetbaar 
anltUeukemlsch 
ManlpulaUe van het transplantaat 
en/of behandellng van de ontvanger 
GVL 
Flguur 7.1 Schematische weergavc van de hypothese dat GVL (binnen de therapeutische marge) gelijk is aan 
subklinische GVHD. Verschil in de gevoeligheid voor donor Iymfocyten tussen leukemische en normale cellen 
resulteert in een "drempel" effect, hetgeen kan leiden tot de \'erwarring dat GVL en GVHD twee verschillende 
reakties zouden zijn; T-W, therapeutisch "window" of marge. 
We hebben aangetoond dat het niet mogelijk was in deze ratteleukemieen eell 
antileukemisch effect te induceren met syngene (identieke rattestam; Hoofdstuk 3) of semi H 
allogene (kruising/hybride naar ouderstam; Hoofdsfuk 6) BMT. Daar de transplantatie van 
volledig MHC-verschillend allogeen beenmerg in de rat geen GVL of GVHD induceert, 
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vergclijkcn we de lransplantatie van alJogecn BM in de rat met allogene HLA-identicke T-cel 
gedepleteerde BMT in de mens (Hoofdstuk 3). De toevoeging van toenemende hoeveelheden 
donor rniltcellen, als cell bron yoar lymfocyten, aall het beenmerg transplantaat induceert 
GVL en, bij grote aantallen, lctale acute GVHD. Daarom wordt de transplantatie van allogecn 
ratte-becnmerg met toevoeging van miltcellen beschouwd als cell model voar 
ongedepleteerde BMT in de mens. In deze modellen lijken GVL en GVHD 
geYnducecrd/gcmediccrd door dezelfde cclpopulatic(s). Echter, kwantitatieve verschillen in 
(donor lymfocyten) gevoeligheid tllssen leukemischc en normale cellen lijkt Ie resuIteren in 
een "drempel" effect, hetgeen leidt tot een meetbaar GVL effect voordat GVHD 
waarneembaar wordt. De antileukemische reaktiviteit neernt verder toe (over de "drempel") 
bij een toename van het aantal donor miltcel1en, maar tegelijkertijd worden dan de 
symptomen van GVHD evident. De therapeutische marge blijkt klein, de resulterende 
toename in overlevingstijd correleert met een afname van 2-3 log aan leukemiecellen, am die 
rcden vcronderstcllcn we dat GVL, binnen de therapeutisch marge, niets andel'S is dan 
subklinische GVHD (Figuur 7.1). Desalniettemin kon een significant antileukemisch effect 
worden waargenomen wanneer een specifiek aantal allogene miltcellen werd toegevoegd aan 
het beenmerg transplantaat (Hoofdstuk 3). Deze "scheiding" van GVL en GVHD kon echter 
niet langer bewerkstelligd worden nada! de micro flora in de darmen van de ratten was 
gewijzigd, Toch zijn de data in overeenstemming met die welke gerapporteerd werden door 
andere onderzoekers die particel gedepleteerde BM transplantaten gebruikten, Die resultaten 
suggereren dat er een "optimale" hoeveelheid donor lymfocyten in het transplantaat zou 
kllnnen zijn, die de incidentie en ernst van GVHD zou verminderen tot cen toelaatbaar niveau 
zander het antileukemische effect te verliezcn,20-22 
7.3 DEPLETffi VAN LYMFOCYTEN SUBPOPULATlliS 
Het wordt algemeen aangenomen dat donor T -cellen de belangrijkste mediatoren zijn van de 
antileukemische reaktie en GVHD, Verondersteld dat er niet aileen een kwantitatief effect 
van allogene T-cellen op de GVL en/of GVH reaktie is maar bovendien een kwalitatief 
verschil {ussen de T -cellen, dan zou een alternatieve benadering voor de vermindering van het 
aantal T -cellen ter voorkoming van GVHD, het depleteren van specifieke subpopulaties van 
Iymfocyten kunnen zijn. In een poging de waargenomen GVL en GVHD inducerende 
capaciteit te scheiden zijn lymfocyten sllbpopulaties gedepleteerd van de allogene donor 
miltcellen voor de transplantatie in het BNML model (Hoofdstuk 3). De depletie werd 
uitgevoerd m.b.v. monoklonale "ntilichamen (MCA's) specifiek voor CD4 en CDS, en 
magnetische bollen bedekt met een MCA die de Fc van de CD4 en CDS MCA's bindl. De 
een-staps, twee log depletie van CD4 of CDS positieve Iymfocyten was bewerkelijk maar 
uitvoerbaar. Vervolgens werd de CD4 of CD8 negatieve fraktie van de donor miltcellen 
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toegevoegd aan het BM transplantaat, gecorrigeerd voor het percentage CD4 of CDS 
negatieve cellen aanwezig in de oorspronkclijke miltcelstlspensie. 
Duidelijk werd dat de depletie van CD4 positieve cellen de GVHD-inductie volledig 
voorkwam. De verwijdering van CD8 positieve cellen kon de GVHD niet voorkomen, weI 
weed de progressie van de ziekte in aile ratten vertraagd. In dit experiment werd geen 
duidelijk antileukemisch effect waargenomen met de dosis donor miltcellen die normaal 
gesprokcn de maximale GVL induceert. Om die ceden kunnen we geen conc1usie trekken uit 
de depletie van CD4 of CDS positieve cellen voor wat betreft het GVL effect. Doordat GVL 
en GVH effecten niet langer onaflmnkelijk waarneembaar bleken (zie boven), is cen cmciaJe 
rol van CD4 positieve cellen in de antileukemische reaktie njet bewezen, Maar, met het DOg 
op de duidelijke link tussen GVL en GVH, lijkt het tach aannemelijk dat in deze 
rattemodellen de CD4 positieve cellen het antileukemische effect bewerkstelligen, 
Ooze conclusies zijn in overeenstemming met expedmentele gegevens gerapporteerd door 
Truitt et a1. en Sykes et a1. Zij hebben aangetoond dat CD4 positieve cellen een belangrijke 
rol spelen in GVHD in volledig MHC-verschillende muizen (donor-ontvanger) combinaties, 
en dat toediening van allogene CDS positieve T-cellen aileen geen acnte GVHD induceert.23-
25 Bovendien is het in deze muizemodellen bewezen dat CD4 positieve cellen een bijdrage 
kunnen leveren aan het GVL effect.23 Korngold et a1. hebben beschreven dat zowel CD4 als 
CD8 positieve cellen een belangrijke rol spelen bij GVHD in mnizen, Het blijkt dat de 
verantwoordelijke T-cel subpopulatie wordt bepaald door de MHC of minor 
histocompatibility (mH) antigenen-verschillen tussen de donor en de ontvanger.26 In 
sommige mH verschillende muizestammen zijn beide subpopulaties in gelijke mate 
betrokken,27 
Een veelbelovend klinisch onderzoek van selectieve CDS depletie gaf meer duidelijkheid 
betreffende T subpopnlaties die GVL en GVHD medie;;ren (HLA-identieke broerlzus BMT 
voor CML in chronische fase), Deze studie demonstreert een vermindering in, maar geen 
afwezigheid van, GVHD. terwijl de incidentie van leukemie recidief laag was,28,29 Wanneer 
de incidentie van leukemie recidief laag blijft gedurende een adegnate vervolgtijd, lijkt CDS 
depletie van het allogene transplantaat of de toevoeging van CD4 positieve cellen aan T -eel 
gedepleteerd beenmerg de juiste kenze bij HLA-identieke BMT, in vergelijking met depletie 
van aile T -cellen of CD4 positieve cellen, 
7.4 GVL EN LAK AKTIVITEIT 
Enkele auteurs hebben een associatie tussen NK aktiviteit en GVHD beschreven.30-32 en 
donor NK cellen of LAK cellen als effectorcellen in GVHD aangeduid, 
Anderen menen dat NK cellen en LAK cellen mogelijk een rol spelen in de GVL 
reaktie. 5,33,34 Deze cellen zijn. het meest efficient in de aanwezigheid van IL-2, in staat om 
140 
_______________________ Samellvatling ell DisclIssie 
sommige tumorcellen te lyseren met een gering effect op normale ceHen. Deze eel-lysis is 
niet bepcrkt tot soli de tumoren, maar oak blasten van ALL en AML zijn gevoelig gebleken 
voar de lytische aktivitcit van autoJoge en allogene LAK ceHen in vllro. 35 -39 Klinische 
studies bevestigcn deze preklinische resuitaten betreffende acute leukemieen.40,41 Andere 
studies suggereren dat in AML, maar niet in ALL, de LAK cellen cell beJangrijkc rol speJcn 
in het vedoop van de ziekte.42 
Wij hebben besludeerd of Iymfokine-geakliveerde killer (LAK) cellen een rol spelen in de 
GVL reaklie waargenomen in de rattemodellen na allogene BMT (Hoofdstuk 4). Miltcellen 
van W AG/Rij en BN catten werden geactiveerd ill vitro met recombinant humaan 
inlerleukine-2 (rhIL-2). De ratte LAK cellen bleken niel in slaal de ratteleukemieen Ie 
lyseren, terwijl dat wei het geval was in raIte soU de tumorcellijnen. Of cytokinen 
geproduceerd door LAK cellen eventueel leukemiecel lysis zou medieeren werd bestudeerd 
door verschillende hoeveelheden ratteleukemiecellen en LAK cellen te co-cultiveren. Dit 
resulteerde in cen lichte suppressie van de koloniegroei. Dus Iijkt de GVL reaktie 
waargenomel1 in de rattemodellen fla allogene BMT niet te berustel1 op een direct 
antileukemisch effect van LAK cellen. Deze resultaten zijn in overeenstemming met onze T-
eel deplelie dala die impliceren dal GVHD (en GVL) werden voorkomen door de deplelie van 
CD4 positieve cellen. 
Recenl is beschreven dal acule GVHD mogelijk de Iylische aktiviteil van NK cellen doe I 
toenemen maar niet de aantallen LAK preclIfsorcellen verhoogt. LAK precursor aantallen zijn 
lager dan normaal gedurende de eerste twee maanden na BMT. De ral van LAK effector 
cellen in GVL hangt waarschijnlijk meer samen met de mate van cellulaire aktiviteit dan met 
de aantallen geaktiveerde cell en. 43 
7.5 GVL EFFECTEN GEiNDUCEERD DOOR IL·2 
In vele preklinische24,44-S1 en klinische sludiesS2-SS is de rol van IL-2 in GVL effeclen en 
GVHD onderslreept. 
Om mogelijke verslerking van hel GVL effeci zonder de inductie van letale GVHD m.b.v. 
immunolherapie Ie besluderen, werd IL-2 behandeling posl-BMT loegepasl in hel BNML 
model (Hoofdstuk 5). De resultalen duiden op de indue lie van een klein anlileukemisch 
effecl in ratten mel minimale residuele leukemie behandeld mel hoge doses IL-2 na syngene 
BMT (equivalent van humane autologe BMT). Studies naar de toediening van syngene 
lymfocyten, al dan uiet geactiveerd met IL-2 in de aanwezigheid van bestraalde BNML 
cellen, aan het BM transplantaat gecombineerd met hoge dosis IL-2 therapie zouden kunnen 
uitsluiten of IL-2 behandeling na aulologe BMT kan leiden 101 anlileukemische effeclen. 
Oniangs is er een publikatie omtrent IL-2 therapie en autologe BMT verschenen. 
Transpiantatie van autoioog, met IL-2 geactiveerd" BM, gevolgd door IL-2 toediening is een 
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nieuwe benadering welke ex vivo purgeren en in vivo immunotherapie combineert. De eerst 
klinische resuItaten bevestigen de toepasbaarheid56 
Herhaalde IL-2 toediening vanaf 3 dagen na allogene BMT in het BNML model, heef! 
geen significant antileukemisch effect of letale acute GVHD als gevolg wanneer er, 
respectievelijk, "Iage" of "hoge" doses IL-2 werden gebruikt. Een tussenliggend dosis 
(2x78,OOO IV/day) Proleukin® resuIteert weI in een significant antileukemisch effect, met een 
toename in overlevingstijd die correleert met cell afname in leukemiecellen van 6.4 log, 
zonder de inductie van GVHD (Hoofdstuk 5), We hebben aangetoond dat de maximale GVL 
reaktie (zonder duidelijke GVHD), ge'induceerd door toediening van cruciale aantallen donor 
Iymfocyten aan het allogene transplantaat, overeenkomt met 2-3 log leukemiecel afname, Het 
blijkt dat de GVL reaktie, die verdwijnt na T -cel depletie van het allogene transplantaat, 
waarschijnlijk meer dan volledig gecompenseerd kan worden door IL-2 toediening fia 
allogene T-cel gedepleteerde BMT (Tabel 7,1), Onze data duiden dus op een mogelijk 
belangrijke bijdrage van JL-2 aan de GVL reaktie na allogene T-cel gedepleteerde BMT, 
hetgeen de therapeutische marge van klinische allogene BMT duidelijk vergroot. 
Tabel7.1 De rat als een model voor humane nllogene BMT 
Rattemodel 
Ongedepleteerd BM 
Ongedepleteerd BM + miltcellen (A) 
Ongedepleteerd BM + IL-2 (B) 
Log leukemiecel afname in het BNML model: 
(A) 2-3 
(B) 6.4 
Humane equivalent 
T -eel gedepleteerde BMT 
Ongedepleteerd BM 
T-cel gedepleteerde BMT + IL-2 
GVL 
+ 
+++ 
In studies met transplanteerbare leukemie in muizen, hebben Sykes et aJ. geobserveerd dat 
na transplantatie van compleet MHC-verschillend BM en toegevoegde allogene Iymfocyten, 
vroege behandeling met IL-2 (vanaf de dag van BMT) selectief de door CD4 positieve cellen 
gc'inducecrde GVHD remt, maar niet de antileukemische effecten van CD8 positieve cellen 
beYnvloedt.24,51 Bij BMT, gebruik makend van verschillende muizestam combinaties in 
welke zowel GVL als GVHD CD4 afhankelijk waren, remde IL-2 behandeling GVHD maar 
niet de antileukemische effecten van CD4 positieve cellen.51 Deze bevindingen suggereren 
dat het inhiberende effect van IL-2 is gericht tegen cen gelimiteerde subset of funetic van 
CD4 positieve cellen, en dat GVL en GVHD gemedieerd kunnen worden door verschillende 
CD4 mechanismen. Tenslotte hebben deze auteurs aangetoond dat de CD4 aktiviteit welke de 
GVHD medieert wordt bepaald door de histo-incompatibiliteit tusseo donor en ontvanger,25 
en dat IL-2 zowel CD4 als CD8 gemedieerde GVL aktiviteiten in stand houdt.57 Wannecr de 
toediening van JL-2 langer na BMT wordt gestart, bijvoorbeeld na 7 dagen, kan IL-2 de ernst 
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van GVHD juist doen toenemen.48 ,49 Bevestiging van deze gecompliceerde interakties moet 
worden afgewacht alvorcns implicaties voor de kliniek kunnen worden geevalueerd. 
Concludercnd, blijft het dubieus of IL-2 behandcling een GVL effect kan induceren na 
syngene BMT in leukemische ratten. Nieuwe studies naar de toediening van syngene 
lymfocyten gecoOlbineerd met hoge dosis IL-2 bchandeling zal deze vraag beantwoorden. De 
resultaten van Sykes et al. duiden op GVHD-suppressieve effecten van onmiddellijke initiatie 
van IL-2 behandeling na allogene, niet T-cel gedepleteerde BMT zonder vermindering van 
het GVL effect. Zij hebben aangetaond dat deze reaktie op IL-2 zeer afllankelijk is van het 
tijdstip van toediening en de mate van histo-incompatibiliteit tusseo de donor en de 
ontvanger. Desalniettemin lijkt deze benaderillg ceo grote kans op ernstige GVHD te 
veroorzaken. Onze data duiden er op dat IL-2 behandeling na allagene, T-cel gedepleteerde 
BMT een significant grotere therapeutische marge geeft dan allogene niet T-cel gedepleteerde 
BMT. Bovendien zijn er onlangs veelbelovende gegevens van eell fase II studie gepubliceerd 
betreffende lage dosis IL-2 behandeling na allogene T-cel gedepleteerde BMT voor 
hematologische maligniteiten.55 Dus, eell gerandomiseerde studie naar IL-2 imnlUnotherapie 
na allogene (HLA-identieke) T-cel gedepleteerde BMT voor Ieukemie is gewenst. 
7.6 GVL EFFECT; LEUKEMIE·SPECIFIEK OF EEN ALLOGENE REAKTIE? 
Tot op heden is de discussie nog a!tijd gaande of het GVL effect en GVHD twee 
verschillende reakties zijn of dat beide reakties volgens dezelfde mechanismen verlopen. De 
T-cel depletie studies en de IL-2 experimenten hebben tot nu toe geen van beide een GVL 
effect los van GVHD kuonen aantonen. Beide reakties zijn zeer afhankelijk van de mate van 
histo-incompatibiliteit tussen donor en ontvanger. Zelfs wanneer deze MHC-identiek zijn 
kunnen verschillen in minor histocompatibiliteit antigenen aallieiding geven tot GVL en GVH 
reakties. 
Met de BNML en de L4415 ratteleukemie werd getracht een GVL reaktie te induceren los 
van GVHD door semi-allogene (hybride-naar-ouder of ouder-naar-hybride) BMT toe te 
passen (Hoofdsluk 6). Het is niet mogelijk om in een hybride-naar-ouder transplantatie 
GVHD te indnceren. Ook de toediening van grote aantallen Iymfocyten aan het hybride BM 
transplantaat bleek niet te resu!teren in een antileukemisch (GVL) effect. 
In de ouder-naar-hybride transplantatie waarbij het transplantaat dezelfde alloantigenen 
draagt als de leukemie cellen werd geen GVL effect waargenomen, onafhankelijk van de 
aantallen toegevoegde Iymfocyten of de inductie van (Ietale) GVHD. Wanneer het ouder-
transplantaat histo-incompatibel was met de leukemiecellen was het BM transpiantaat zonder 
toevoeging van lymfocyten in staat een antileukemisch effect te induceren. Toevoeging van 
kritische aantallen semi-allogene Iymfocyten kOIl de GVL verdeI' doen toenemen zonder 
verschijnselen van ernstige GVHD. Het antileukemische effect van BM zander toevoeging 
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van donor lymfocytcn ZOtl verklaard kuonen worden door het reit dat de lcukemiecellen in 
deze setting de enige cellen zijn die volledig MHC-afwijkend zijn ten opzichte van de haplo-
identieke ontvanger. hetgeen de GVLlGVHD "drempel" verhoogt. Hogere aantallen 
lymfocyten in het transplantaat induceerde acute letale GVHD. Deze resultaten geven het 
overtuigende bewijs dat het GVL effect. waargenomen na MHC-afwijkende BMT in deze 
rattcmodellen voor ALL en AML, bemst op aUogene reakties, en dus Diet te schejden is van 
GVHD. De data duiden opnieuw op een kwantitatief verschil in gevoeIigheid van 
leukemische en normale cellen. wat leidt tot schijnbaar verschillende GVL en GVH reakties. 
hetgeen onze eerder geponeerde (Hoofdstuk 3) "drempel" hypothese bevestigd. 
Een andere benadering om de gunstige van de kwalijke effecten van allogcne T -cellen te 
scheiden is de in vitro expansie en klonering van donor T -cellen die specifick reageren met 
lcukemiecellen, maar niet met de nict-maligne ontvanger cellen. Men heeft aangetoond dat 
leukemie "specifieke" cytotoxisch T-cel (CTL) lijnen en klonen gegenereerd kunnen worden 
uit perifeer bloed van MHC-identieke familieleden van patienten met leukemie. welke niet 
reageren met niet-maligne cellen van diezelfde patient in vitro. 58,59 De specificke 
herkenning van sommige leukemieenllymfomen door effectorcellen ZQU verklaard kunnen 
worden door de expressie van zogenaamde fusie protelnen, gecodeerd door 
genrearrangeringen die een gevo!g zijn van chromosomale translokaties. Bekende 
voorbeelden zijn BCR-ABL. een gevolg van de translokatie t(9;22) in Philadelphia 
chromosoom (Phi) positieve CML en ALL. het E2A-PBX eiwit geassocieerd met t(I;19) in 
pre-B cel ALL. PML-RAR bij t(l5;17) in acute promyelocyten leukemie (PML) en DEK-
CAN in t(6;9) AML.60-62 De AML cellen gebruikt om de "specifieke" CTL klonen te 
stimuleren zijn gekenmerkt door t(8;16), Desondanks was de specificiteit niet geassocieerd 
met deze translokatie daar de andere leukemieen die herkend werden door deze CTL niet de 
t(8;16) vertoonden59 Om inzicht te krijgen in de mogeJijke klinische toepassing van donor 
CTL lijnen welke reageren met de leukemieen van patienten die een leukemie recidief 
vertonen na allogene BMT. hebben Falkenburg et aJ. een pilot studie uitgevoerd waarbij acht 
verschillende donor-ontvanger combinaties gebruikt werden. 63 In vijf van deze gevallen 
bleken de CTL Iijnen reaktief met de leukemiecellen en niet met de IL-2 geaktiveerde 
lymfocytell van hetzelfde individu, hetgeen de "relatieve specificiteit" voor leukemiecellen 
demonstreert. pit sluit niet uit dat deze cell en mogelijk toch reageren met antigenen van de 
target organen van GVHD63 Het Jijkt aannemelijk dat deze "Ieukemie-specifieke" T-cellen 
slechts in zeer lage aantallen voorkomen in normaal perifeer bloed. Het scheidell van deze T-
cellen van cellen die wei GVHD induceren, en vervolgens de ill vitro klonering en 
vermeerdering zouden onpraktisch kunnen blijken voor de toepassing in BMT.64 
Een minder verfijnde. maar tot ntl toe beter toepasbare methode am een remissie te 
induceren in patienten met een CML of AML recidief na allogene BMT is de toediening van 
donor buffy coat cellen.65-73 Hoewel details in de protocollen varieren, is bewezen dat 
aJlogene buffy coat mononucleaire cellen CML ill vivo kunnen uitroeien. Zelfs wanneer 
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ernstige aClite GVHD aptrad (graad II-IV in 51% van de patienten), was GVHD slechts in een 
patient de directe doodsoorzaak (::::;2.2%), Een rctrospectief onderzoek naar de ziektevrije 
overleving in deze studies in vergelijking met die na cell tweede BMT, toont dat zowel de 
recidief-percentages als de therapie-gereiateerde mortaliteit substantieel lager liggen na buffy 
coat transfllsies. 74•75 Het blijkt dat de GVL reaktic effectiever is in chronische fase CML dan 
in andere hematoiogische maligniteiten of progressieve CML. Tach duiden retrospectieve 
analyses oak op cen GVL effect in non-Hodgkin lymfomen76 en acute leukemieen.5,69 
Verdere studies naac een betrouwbare remissie-inductie met donor buffy coat transfusies, 
zander ernstige (letaie) GVHD te induceren, zijn thans van groat belang. 
7.7 TOEKOMSTVERWACHTING 
Lapende studies zullen aphelderen of het mogelijk is de gebruikte kweek-, stimulatie- en 
klonerings-technieken te optimaliscren om leukemie specifiekc CTL lijnen te genereren, bij 
voorkeur voar elke afzonderlijke patient (in remissie), en weI in cen dermate korte tijd dat de 
residuele leukemie geelimineerd kan worden alvorens deze tot grate celaantallen uitgroeit cn 
niet Janger met immunotherapie te behandelen is. Nieuw ontdekte cytokines en cytokine-
thcrapic studies zuBen voortdurend de kennis verbeteren betreffende de ex vivo kweck. 
stimulatie en klonering van lymfocytcn, en de preventie van anergic enlof apoptosis van deze 
cellen na toediening. 
Intussen zal cen adequate vervolgtijd van paticoten die reeds behandeld zijn en nieuwe 
studies naac de toediening van donor buffy coat lymfocyten aan patienten met een leukemie 
recidief na allagene BMT leiden tot een mogelijke verbetering van deze behandeling. Tot nll 
toe hebben aileen Drobyski et a1.67 getracht een standaard aantal donor T-cellen toe te dienen. 
Complete maleclliaire remissie werd gei'ndnceerd met "slechts" 0.34 x 108 cellenlkg, terwijl 
sommige patienten die een veel hogere dosis ontvingen geen respons vertoonden. Het is 
belangdjk om een mogelijk "optimale" dosis tc bepalen in combinatie met de mate van histo-
incompatibiliteit, en am een hoeveelheid cellen toe te dienen voldoende om een remissie te 
induceren, maar tevens zo klein mogelijk am de kans op ernstige GVHD te beperken.77 
Momenteel wordt er een nieuwe therapie bestudeerd ter vergrating van de therapeutische 
marge van GVL. Door cellen te transduceren met het Herpes Simplex thymidine kinase 
(HSV-tk) gen worden zij gevaelig voor destructie door ganciclovir, hetgeen de niet-
getransduceerde cellen niet schaadt. Ganciclavir wordt gefasforyleerd door HSV -tk tot een 
monofasfaat derivaat, wat uiteindelijk wordt gefasforyJeerd tat ganciclovir-trifasfaat, een 
competitieve rennner van de DNA-synthese,78 met als gevoJg een selectieve celdood van de 
HSV -tk expresserende cellen. Bewezen is dat deze benadering zeer efficient is in de 
behalldeling van getransfecteerde (experimentele) tumarceHen.79 Om het antileukemische 
effect van GVHD te benlltten zander de nadeJige effecten van GVHD zollden HSV -tk 
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expresserende donor T-cellen kunnen worden toegevoegd aan het allogene (T-cel 
gedepleteerde) BM transplantaat om GVL enlof GVHD te induceren. GVHD zal dan binnen 
toelaatbare grenzen gehouden worden door behandeJing met ganciclovir, waarbij selectief de 
delende Iymfocyten die GVL en GVHD veroorzaken worden geelimineerd. Deze behandeling 
zou het rnogelijk maken een significant antileukemisch effect te induceren zander letale 
GVHD. Cruciaal in de preklinische ontwikkeling (BNML en lA415 leukemie modellen) van 
deze llsui'cide gen" behandeling zal de transfectie-efficientie zijn van de donor lymfocytcn 
met het HSV -tk gen, het efficient depleteren van de Iymfocyten uit het allogene transplantaat 
om oncontroleerhare GVHD te voorkomen en de optimale timing van de onmiddellijke 
stopzetting van de GVLlGVH reaktie om het antileukemische effect optimaal te kunnen 
benutten. 
In de voortdurende ontwikkeling van nieuwe medicijnen voce de behandeling van humane 
ziektes kunnen oak niellwe middelen worden gegenereerd die de behandeling van leukemie 
verder verbeteren. Een opvallend voorbeeld hiervan is dinaline (4-amino-N-(2'-aminophenyl) 
benzamide), een middel dat oorspronkelijk werd gepresenteerd als een uiterst probaat middel 
tegen convulsies.80 Het is bewezen dat dit geneesmiddel en zijn geacetyleerde vorm 
acetyldinaline (ACD) sterk immunosuppressief zijn81 en zeer effectief tegen langzaam 
groeiende experimentele tumoren82 en de BNML83 In dit ratternodel toont ACD een 
exception eel sparend effect op normale hemopoiese en in tegenstelling tat de meeste andere 
middelen vormt ACD geen gevaar voor het (syngene) BM transplantaat wanneer het post-
BMT worden gegeven. Een optimaal antileukemisch effect wordt bereikt door herhaalde 
dagelijkse orale toediening gedurende een langere periode, hetgeen het leukemiecel aantal 
met 8 log doet afnemen met tegelijkertijd slechts minder dan I log vermindering van de 
nannale hemopoietische stamcellen.84 ,85 Preliminaire resultaten laten zien dat een korte 
behandeling met ACD na allogene BMT met hoge aantallen all ogene Iymfocyten, de 
incidentie van acute letale GVHD reduceert van 100% tot 37.5% terwijl het antileukemische 
effect (5 log afname in leukemiecellen) bewaard blijft. Verdere studies met het BNML model 
zijn dus nodig naar de efficientie van ACD als een antileukemisch, immunosuppressief en 
BM ablatief middel (hetgeen een lagere dosis totale lichaamsbestraling zou toestaan) en op de 
eradicatie van minimale residuele leukemie en GVHD in de post-BMT periode. Mamenteel 
wordt er een fase I studie met ACD uitgevoerd. 
7.8 TENSLOTTE 
Om terug te komen op de tite! van dit proefschrift, voor wat betreft de klinische 
toepasbaarheid van GVL, kan het volgende worden geconcludeerd. Het GVL effect zonder 
duidelijke symptamen van GVHD, waargenomen in ons rattemodel evenals in gerapporteerde 
experimenteie en klinische studies, is niets meer of minder dan een subklinisch GVH-effect. 
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Sommige onderzoekers beschouwen het GVL effect (zander symptomen van GVHD) als een 
losstaande reaktie, misleid door de kwantitatieve verschillen in gevoeligheid van leukemische 
en normale cellen voar de allogene lymfocyten. resulterend in een "drempel-effect" (Figuur 
7.1). 
De intensiteit van het GVL effect geYnduceerd in MHC-identieke all ogene BMT varieert 
tussen de verschillende lcukemieen en donor-ontvanger combinaties in muizen. 86 
Vergelijkbaar vertonen humane leukemieen een extreme variabiHteit in aHo-stimulatie en 
speeJt HLA-DR exprcssic cen centrale rol in de bepating van de allo-herkenning van 
leukemiecellen87 am die redenen is het onmogelijk om allogene BMT in patienten te 
standaardiseren. Omdal het eenvoudiger bJijkt om GVHD tc voorkomcn dan om een aktieve 
GVH reaktie te stoppen) 88 wordt het sterk afgeraden om moedwi1lig cen GVHD te indllceren 
om zijn antileukemische effect, totdat betrollwbare methoden zijn ontwikkeld om GVHD te 
stoppen, Een uitzondering zou gemaakt kunncn worden voar BMT bij de behandeJing van 
CML, waarbij een beperkte T-cel depletie (een log in plaats van twee log) van het beenmerg 
transplantaat optimaallijkt te zijn. Optimalisatie van de behandeling voar en na aJIogene T-
cel gedepleteerde, HLA-identieke BMT zou de spi! van verdere studies ter vermindering van 
leukemie recidieven in de behandeling van leukemie moeten zijn. De studies in het BNML 
model duiden erop dat ACD behandeling in combinatie met de huirlige conditionerings 
regimes, of zelfs in combinatie met geredllceerde doses tot ale lichaamsbestraling) de optimale 
behandeling zou zijn pre-BMT. Behalve optimale conditionering, zou momenteel T-cel 
gcdepleteerde HLA-identieke BMT en post-BMT IL-2 behandeling de beste benadering 
kunnen zijn in de behandeling v(ln CML en acute leukemieen. Bij moleculaire detectie van 
een leukemic recidief (PCR) zouden buffy coat transfusies (± 1-2 x 108 mononucleaire 
cellenJkg) toegediend moeten worden, gevolgd door ACD behandeling wanneer symptomen 
van acute GVHD waargenomcn worden. Studies naar de toe passing van Iymfocyten die het 
Itsui'cide gen" tot expressie brengen,89 zouden in de nabije toekomst kunnen leiden tot de 
bewuste inductie van GVL zonder de catastrofale gevolgcn van GVRD te riskercn. 
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ABBREVIATIONS 
ACD : acetyldinaline EBV : Epstein~Barr virus 
ADCC : antibody-dependent cellular ED50 : 50% effective dose (affecting 
cytotoxicity 50% of the animals) 
Ag : antigen ELAM : endothelial leukocyte 
ALL : acute lymphocytic leukmemia adhesion molecule=E-selectin 
AML : acute myelocytic leukemia Fl : hybrid strain 
APC : antigen presenting cell FACS : fluorescence activated cell 
ATG : anti thymocyte globulin sorter 
BM : bone marrow f-factor : fraction of cells entering the 
BMT : bone marrow transphmtation spleen 
BN : Brown Norway rat GM-CSF : granulocyte-macrophage 
BNML : Brown Norway acute colony stimulating factor 
myelocytic leukemia GVH : graft-versus-host 
Bu : busulfan GVHD : graft-versus-host disease 
CD : cluster of differentiation GVL : graft-versus-Ieukemia 
CFU-S : colony forming unit-spleen GVLR : graft-versus-leukemia reaction 
CLL : chronic lymphocytic leukemia Gy : Gray 
CML : chronic myelocytic leukemia HLA : humallieukocyte antigen 
CMV : cytomegalovirus HSV : herpes simplex virus 
CNS : central nervous system HSV-tk : herpes simplex vims-
CR : complete remisson thymidine kinase 
CsA : cyclosporine A ICAM : intercellular adhesion 
CTL : cytotoxic T lymphocyte molecule 
Cy : cyclophosphamide IFN : interferon 
Do : dose inducing a surviving Ig : ifillllullogJobulin 
fraction of 0.37 IL : interleukin 
DFS : disease free survival IL-lra : illterleukin-l receptor 
DIC : diffuse intravascular antagonist 
coagulation IL-2R : interJeukln-2 receptor 
DMBA : 9,IO-dimethyl-I,2- ILS : increase of life span 
benzanthracene i.p. : intraperitoneal 
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Lt. : intrathecal PB : peripheral blood 
IV : international unit PBL : peripheral blood lymphocytes 
i. v, : intravenolls PCR : polymerase chain reaction 
LAK : lymphokine activated killer PLA2 : phospholipase A2 
LCFV-S : leukemic-colony forming unit- PNH : paroxysmale nachtelijke 
spleen hemoglobinurie 
LCK : log leukemic cell kill R2 : correlation coefficient of 
LFA : leukocyte function antigen variation 
LGL : large granular lymphocyte s,c. : subcutaneous 
LN : lymph node SCA : spleen-colony-assay 
MCA : monoclonal antibody scm : severe combined 
MDS : myelodysplastic syndrome immunodeficiency disease 
MdST : median survival time S.D. : standard deviation 
mH : minor histocompatibility S.E. ; standard error 
complex SPF : specified pathogen free 
MHC : major histocompatibility TBl : total body irradiation 
complex TCD : T-cell depletion 
MRD : minimal residual disease TCR : T-cell receptor 
mRNA : messenger ribonucleic acid TGF : transforming growth factor 
II : number in group Th : T helper cell 
N : extrapolation number Thp : T helper precursor cell 
NK cell : natural killer cell TNF : tumor necrosis factor 
NKSF : natural killer cell stimulatory VOD : veno-occlusive disease 
factor WAGiRij : Wistar Albino Glaxo rat 
NS : not significant (bred in Rijswijk) 
p : probability WBC : white blood cells 
P : parent 
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CURRICULUM VITAE 
Dc schdjver van dit proefschrift werd geboren op 27 juni 1962 te Sehiedam, Nadat de 
diploma's HA VO en VWO behaald waren aan de scholengemeenschap Etten-Leur, werd in 
1982 met de studie Biologic aangevangen. Gedurende deze studie werden de dcie 
hoofdvakken Moleculaire Celbiologie o,/.v, Dr. Verhoef (Rijksuniversiteit Utrecht, 14 
maanden), Immunologie o./,v, Dr. Sterenberg en Prof, Dr. den Otter (RIVM, Bilthoven, 9 
maanden) en Gcnetica o.Lv. Dr. Ostrcr en Prof. Dr. Voorma (Universiteit van Florida, 
Gainesville, USA, 10 maanden) door/open, Het doctoraal examen Medisehe Biologie (B5*) 
werd in februari 1989 behaald, 
Van april 1989 tot september 1994 werd het hier beschreven promotieol1derzoek verricht 
binnen het Instituut voor Tocgepaste Radiobiologic en Immunologic (ITRI) - TNO tc 
Rijswijk en vanaf januari 1993, het Instituut voor Hematologic van de Erasmus Universiteit 
Rotterdam, o./,v, Prof. Dr. A, Hagenbeek en Prof. Dr. D,W, van Bckkum, 
Sedert september 1994 is de Huteur aangesteld als wetenschappelijk medewerker (post-
doc) binncn de afdeling Hematologie van het Academisch Ziekenhuis Leiden. 
ISS 

DANKWOORD 
Ben van de mores bij cen promotie. naast het schier eindeloos verzamelen van 
handtekeningen, is het afsluiten van cen proefschrift met cen dankwoord. Het is derhalve 
onmogelijk om origineel te zijn en het zal blijken dat oak ik mensen vergeet te naemen die 
weI degeJijk een steentje hebben bijgedragen (promoveren doe je niet bepaald aileen!). 
Allereerst wiI ik in het bijzonder bedanken mijn eerste Promotor Ton Hagcnbeek. Tot mijn 
grate vreugde was jij het die mijn sollicitatiebrief. gericht aan de afdeling Immunologic van 
de Dr. Daniel den Hoed Kliniek, bij de personeelsdienst inzag en vervolgens vroeg of ik 
misschien gei'nteresseerd was in cen vacature in cen projekt in de Werkgroep Leukemic 
Onderzoek TNO te Rijswijk. Je hebt me op een bijzonder pleziedge wijze ingewijd in de 
veelzijdige wereld van de Hematologic en beenmergtranspiantatie. Gedurende het gehele 
projekt heb je me, ondanks jouw vaak overvolle agenda, altijd weten te inspireren en zeker 
ook bij het schrijven van de verschillende stukken was jouw bijdrage essentieeJ. Ik hoop oak 
in de toekomst nag vaak met je te mogen samenwerken. 
Mijn tweede Promotor Dick van Bekkum wil ik zeer veel dank zeggen voor de bijzondere 
wijze (overrompelend en uitdagend) waarop hij mij heeft weten te stimuleren gedurende het 
onderzoek en het schrijven van dit proefschrift. Ik ben er trots op binnen "jouwl1 instituut te 
hebben mogen werken. 
Ik wil de professoren Lowenberg, Vossen en Willemze hartelijk danken voar het kritisch 
beaardelen van het manuscript. Oak professor Benner en Dr. Haogerbrugge wil ik bedanken 
voar het zitting nemen in de promotiecommissie. I especially appreciate it that Prof. Goldman 
from the Royal Postgraduate Medical School in London was willing to come to Rotterdam to 
complete the promotion conunittce. 
Anton, als altijd aanwezige expert op het gebied van de experimentele Hematologie en de 
ratteleukemieen in het bijzonder, was je onmisbaar voor mijn te pas en te onpas opborrelende 
"korte vragen". Zoals het een oude "rat" in het yak betaamd wistje op geduldige wijze steeds 
weer een passend antwoord te produceren. 
De twee sterkste motoren achter de vele experimenten die zijn uitgevoerd waren Margret 
Tielemans en Irene Blokland. Margret, samen zijn we begonnen aan een voor ons beiden 
niclIw onderzoek. Je hebt altijd een enorme inzet getoond zowel m.b.t. het werk als de sociale 
activiteitcn binnen het lab. Niet altijd wist ik met mijn zeer direkte manier van omgaan met 
menSCH, jouw die perc gedachtengang direkt te volgen. Ondanks dat denk ik dat we op een 
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uitzonderlijk vriendschappelijke manier hebben samengewerkt. Na twee jaar voortvarend 
onderzoek doen, heb je begrijpelijk gekozen voar een vaster contract in Leiden. Irene, na een 
toevallige kennismaking, nam jij de openstaande plaats in en wist je met grate 
voortvarendheid de experimentele vaardigheden eigen te maken. Je hebt anderhalf jaar met 
grote inzet aan lions" projekt gewerkt alvorens je je stortte op de moleculaire biologie binnen 
het lab. Naast de direkte samenwerking met de voorgenoemde dames heeft oak Koos Gaiser 
een duidelijke bijdrage geleverd aan dit proefschrift, waarvoor uiteraard zeer veel dank. 
Tenslotte wil ik v.w.h. het praktische werk Carla bedanken, zij was degene die me de eerste, 
uiterst belangrijke, handelingen met de ratten bijbracht. 
De sfeer binnen de Hemato-Oncologie groep was uitzonderlijk goed te ooemen, zowel 
binnen de muren van TNO als die van de BUR. Daarvoor waren naast voorgenoemden mede 
verantwoordelijk Bls, Elwin, Eric, Gwen, Hazel, Henk, Jan Hendrikx, Kees, Michele, Shosh, 
Steven en met name Ger Arkesteijn en Jan Bayer tijdens het delen van een "room with a 
viewH • Sameo met vele andere collega's werden buitenlabse activiteiten ondernomen zoals 
squashen, kanoen, skien en weekendjes Ardennen met dank aan o.a. Rob, Eric, Hans, Cecilia, 
Jan Bauman, Jan Visser, Mark, JUlIS, Bas, Victor Smit, Victor van Beusechem, Rolf, Folkert, 
Jan Jansen, Radha en Jeroen. 
Zeer belangrijk bij het doen van experimenten met proefdieren is de verzorging van deze 
dieren zodanig dat deze zo "schoon" mogelijk blijven. Al de mensen die d.araan hebben 
bijgedragen ben ik dan ook veel dank verschuldigd. 
Bij de totstandkoming van de verschillende publicaties hebben Eric van der Reijden en 
Henk Westbroek de "finishing touch II in veel van de figuren gehad. Mirjam Bosman wist bij 
de finalisatie van dit proefschrift nag enkele grafische knelpunten op te lassen en het geheel 
te "coveren". 
Fred Falkenburg wil ik bedanken voor de gelegenheid de opgedane ervaring in de 
experimentele Hematologie verder uit te brei den in een wederom voaraanstaand 
laboratorium. Voor \Vat betreft dit proefschrift heeft hij de laatste grote "boost" gegeven in de 
finalisatie, want zonder deadline ... {zie stelling thesis Laura Faber). 
Wederom een mas bij het promoveren is het hebben van twee paranimfen. Hiervoar heb ik 
twee "vrienden van formaat" uitgezocht. Samen met JUllS Nooteboom heb ik veelvuldig 
tllssen Utrecht en Rijswijk de dagelijkse problematiek besproken. maar vooral oak waarom al 
die auto's steeds weer stH moesten staan. Hans van Gorp is altijd in voor een sportief duel 
waarna het goed "La ChouffenH is. 
Vrienden en naaste familie wil ik danken voar de stelln en de belangstelling tijdens de 
promotiejaren C'wanneer is je scriptie nou eens klaar?"). 
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Ik draag dit bockje op aan mijn ouders, Zander hen was ik nooit aan promoveren 
toegekomen, Samen hebben zij ervoor gezorgd dat het mogelijk was da! ik ging studeren, Zij 
vormden een thuisbasis waarop ik altijd kon terugvallen tijdens die voor hen zo ongrijpbare, 
voor mij zo turbulente jaren, Mede door hun voortdurende stimulalie en interesse is dit 
proefschrift tot stand gekomen, Het laalste dee I van de promotie heeft Pa niet meer mogen 
meemaken, gelukkig vormt Ma nog altijd ecn rots in de branding, 
Tenslotte is er nog ftmijn" lieve "wijffie" Antoinette, Ik dank je voor aile goede zorgen en 
stclin die je me geeft. JOllW onuitputtelijke energie en vrolijkheid maken elke dag weer 
bijzondcr. 
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